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The dramatic increase in oropharyngeal squamous cell carcinomas (OPSCC) 
over the past few decades is attributable to oncogenic types of human 
papillomaviruses (HPV). The presence of HPV in OPSCC has important clinical 
significance since patients with HPV-positive OPSCC tumours have improved 
response to conventional therapeutic agents such as radiation and cisplatin 
compared to those with HPV-negative tumours. The overall aim of this study 
was to investigate potential mechanisms of improved therapeutic response of 
HPV-positive OPSCC. 
 
Following confirmation of HPV status in a panel of five HPV-positive and two 
HPV-negative head and neck cancer cell lines, an in vitro model of relative 
sensitivity to conventional therapeutic agents was established. All HPV-positive 
cells were more sensitive to radiation and cisplatin compared to HPV-negative 
cells. Stabilisation of functional p53 tumour suppressor protein was observed 
following treatment of HPV-positive cells to radiation and cisplatin. Attenuation 
of p53 in HPV-positive cells increased resistance to these agents indicating 
sensitivity of these cells to conventional therapeutic agents in vitro is p53-
dependent. Furthermore, abrogation of the HPV oncogene E6 also caused 
stabilisation of p53 and slightly sensitised cells to radiation and cisplatin. The 
functional role of E6 was further explored by expressing this protein in p53 
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mutant HPV-negative cells. Interestingly, expression of E6 increased sensitivity 
of HPV-negative cellsto radiation and slightly to cisplatin. 
 
This study went on evaluate the response of the aforementioned panel of cells 
to targeted and novel therapeutic agents. By contrast to conventional 
therapeutic agents, HPV-positive cells were more resistant to cetuximab (an 
inhibitor of the Epidermal Growth Factor Receptor, EGFR) and Tumour 
Necrosis Factor-related Apoptosis-Inducing Ligand (TRAIL). Expression of 
EGFR protein in HPV-negative cell lines was consistently high whereas there 
was variable protein expression in HPV-positive cells; response to cetuximab 
corresponded to the EGFR protein levels in the latter. An inverse correlation 
between HPV status EGFR protein expression was also present in formalin-
fixed paraffin embedded OPSCC tissue samples, but EGFR protein levels did 
not provide additional prognostic value beyond HPV status in the study cohort. 
 
The current study provides an in vitro model of relative sensitivity in HPV-
positive OPSCC and possible supportive mechanisms to explain this 
observation. This study also raises the possibility that HPV-positive OPSCC 
may be relatively resistant to EGFR-targeted and TRAIL therapies.  
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CHAPTER 1 - General Introduction 
 
  




1.1Head and Neck Squamous Cell Carcinoma 
Head and neck cancer (HNC) is a collective term defined on an anatomical-
topographical basis to describe the malignant tumours of the upper aero-
digestive tract, including the nasal cavity and paranasal sinuses, nasopharynx, 
hypopharynx, larynx, oral cavity and oropharynx.1 Numerous types of cancers 
effect the head and neck region but the vast majority arise from the stratified 
squamous epithelium of the upper aero-digestive tract and are therefore 
collectively termed as head and neck squamous cell carcinomas (HNSCC).2 
 
1.1.1 Site distribution and associated risk factors of HNSCC 
HNCs are a heterogeneous group, consisting of cancers of the oral cavity 
(ventral surfaces and posterolateral border of tongue, gingiva, floor of mouth 
and hard palate), pharynx (oropharynx, nasopharynx, and hypopharynx), 
sinonasal tract and larynx. Tongue cancer is described as the most common 
site for oral cancer worldwide, with most tumours arising on the ventral 
surfaces and posterolateral border.3,4 
 
HNSCCs are associated with variable risk factors. Tobacco smoking and 
chewing habits and alcohol intake are considered the most important 
aetiological agents.5,6 The use of tobacco in combination with alcohol together 
demonstrate a greater risk of developing HNSCC compared to use  
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of tobacco or alcohol alone.4,7 In addition to tobacco and alcohol, Human 
Papillomavirus (HPV), primarily types 16 and 18, have been acknowledged as 
a common aetiological agent in some HNCs.8 
 
1.1.2 Molecular characterisation of HNSCC 
A plethora of oncogene activation and/or tumour suppressor gene inactivation 
has been reported as being important in driving head and neck carcinogenesis. 
However, several genes including p53, cyclin dependent kinase inhibitor 2A 
(CDKN2A or p16), epidermal growth factor receptor (EGFR) and cyclin D1 
(CCND1) are consistently altered and will be discussed in further depth for the 
purpose of this introduction.9-11 
 
Loss of chromosome region 17p13 encoding the tumour suppressor gene TP53 
is mutated in up to 70% of HNSCC.9,12p53 is a nuclear phosphoprotein involved 
in DNA synthesis, repair, apoptosis and cell cycle control.13Activation of p53 
results in the formation of p53 tetramers, which can then act as a transcription 
factor.14 One of the functions of the p53 tetramer is to induce expression of the 
CDK inhibitor p21CIP, which negatively regulates cyclin A/CDK1, cyclin B/CDK1 
and cyclin E/CDK2 complexes, preventing cell cycle progression.15,16 p53 
mutations have been associated with a decreased overall survival, thus 
establishing its significance in HNSCC progression.12,179p21-22 is a frequent 
chromosomal region, which is lost in HNSCCs.  Genes included in this region 
include p16INK4a (p16) and p14ARF at the CDKN2A locus.18The p16 gene (also  
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known as cyclin-dependent kinase inhibitor 2A, CDKN2A) acts as a tumour 
suppressor gene. The p16 protein, by binding to cyclin dependent kinase 4 
(CDK4) or CDK6, inhibits phosphorylation of the retinoblastoma protein (pRb) 
thus impeding G1 to S phase transition of the cell cycle.19 Loss of its function, 
either through mutations, deletion or hypermethylation is common in 
HNSCC.20,21In addition, the overexpression of cyclin D1 (encoded by CCND1) 
due to amplification of chromosome 11q13, is found in over 80% of cases.22 
There is evidence that overexpression of cyclin D1 serves as a rate-limiting 
controller of G1 phase progression and is associated with a more aggressive 
tumour phenotype.23 
 
Epidermal growth factor receptor (EGFR) is a glycoprotein cell surface receptor 
composed of an extracellular ligand-binding domain, transmembrane domain 
and cytoplasmic tyrosine kinase (TK) domain. EGFR is present in normal 
epithelia, it plays a vital role in cell growth, apoptosis and angiogenesis and is 
overexpressed in several types of carcinomas. EGFR is highly expressed 
(42%–80%) in HNC and its expression is associated with poor outcome.24,25,26 
 
1.1.3 Epidemiology 
1.1.3.1 Global incidence of HNSCC 
HNSCC is the sixth most common cancer worldwide, with approximately 
680,000 new cases diagnosed and 370,000 deaths recorded in 2012 by  
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Global Burden of Cancer Study (Globocan).27,28Males are affected more than 
females with a ratio ranging from 2:1 to 4:1.29 
 
In the United States (US), HNC accounts for 3% of malignancies, with almost 
60,000 Americans developing these tumours annually and 12,000 dying from 
the disease.30 In Europe approximately 250,000 cases (estimated 4% of the 
cancer incidence) and 63,500 deaths were reported in 2012.31 There is 
considerable geographical variation in the incidence of HNSCC; for example, in 
the United Kingdom (UK) in 2008 there were 11,682 reported HNCs, which 
constituted 3.73% of all cancers compared to 200,000 cases of HNCs in India, 
accounting for over 30% of all cancers in the latter.27,32,33 
 
Despite the fact that advances have been made in diagnosis and treatment of 
HNC, mortality rates have only marginally decreased over the last decades and 
the 5-year survival rate currently ranges between 40%–60%.34 
 
1.1.3.2 Changing trends in HNSCC 
Over the past 30 years there has been a marked increase in the incidence of 
HNSCC in several countries including North America (United States35 and 
Canada36), Western Europe (Denmark,37 Netherlands,38 Norway,39 Sweden,40 
the UK41) and Australia.42 The incidence rose from 16.3% during 1984 to 1989 
to 71.7% during 2000 to 2004 in the US.35 This trend was  
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observed in parallel with a reduction in the incidence of other smoking related 
cancers such as Non-small cell lung cancer (NSCLC) of lung.43 
 
Subsite analysis of the increase in incidence demonstrated that the rise in HNC 
was due to the exponential increase in the cancers of the oropharynx (faucial 
tonsils, base of tongue and soft palate).44,45 The marked increase in 
oropharyngeal squamous cell carcinoma (OPSCC) was seen in parallel with a 
decrease in incidence of other HNCs including that of the larynx and oral cavity. 
The latter observation may be explained by the reduction in tobacco smoking 
over the same period, while the increase in OPSCC is attributed to HPV.46,47 
 
1.1.4 Evidence for HPV as the cause for increase in OPSCC 
Evidence for a causal involvement of HPV in the pathogenesis of OPSCC 
comes from epidemiologic and molecular studies. The earliest suggestion of a 
possible link between HPV and squamous cell carcinomas of the oral cavity 
(OSCC) was made by Syrjanenet al (1983) where the group observed that 
some of these tumours have morphological and immunohistochemical features 
indicative of HPV infection.48 Subsequent studies have supported the 
predilection of the virus for oropharyngeal cancers (OPC). In two case series 
(1996 and 1997), 50% and 60% of tonsillar carcinomas were HPV positive, 
respectively, in comparison to 6% and 10% of tumours at other oral sites.49,50 
Additionally, Gillisonet al (2000)  
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andStranskyet al (2011) confirmed that the only HNC subsite with a 
demonstrated carcinogenic role for HPV was the oropharynx.21,51 
 
The mechanism of initial phases of HPV infection in oropharyngeal mucosa 
remains largely unknown. To date, there is lack of any functional evidence for 
the predilection of high-risk HPV for the oropharyngeal mucosa. The lamina 
propria of the oropharynx, particularly the palatine (fauceal) tonsil and base of 
tongue comprise lymphoid tissue invaginated by epithelial-lined crypts.  The 
epithelium is of reticulated crypt type and forms a loose network infiltrated by 
lymphocytes (Figure 1.5, page 55). Some authorities liken this epithelium to that 
of the cervical transformation zone, but there is currently insufficient evidence to 
support either structural of functional similarity.52,53 The reticulated crypt 
epithelium is infiltrated by lymphocytes to form a complex lymphopithelial 
structure, which is the site of antigen trafficking to the underlying lymphoid 
tissue.54 Immune escape, together with increase permeability of the reticulated 
crypt epithelium, may be the source of persistent HPV infection and subsequent 
carcinogenesis. This theory is supported by the observation that HPV-associate 
OPSCC originates within the crypts of this lymphoepithelial region.55,56 
 
Temporal studies have supported HPV as the causative role in the increase of 
OPSCC. Nasmanet al (2009) analysed the increased incidence of tonsillar 
cancer in the Stockholm area between 1970 and 2007. They showed that the 
percentages of tonsillar cancers that were HPV-positive was 23%, 29%, 57% 
and 79% during the 1970s, 1980s, 1990s and  
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2000–2007, respectively.57 Similarly, in the UK, Scacheet al (2011) 
demonstrated an increase in the prevalence of HPV positivity in OPSCC 14% 
to 57% in the period between 1998 and 2009.58 In the United States, 
Chaturvediet al (2011) confirmed the temporal increase in the proportion of 
OPSCC that were HPV positive from 20% in 1988 to more than 70% in 
2004.59,60 
 
The last 25 years has seen an exponential growth in the literature surrounding 
this field, and there is now a strong and consistent molecular evidence base for 
a causal role of HPV in OPSCC. Indeed, in 2009 HPVwas authoritatively 
recognised as a causal agent in the development of OPSCC.61 
 
1.2 HPV 
1.2.1 Classification of HPV 
HPV is an epitheliotropic virus with an average size of approximately 8000 
base pairs (bp).62More than 100 different types of HPV have been identified by 
DNA sequence analysis.63 HPV subtypes can generally be divided into low- 
and high-risk groups. Low-risk groups, for example HPV-6 and HPV-11, are 
associated with benign lesions such as cutaneous or genital warts and 
laryngeal papillomas. There are approximately 15 high-risk types, so called 
because of their association with malignant neoplasm. The most common high-
risk types are HPV-16 and HPV-18.63  
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There are several evolutionary genera of HPV (Figure 1.1). The main groups 
are the Alpha and Beta papillomaviruses. Classification of papillomaviruses is 
based on the nucleotide sequence of the major capsid protein, L1, which 
categorises viruses into genera.64 These account for approximately 90% of the 
known HPV subtypes. The Alpha papillomaviruses make up the largest group 
that contains the high-risk mucosal subtypes responsible for both cervical 
carcinomas and OPSCC. HPV-16 is the most common high-risk subtype in the 
general population from alpha papillomaviruses, and isresponsible for 
approximately 70% of cervical carcinomas and 85-90% of HPV associated 
OPSCC.8,65-67 Beta papillomaviruses are usually associated with benign 
cutaneous infections. However, in immunocompromised patients, these 
infections can be associated with the development of non-melanoma skin 
cancer. The remaining types of HPV belong to the Gamma, Mu and Nu genera. 
These cause cutaneous warts (verrucous and palmar warts) and are not 
associated with malignancy.68  








Figure 1.1. The evolutionary genera of HPV. 
Phylogenetic analysis based on the L1 open reading frame (ORF) sequences of HPV 
types.68  
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1.2.2 Structure of HPV 
HPV is a small (50-55 nm in diameter), non-enveloped circular double stranded 
DNA virus with an icosahedral capsid coat.62 The viral genome can be 
considered as having three distinct regions (Figure 1.2). 
1. A non-coding upstream regulatory region of 400 to 1000 bp, also called 
the long control region (LCR, 10%), or the upper regulatory region 
(URR), located between the L2 and E6 open reading frames. 
2. An early region (50%), consisting of ORFs E1, E2, E4, E5, E6, and E7, 
which are involved in viral replication and oncogenesis. 
3. A late region (40%), which encodes the L1 and L2 structural proteins for 
the viral capsid.69 
 
The three regions in all papillomaviruses are separated by twopolyadenylation 
(pA) sites; early pA (AE) and late pA (AL) sites.
70  








Figure 1.2. Genome organization of Human papillomavirus type 16. 
Schematic representation of the HPV-16 genome showing the location and functions of 
the early (E) and late genes (L1 and L2) adapted from Malik H et al.71  
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1.2.3 HPV proteins 
1.2.3.1 E1 and E2 
E1and E2 are involved in viral DNA replication and the regulation of early 
transcription. E2 binds to the non-coding region of the viral genome and forms 
a complex with E1, thus bringing E1 into approximation with the origin of 
replication.72 
 
In lesions containing HPV in the nucleus as episomes (circular 
extrachromosomal element), the E2 protein directly represses the expression of 
other early genes as a mechanism to regulate the copy number. The relative 
abundance of E2 proteins within the cell is an important factor regulating 
papillomavirus DNA replication. It is suggested that the viral copy number 
remains relatively constant in HR-HPV-positive cells, which indicates that 
regulatory circuits are active to control copy number.62 In addition to full-length-
form of E2, several papillomaviruses (PV) express a spliced mRNA which links 
a splice donor site in E1 to the major splice acceptor site in the E2/E4 region. 
This transcript encodes an E8^E2C (or E8/E2) protein which consists of the E8 
gene product fused to the C-terminal half of E2, which mediates sequence-
specific DNA binding and dimerization of E2 proteins.73,74 Genetic analyses 
have revealed that E8^E2C is a potent inhibitor of the genome replication.75 
Hence E2's prime function for viral DNA replication is to enhance E1 binding to 
the origin and recruitment of cellular proteins that contribute to viral DNA 
replication.76  
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Integration of the HPV genome in the host cell chromosome usually disrupts E2 
expression, causing a deregulated expression of early viral genes, including E6 
and E7, and this event can favour the transformation of human cells and the 
transition into a malignant state as the integrated viral transcripts confer 
stronger transforming capacity than those derived from episomes, due to longer 
half-life of transcripts. However, unlike models of HPV-induced cervical 




The 17 kDa E4 is a cytoplasmic protein. Although expressed at low levels 
during the early phase of viral infection, expression of E4 increases 
dramatically during the late phase of infection, when viral particles are 
produced and released, hence it is a facilitator of viral genome packing and 
maturation of the viral particles and is expressed together with the capsid 
proteins in the upper layers of the epithelium.72,79 The mRNA encoding E4 is 
the most abundant and it has been proposed that the HPV E4 protein can 
account for up to 20-25% of the cell’s total protein content.80 
 
1.2.3.3 E5 
The 8-10 kDa E5 protein is a small hydrophobic peptide, approximately 83 
amino acids in size that localises primarily to the endoplasmic reticulum. When 
expressed alone, HPV E5 has weak oncogenic properties. However, HPV E5 
can enhance the transforming activity of E6 and E7, suggesting that  
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it may have a supportive role in tumour progression.72,81,82 It has also been 
suggested that E5 increases cellular proliferation in the presence of EGFR and 
increases its activation.83,84 The coding sequence for this protein is frequently 
deleted or disrupted in the process of viral DNA integration in established or 
later infection, leading to the presumption that its persistent expression is not a 
fundamental requirement or necessity for ongoing oncogenesis.85 
 
1.2.3.4E6 
The16-18 kDa E6 is a main transforming protein.72,86,87 It is a 151 amino acid 
protein in length containing four cysteine arrays comprising two relatively large 
zinc fingers, which together are needed for full function.88 The E6 oncogene is 
expressed as full-length or as alternate transcripts designated E6*I and E6*II. 
Alternate E6* expression has been implicated in oncogenesis and may be 
related to viral integration and/or loss ofregulation by E2.89 The sequences of 
the E6*I and E6*II proteins are almost identical, differing only in the last two to 
five amino acids. Thus, it appears likely that the carboxy-terminal region of E6*I 
is important in mediating some of its effects.90 
Intriguingly, E6 protein has very limited enzymatic activities and nearly all of the 
activities are inducted by protein–protein interactions (Figure 1.3).91 E6 
associated protein (E6AP), is an enzyme that in humans is encoded by 
the ubiquitin-protein ligase E3A (UBE3A) gene. This enzyme is involved in 
targeting proteins for degradation within cells. E6AP is one of the initial and  
  Chapter 1. Introduction 
 
 38 
most common proteins to interact with E6.92 p53 is one of the key targets of E6 
protein.93 E6 binds directly to E6AP causing the degradation of p53 through the 
ubiquitin proteasome pathway and removes the cell cycle checkpoint control 
(G1/S and G2/M) usually provided by p53, preventing apoptosis and promoting 
the replication of viral DNA.94Studies have suggested that E6AP is not involved 
in the regulation of p53 levels in cells that do not contain E6.95,96 Advances 
have been made at blocking E6AP activity, either by the use of antisense 
oligonucleotides or dominant negative mutants, resulting in increased levels of 
p53 in HPV-positive, but not in HPV-negative cells, confirming that E6AP plays 
an essential role in E6-directed degradation of p53 protein.95,96 
 
However, under stress conditions, e.g. radiation and drugs, the expression of 
E6 oncoprotein is supressed, the degradative pathway is inhibited and p53 is 
both stabilised and activated.97 
 
The binding of E6 to p53 varies between low and high-risk HPV types.98 
Although low risk HPV E6 can bind to p53, it does so with reduced affinity and 
is largely unable to bind to E6AP or induce p53 degradation.99,100E6 can also 
inhibit the transcriptional activities of p53 independently ofE6AP.101 Three 
different mechanisms have been proposed to explain E6AP-independent p53 
inactivation. 
1. The inhibition of p53 binding to its target sequence in the genome.102,103  
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2. E6 may be able to inhibit p53 signalling by maintaining it within the 
cytoplasm.104 
3. E6 with the histone acetyltransferases p300, CREB binding protein 
(CBP) and ADA3, transcriptional co-activators essential for cell growth 
and differentiation prevents p53 acetylation (Ac), inhibiting the 
transcription of p53-responsive genes.105,106 However, unlike p300, E6 
interaction with hADA3, a transcriptional co-activator protein (part of 
histone acetyltransferase complexes) results in hADA3 degradation 
suggesting a mechanism for inhibiting p53 activation by blocking the 
p14/ARF pathway.107 
 
Several functions of high-risk E6 enable inhibition of apoptosis in a p53 
independent manner. HPV-16 E6 oncoprotein interacts with the extrinsic 
apoptotic pathway by binding to and altering the functions of upstream 
signalling molecules. It can bind to the TNF receptor-1 (TNFR1) and 
subsequently inhibit TNFR1 induced apoptosis.108E6 also interacts withthe 
adaptor protein FAS-associated protein with death domain (FADD) and 
caspase 8 to block cell death in response to FAS and TRAIL. E6 can also 
interfere with induction of the extrinsic and intrinsic (mitochondrial) apoptotic 
pathways through interactions with the pro-apoptotic Bcl2 members BAK and 
BAX and down-regulates caspase dependent apoptotic cascade.109,110 
 
E6 also inhibits the immune response by interacting with host interferon 
regulatory factor-3 (IRF3). E6 inhibition of IRF-3 transcriptional activity impairs 
the induction of interferon beta (IFNβ) in response to viral
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infection.111 The interaction of HPV-16 E6 with IRF-3 and the inhibition of its 
transactivation function could contribute to the ability of the virus to disrupt the 
cellular antiviral response.111 
 
High-risk E6 also stimulates cellular immortality. In normal somatic cells, each 
cell division results in shortening of telomere length, a system of cellular 
ageing. The interaction of E6 with transcription factor SP1 also known as 
specificity protein, myelocytomatosis oncogene cellular homolog (Myc), a 
nuclear transcription factor, X box-binding protein-123 (NFX123) and E6AP 
activates telomerase reverse transcriptase (TERT) and telomerase, preventing 
telomere shortening in response to persistent proliferation and in turn 
promoting immortalisation.112 
 
Unlike low-risk HPV, high-risk HPV-16 E6 contains a PDZ domain.113PDZ 
domain or binding motif is an abbreviation combining the first letters ofthree 
proteins, post synaptic density protein (PSD95), drosophila disc large tumour 
suppressor (Dlg1), and zonula occludens-1 protein (zo-1), which were first 
discovered to share the domain. On account of this motif, E6 is capable of 
interrelating with a large number of cellular proteins that contain PDZ domains 
that are mostly involved in regulation of processes associated with the control 
of cell attachment, cell proliferation, cell polarity and cell signalling.114 The 
targeted degradation of PDZ domain-containing cellular proteins results in 
cellular transformation owing to loss of cell-cell contact and loss of polarity, and 
may play a role in tumour metastasis by interrupting  
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normal cell adhesion.115 The key oncogenic functions of HPV-16 E6 are 
summarised in Figure 1.3. 
 
 
Figure 1.3. Summary of key oncogenic functions of HPV-16 E6. 
High-risk E6 proteins inhibit p53-dependent growth arrest and apoptosis in response to 
aberrant proliferation through several mechanisms, resulting in the induction of 
genomic instability and the accumulation of cellular mutations. Formation of an E6–
E6AP–p53 trimeric complex results in p53 degradation, and the interaction of E6 with 
p300, CBP and ADA3 prevents p53 acetylation (Ac), inhibiting the transcription of p53-
responsive genes. E6 also inhibits apoptotic signalling in response to growth-
suppressive cytokines through interaction with the tumour necrosis factor (TNF)-α 
receptor TNFR1, FADD and caspase 8, and through the degradation of pro-apoptotic 
BAX and BAK. E6 interaction with SP1, MYC, NFX123 and E6AP activates telomerase 
reverse transcriptase (TERT) and telomerase, promoting immortalisation. E6-mediated 
degradation of PDZ proteins leads to loss of cell polarity and induces hyperplasia. E6 
subverts the interferon (IFN) response through interaction with IRF3.  




Another major transforming protein, E7, is a small 11kDa protein with a role 
both in immortalisation and cellular transformation.72,116 The primary function of 
E7 protein is that it binds with cullin 2 ubiquitin ligase complex and causes 
ubiquitination of the retinoblastoma tumour suppressor protein (pRb) through 
proteosomal degradation.117 When E7 binds to pRb, the transcription factor E2F 
is released from the latter and this stimulates the transcription of the vital cyclins 
and cyclin dependent kinases for G1‐S phase transition.118 E7 also interacts 
with pRbrelated pocket proteins, p107 and p130, and the cyclin dependent 
kinase inhibitors (CDK) having a further inhibitory effect on cell cycle arrest.110 
 
Functional inactivation of pRb by E7 also induces an up-regulation of p16INK4A 
(p16) expression. Overexpression of p16 has often been used as an important 
marker for HPV E7 activity.118 In addition, E7 can also interact with cyclin A, 
cyclin E and histone deacetylases.119,120The expression of cyclins A and E, 
regulatory subunits of CDK2, is induced by E2F and thus is increased by E7.121 
 
1.2.3.6L1 
This major capsid protein is the major determinant for attachment to cell surface 
receptors.122 It is highly immunogenic and has conformationalepitopes that 
stimulate the production of neutralising type-specific antibodies against the 
virus.123  




As a minor capsid protein, L2 contributes to the binding of the virion to the cell 
receptor (Kapβ2 and Kapβ3), supporting its uptake, transference to the nucleus, 
and delivery of viral DNA to replication centers. L2 with L1 helps the packaging 
of viral DNA into the capsids.124,125,126 
 
1.2.3.8 LCR 
LCR is a segment of about 850 bp, has no protein-coding function and is the 
origin of replication and regulation for HPV gene expression. It is only 
expressed in squamous epithelial cells which are terminally differentiated.127 
 
1.2.4 Role of HPV in carcinogenesis 
Much of what is known of the initial phases of HPV infection has been 
determined using models of cervical cancer and pre-cancer. In the context of 
cervical carcinogenesis, the HPV life cycle originates with infectious virion 
particles acquiring entry to epithelial basal lamina possibly through micro-
abrasions in the epithelial layer, permitting approach to the basal layer where 
the virus infects basal cells. Within the HNC, the virus favours the 
highlyspecialised reticulated crypt epithelium in lymphoepithelial tissue of 
Waldeyer’s ring.128 These sites lie deep within complex crypts and as such are 
not readily reachable to surface trauma. Therefore, micro-abrasion, as 
suggested, as the initial phase of HPV-associated cervical oncogenesis is not 
likely to play a comparable role the oropharyngeal carcinogenesis; the 
mechanism of initial phases of HPV infection in oropharyngeal mucosa
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remains largely unknown, but may be associated to the distinctive presence of 
transitional mucosa in the oropharynx, predominantly found in the tonsillar 
tissue and which demonstrates histological similarities to the cervical 
mucosa.52,53 Another possibility lies within the genetic features of HPV 16, 
which accounts for more than 90-95% of all HPV associated oropharyngeal 
cancers, as it may facilitate survival in the tonsillar crypt epithelium.55,56 
It is also possible that the invagination of the mucosal surface of the tonsil may 
favour virus capture and maintenance by promoting its access to basal cells.54 
 
Entrance of virions into the basal epithelial cells is an active process. It is 
suggested that heparin sulphate proteoglycans, and in particular syndecan-1, 
play a role in the preliminary attachment and that a secondary receptor (beta 6 
integrin) is then essential for complete infection.129,130 Subsequent to receptor 
binding, HPV particles enter the cell via endocytosis. They are then 
disassembled in lysosomes and the genome is moved to the nucleus, the L2 
capsid protein enables the progression. The viral genome is established within 
the nucleus of the host cell as an episome, i.e. the viral genome is not 
integrated with that of the host cell, once a cell is infected. This stage 
progresses with the assistance of viral proteins E1 and E2, resulting in 
augmented number of infected cells and multiple copies, resulting in the 
establishment of 20 to 100 copies of the viral episome within each basal cell.131  
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Replication of the HPV genome is highly dependent on the reproductive cellular 
processes of the host and exclusively occurs in dividing cells.132 As the HPV-
infected keratinocytes travel toward the epithelial surface upon differentiation, 
distinctive viral genes are expressed, allowing high viralgenome amplification 
and the expression of the late region genes (L1 and L2) that encode the viral 
capsid proteins. As the cells get to thesurface, the HPV episomes are packed 
within the capsids for final viral assembly and release of mature infectious 
virions.131 
 
Frequently, the infection becomes latent and no infectious virus is produced, 
although HPV DNA can be detected in desquamated cells. A large proportion of 
the healthy population is infected with high risk- HPV (HR-HPV) but malignant 
transformation is comparatively rare, and transient infection is usually cleared 
by immunological mechanisms within 1-2 years.133,134 However, in some 
individuals, rare malignant transformation occurs where viral persistence, 
arguably the most important factor in malignant progression, with HPV E6 and 
E7 oncogenes increasing cellular proliferation in the basal and supra basal 
levels by pushing the cells into S-phase. Integration events can disrupt E2, 
allowing up-regulation of the HPV E6 and E7 oncogenes, which then further 
promotes growth promotions and genomic instability by binding and targeting 
p53 and Rb proteins for degradation, respectively (Figure 1.4).135 
 
Nevertheless, it should be emphasised that much of what is known about HPV-
induced malignant transformation has been determined in models of
  Chapter 1. Introduction 
 
 46 






Figure 1.4. Schematic view of the roles of HPV-16 E6 and E7 in HPV infection   of 
a mucosal cell. 
Both viral episome or integrated forms of the viral DNA are capable of expressing viral 
oncoproteins such as E6 and E7 that are able to degrade p53 and inhibit pRb, 
respectively. E7 oncoprotein with dissociation of pRb and E2F causes a successive up-
regulation of p16INK4A. The figure is modified from Allen et al (2010).136  
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1.2.5 Epidemiology of HPV-associated OPSCC 
There appears to be a significant geographic variation in the prevalence of HPV 
in OPSCC. A systematic review by Kreimeret al (2005) reported that the 
proportion of OPSCC attributable to HPV was 35.9%, with 47% in North 
America, 46% in Asia, 36% in South/Central America, Australia and Africa, and 
26% in Europe.8 Other reports have indicated variation between countries within 
a given region.  In Europe, prevalence rates range from 20% in the Netherlands 
(1997–2002),137 to 41% in Switzerland (1998–2003),138 55% in Germany 
(1997–2005)139 and 62% in France (1987–2005).140 In the United States, 
prevalence rates are higher, varying from 64% in Texas (2002–2005)141 to 72% 
in Maryland (2000–2006).142 Recently Mehannaet al (2013) showed a sharp 
rise in the proportion of HPV-positive OPSCC over the last decade and a higher 
rate was observed in Europe compared to North America(73.1% versus 69.7 %, 
respectively). The group showed a significant increase in the overall prevalence 
of OPSCC from 40.5% before 2000, to 64.3% between 2000 and 2004 and 
72.2% between 2005 and 2009.143 
 
The reason of the rapid increase in prevalence of HPV positive OPSCCs 
remains elusive. One of the explanationsmay be a change in sexual behaviour, 
i.e., increasing practiceof oral sex and increasing numbers of lifetime sex 
partners.144The reason of the rapid increase in prevalence of HPV positive 
OPSCCs remain has been attributed to change in sexual behaviour, namely, 
increasing practice of oral sex and increasing numbers of lifetime sex 
partners.144 Others have surmised that the reduction in
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prophylactic tonsillectomies increases the reservoir of excess lymphoepithelial 
tissue to persistent HPV infection. Nevertheless, these are still observational 
studies, which lack any interventional evidence. It is, however, unlikely this rise 
is due to more sensitive detection methods, borne out by stringent controls 
adopted in longitudinal studies.145  
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1.3 HPV detection methods 
Diagnostic techniques differ in virus detection sensitivity, required information (a 
broad group of high-risk HPV or specific HPV genotypes), available tissue type 
(fresh frozen tissue, fixed tissue, brush cytology, saliva, serum, fine needle 
aspiration biopsy), the target molecule (DNA, RNA, and protein), labour 
intensiveness, complexity of the procedure, and costs.146,147 
 
Persistent expression of high-risk HPV E6/E7 viral oncogene is a fundamental 
requisite for both the commencement and the continuation of an HPV-driven 
malignant phenotype. As a result, demonstration of transcriptionally active 
oncogenic viral infection on samples derived from fresh tissue has been 
considered to the reference or ‘gold standard’ test. The practical application of 
this test is usually by means of quantitative reverse transcriptase polymerase 
chain reaction (qRT-PCR) amplifying high-risk HPV E6/E7 mRNA 
transcripts.148,149 However, the utility of this reference standard in routine 
diagnosis is unfeasible for practical reasons; diagnostic procedures are mostly 
established on the evaluation of formalin-fixed, paraffin-embedded (FFPE) 
tissue.58 
 
In cells and tissue, the virus may be detected at the levels of DNA, RNA and/or 
protein.  
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1.3.1 HPV DNA 
Target amplification techniques such as consensus (PGMY09/PGMY11, 450 bp 
or GP5+/GP6+, 150 bp) or type-specific polymerase chain reaction (PCR), have 
high sensitivity rates but can detect biologically irrelevant HPV, and is prone to 
contamination resulting in a risk of false positivity.209 DNA in-situ hybridisation 
(ISH) is a signal amplification test which allows direct visualisation of viral DNA 
co-localising with the host nucleus. Although ISH has been shown to have a 
high specificity, its sensitivity limits its use as a single modality test.150,151 
 
1.3.2 HPV RNA 
Reverse transcriptase (RT)-PCR for the detection of HPV E6 mRNA in fresh 
frozen specimens is considered as the reference or ‘gold’ standard for the 
presence of biologically active virus. However, its use in routine diagnosis is 
limited due to reasons of practicality.152 HPV RNA ISH is a novel technique, 
which allows direct visualisation of viral transcripts in FFPE sections.153 In a 
study of 196 OPSCC patients, RNA ISH demonstrated a better sensitivity in 
HPV detection than DNA ISH.154 However it’s a novel technique with limited 
available data and is currently still awaiting European Union in-vitro diagnostic 
(CE-IVD) approval.153  
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1.3.3 HPV proteins 
No commercially available viral protein detection method is currently available. 
However, p16 immunohistochemistry (IHC) is widely used in the diagnostic 
laboratory as a surrogate marker for HPV infection in OPSCC.141 The 
inactivation of pRb determined by HPV E7 is associated with up-regulation of 
CDKN2A with consequent rise in p16. The test is highly sensitive, suitable on 
FFPE material and easy to interpret, it provides proof of transcriptional activity 
of the oncoprotein, easily available commercially, accessible to most 
laboratories and cost effective. However it has low specificity (79-82%) due to 
false positive staining in the absence of HPV infection.155,156 
 
No single standard detecting technique for testing or interpretation of HPV is 
available, each assay have technical limitations with none of the methods 
offering optimal sensitivity and specificity levels. In order to overcome this 
problem, stepwise algorithms that combine different HPV tests have been 
suggested as an approach to counteract the limitations of individual tests. Two 
diagnostic algorithms, applicable in FFPE samples, are considered as clinically 
adequate by several studies and trials. With p16 as a first-line assay, groups 
combined different techniques in order to obtain guaranteed results, for 
instance Smeetet al (2007) used p16 followed by PCR (GP5+/6+), for HPV-
DNA detection, Singhiet al (2010) utilised type-16 specific ISH and Rietbergenet 
al (2013) used E6/E7 mRNA transcripts (RT-PCR).150,157,158  
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1.4 Clinical and pathological features of HPV-
associated OPSCC 
The oropharynx comprises the tonsillar fossa with the faucial tonsil, 
glossotonsillar sulci, soft palate, uvula, lateral and posterior pharyngeal walls, 
vallecula and base of tongue. The squamous mucosa of the oropharynx differs 
from other areas within the head and neck region in that lamina propria of the 
former is composed of lymphoid tissue. Collectively, the lymphoid-rich mucosa 
of the faucial tonsils, base of tongue and adenoids are termed Waldeyer’s ring. 
Furthermore, the surface of the faucial tonsils and base of tongue extend down 
at regular intervals to form crypts. The crypts are lined by a loose network of 
lymphoepithelial tissue known as the reticulated crypt epithelium (Figure 1.5). 
HPV-positive OPSCC originates within the crypts rather than surface 
epithelium.128,159 Within the oropharynx, HPV-positive OPSCC is most prevalent 
in the faucial tonsils, followed by the base of tongue.34,40  















Figure 1.5. Representative photomicrograph of normal tonsil. 
Photomicrograph of low-power (left) and high-power (right) views of normal tonsil 
immunohistochemically stained for pan-cytokeratin demonstrating the greater integrity 
of the surface stratified squamous epithelium in comparison to the crypt epithelium.  
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Further to a strong predilection for lymphoepithelial tissue, HPV-positive 
OPSCC also demonstrates several distinct clinico-demographic features. 
Patients with HPV-positive OPSCC: 
1. Are likely to present with early nodal involvement; approximately 60% of 
these patients present with stage III–IV tumours at diagnosis.160 
2. Tend to be slightly younger with a median age of diagnosis of 54 
years.161 
3. Have a history of minimum exposure to tobacco and alcohol.40,162,163 
4. Hail from higher socioeconomic and educational backgrounds.164 
5. Are three times more likely to be male rather female.152 
6. More likely to be of White rather than Black or Asian ethnicity163,165,166 
 
HPV-positive OPSCC has distinct histological features exhibiting a mainly non-
keratinising morphology in contrast to HPV-negative HNSCC where significant 
keratinisation is usually seen (Figure 1.6).167 The reticulated crypt epithelium, in 
its normal state, is non-keratinised. Therefore, the non-keratinising phenotype of 
HPV-associated OPSCC may be explained by its recapitulation of the 
reticulated crypt epithelium. It is also possible, that the non-keratinising 
characteristic of the reticulated crypt epithelium renders it more susceptible to 
persistent HPV infection.168  








Figure 1.6. Comparative histomorphology of HPV-positive and HPV-negative 
OPSCC. 
Comparative histomorphology of HPV-positive (top, non-keratinising) and HPV-
negative (bottom, keratinising) OPSCC.H&E original magnification x 40.  
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1.5 Genetic distinctiveness of HPV-positive OPSCC 
 
In general, HPV-positive OPSCC contain fewer and distinct genetic mutations 
compared to HPV-negative tumours. Despite these indications that HPV status 
is associated with molecular and clinical differences, all HNSCCs are clinically 
managed irrespective of their HPV status. Understanding of genetic differences 
between HPV-positive and HPV-negative HNSCC tumours might allow to 
develop biomarkers for early detection or recurrence surveillance, to identify 
therapeutic targets, and to begin individualisation of treatment based on the 
biology of these tumours. 
 
Combined data from four independent studies, namelyAgarwalet al (2011)20, 
Stranskyet al (2011)21, Lechneret al (2013)169 and Seiwertet al (2014)170indicate 
that HPV-positive HNSCC harbor fewer gene mutations HPV-negative OPSCC. 
However, there appears to be several consistent gene mutations in HPV-
positive tumours.For instancephosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit alpha (PIK3CA) was the most commonly mutated gene found 
in HPV-positive cancer cells (24% in HPV-positive HNSCC versus 8% in HPV-
negative HNSCC) followed by E1A binding protein (EP300), a gene that plays 
an essential role in regulating cell growth and division, prompting cellular 
differentiation, and preventing the growth of cancerous tumours (6% in HPV-
positive HNSCC versus 3% in HPV-negative HNSCC). Fibroblast growthfactor 
receptor 3 (FGFR3) (7% in  
  Chapter 1. Introduction 
 
 57 
HPV-positive HNSCC versus 3% in HPV-negative HNSCC), V-Ki-ras2 Kirsten 
rat sarcoma viral oncogene homolog (KRAS), a gene that performs an essential 
function in normal tissue signalling (6% in HPV-positive HNSCC versus 2% in 
HPV-negative HNSCC). On the other hand TP53 was mutated in HPV-negative 
tumours with the highest rate of 79% (84 of 107) compared to 4% (3 of 83) of 
HPV-positive samples. Mutation rate of NOTCH1 was lower in HPV-positive 
(8%) compared to HPV-negative HNSCC samples (16%). CDKN2A was only 
found in 11% of the HPV-negative samples, none in HPV-positive samples. 
 
Braakhuiset al (2004)following determining presence of HPV DNA and E6/E7 
mRNA by PCR in 143 consecutively treated HNSCCs correlated HPV status 
with mutations in the gene encoding p53 (TP53) and loss of heterozygosity 
(LOH) in a number of chromosomes generally found to be affected in HNSCC. 
The group observed that HPV-positive tumours had generally lower levels of 
LOH with significantly lower levels of p53 mutations than HPV-negative 
tumours. In the HPV-negative tumours, most LOH was found on chromosomes 
3p (encodes several tumour suppressor genes), 9p (encodes CDKN2A) and 
17p (encodes TP53).137 
 
In addition to fewer mutations per tumour, HPV-positive OPSCCs also have 
been reported to demonstrate distinct DNA gains and losses when compared to 
HPV-negative tumours. Dahlgren et al (2003) investigated the pattern of DNA 
losses and gains in 25 tonsillar tumours, of which 60% were HPV-positive. 
Eleven of 15 HPV-positive samples (73%)had gains at
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chromosome 3q (encodes human telomerase gene), compared to 4/10(40%) in 
HPV-negative tumours (p=0.049).171 By contrast, gains at 7q and amplification 
of 11q13 (encodescyclin D1) were more common in HPV-negative tumours and 
were independently associated with poorer outcome.171 
 
1.6 Improved survival of HPV-positive OPSCC 
It is now well established that HPV-related OPSCC not only represents a 
distinct subtype of HNC but is also associated with a better prognosis. In a 
retrospective study, Gillisonet al (2000) were among the first authors to identify 
a positive survival benefit in patients harbouring the virus HPV in their tumours. 
There was a 59% reduction in disease-specific death compared to HPV-
negative patients.51 Other early work in support of Gillisonet al resulted from a 
study in Sweden that showed increased overall survival in HPV-associated 
tonsillar SCC (65.3%) compared to HPV-negative counterparts (31.5%).172 
Similarly in the Eastern Cooperative Oncology Group (ECOG) protocol 2399, 
confirmed improved survival outcomes for patients with HPV-positive HNSCC in 
retrospective survival analyses.173,174 A systematic review investigating cancer-
specific survival in HPV-related HNSCCs demonstrated a 72% reduction in 
OPSCC specific mortality.175 
 
Since then, several other retrospective studies showed similar findings, and 
there is now significant evidence that HPV-positive tumours have 
greatlyimproved survival compared to HPV-negative HNSCC regardless of  
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treatment modality (radiation, chemotherapy, surgery or concurrent radio-
chemotheray).138,176 Moreover, there is robust evidence demonstrating a lower 
degree of treatment failure and recurrence in HPV-positive tumours, accounting 
for improved survival rates.177 The improved survival of these patients has 
stimulated the formulation of clinical trials in both North America (RTOG 1016) 
and Europe (De-escalate-HPV) to test the feasibility of de-escalation of therapy 
to reduce acute and late toxicities.143,178 
 
1.6.1 Putative mechanisms of improved outcome in HPV-associated 
OPSCC 
The mechanisms for improved survival in patients with HPV-associated OPSCC 
are yet to be fully elucidated. Improved survival may be caused by a 
combination of several factors including a slightly younger age at diagnosis, an 
inverse correlation with tobacco smoking and exposure to alcohol and good 
performance status with absence of significant comorbidities.152 However, there 
is an increasing body of evidence indicating that the favorable outcome and 
increased survival of HPV-positive OPSCC could be due toinherent sensitivity 
of these carcinomas to chemotherapy and/or radiotherapy.179 In general, there 
are fewer somatic molecular alterations in HPV-positive cancers compared to 
HPV-negative counterparts, the latter containing greater numbers of activating 
mutations of oncogenes and/or inactivating alterations in tumour suppressor 
genes acting to confer a more resistant phenotype.141,180  
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1.6.1.1 Role of p53 
At the molecular level, it has been observed that p53 tumour suppressor 
pathways in HPV-positive cancer cells are intact but dormant, controlled by 
E6.181,182 High-risk HPV-16 E6 proteins are able to bind wild-type p53 and 
mediate p53 degradation in vitro through the ubiquitin–proteasome pathway.182 
Although HPV-positive OPSCC have reduced p53 levels due to abrogation by 
E6, p53 mutations are rare in this group, possibly due to reduced exposure to 
tobacco, and it is possible that any remaining p53 is still functionally able to 
exert its effects on abnormal cells.4,183 In a comparative study by Westraet al 
(2008) none of the HPV16-positive tonsillar carcinomas showed disruptive p53 
mutations compared topresence of disruptive p53 mutations in HPV-negative 
HNSCC (0% versus 57%; p=0.008).183 In HPV-positive tumours p53 is generally 
present in low levels and in an inactive state, cellular stress promotes an 
increase in p53 protein levels. When triggered, p53 functions to activate 
pathways for DNA repair, cell cycle arrest and/or apoptosis, depending upon 
the nature and degree of damage.97 
 
1.6.1.2 Other cell cycle regulatory mechanisms 
In general, cells undergoing mitosis are more susceptible to radiation-induced 
death while cells in late S-phase appear to be relatively radio-resistant. To this 
effect, several groups have demonstrated that, following radiation, HPV-positive 
cells showed prolonged G2-M cell-cycle arrest compared to HPV-negative 
cells.184-186 The greater propensity for cell cycle arrest is critically, regulated by 
checkpoint kinases 1 and 2 (Chk1/2).187  
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There is a growing body of evidence indicating a trend towards inverse 
correlation between HPV status and EGFR expression.188,189 Phosphorylation of 
EGFR is an upstream event in mitogen activated protein kinase (MAPK) and 
phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B/mammalian 
target of rapamycin (PI3K/AKT/mTOR) pathways.190,191 Since both these 
pathways are known to be important positive regulators of cell proliferation and 
growth, it is also possible that the relative lower EGFR expression may be 
important in the less aggressive phenotype demonstrated by HPV-positive 
OPSCCs.188 
 
1.6.1.3 DNA damage response 
Evidence from in vitro studies suggest that HPV-positive OPSCC cells have a 
decreased capacity for genomic repair following exposure to DNA-
damagingagents such as radiation, thereby inducing cell death. Rieckmanet al 
(2013) showed increased mitotic catastrophe in HPV-positive cells as a result of 
residual double-strand breaks (DSBs), as demonstrated by γ-H2AX staining.186 
Furthermore, E7-induces a reduction in sub-lethal DNA damage thereby 
directing HPV-positive cells towards cell death following treatment.192 
Interestingly, increased cell death may be also explained by HPV-induced p16 
over-expression. Doket al (2014) showed p16 interferes with RAD51-associated 
homologous recombination-associated DNA repair, by down regulating cyclin 
D1 protein expression. The end result is failure or misrepair of DSBs with 
resultant cell death.193  
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1.6.1.4 Lack of field cancerisation 
Patients with HPV-positive OPSCC demonstrate a lower incidence of local-
regional recurrences (LRRs) and second primary tumors (SPTs). The 
decreased frequency might be explained by the absence of ‘field cancerisation’ 
effect, which is a crucial aspect of LRRs and SPTs in HPV-negative HNSCC 
patients.194 Field cancerisation in HPV-negative tumors is defined as the 
existence of a single or more mucosal fields approximating a tumour that 
comprises of epithelial cells having tumor-associated genetic or epi-genetic 
modifications.195,196Rietbergenet al (2014) showed absence of transcriptionally 
active HPV in 91 out of 97 resection mucosal margins surrounding an HPV-
positive tumour of 20 HPV-positive OPSCC patients, suggesting absence of a 
field cancerisation.197 Similarly Begum et al (2005) showed that HPV integration 
is tightly coupled to the neoplastic process and did not occur outside of the field 
of phenotypically altered cells.159 Other studies have also shown discrete 
boundaries of p16-immunostaing in HPV-positive tonsillar carcinomas that 
distinguish tumor from adjacent uninvolved mucosa.198,199 
 
1.6.1.5 Tumour microenvironment 
It is also suggested that HPV-positive HNSCCs are less hypoxic than the 
negative counterparts and that this apparent lack of hypoxia in HPV -positive 
tumors could be linked to the superior prognosis observed.200,201As HPV-
associated OPSCC appears in the lymphoid tissue of the tonsils and the base 
of the tongue the tumours can generally be characterised by infiltration  
  Chapter 1. Introduction 
 
 63 
of lymphocytes in the stroma and tumour nests.202 A possible account for 
survival advantage may be the tumour-infiltrating T lymphocytes (TILs) that 
infiltrate many HPV-positive OPSCC and generate a defensive effect by an 
adaptive host immune response conducted against viral antigens such as E6 
and E7.203,204 HPV-16-specific CD8-positive T cells have been identified in the 
blood of HPV-positive OPSCC patients and lately, isolated from tumours, 
implicating a role in the anti-tumour response.204-206 
 
1.7 Management of HNSCC 
Numerous treatment modalities including surgery, radiotherapy, chemotherapy 
and/or a combination of these exist for HNSCC. For practical purposes, HNC is 
divided into three clinical stages: early, loco-regionally advanced, and 
metastatic or recurrent.207The clinical management assessments for HNSCC 
are based on the evaluation of the tumour size, regional nodal status and 
distant metastasis (TNM).208 The TNM status is classified into tumour stage 
where patients at stages I or II can be categorised into early and stages III or IV 
as advanced, taking into account metastatic or recurrent disease.208Treatment 
approaches can vary depending on the disease stage. In general, patients with 
early stage disease experience a more satisfactory prognosis,209 whereas those 
with advanced stage disease have a notably poorer clinical outcome.210 
Factorsthat influence the choice of treatment include primary site, stage at 
presentation, age and co-morbidities. For example, the preferential treatment 
option for tumour stages I and II of the oral cavity is surgery with or without  
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post-operative radiation (RT) or chemo-radiation therapy (CRT) when 
indicated.211 For HNSCC located in the pharynx, early stage patients are treated 
with RT alone and more advanced disease (stages III and IV) are treated with 
CRT.208,212 
 
Radiation therapy is the use of high-energy x-rays or other particles to induce 
cancer cell death. A radiation therapy regimen usually consists of a specific 
number of treatments given over a set period of time. It can be as a single 
modality treatment, or as adjuvant treatment following surgery, depending on 
stage, nodal and margin status. Radiation results in DNA damage in the form of, 
intra- and inter-strand cross-links and single and double strand breaks (DSBs). 
Unrepaired DSBs are thought to be the main cytotoxic lesions.213 The 
interaction of radiation with tissues results in the production of free radicals. 
Free radicals are short-lived but their half-life is increased in the presence of 
oxygen, which is said to fix the radicals and increase the chances of interacting 
with DNA. Hypoxia is associated with production of fewer radiation-induced free 
radicals, reducing their overall interaction with DNA thereby causing less 
radiation-induced DNA damage and a reduction in tumour cell killing.214 
 
Probably the most commonly used single chemotherapeutic agent, in HNSCC is 
cisplatin. It can be administered as first line therapy, neoadjuvantor induction 
(prior to surgery and/or RT), concurrent chemo-radiotherapy (administered at 
the same time as RT) or as an adjuvant therapy following surgery or 
radiation.215Cisplatin acts via crosslinking DNA and making its
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repair impossible, thus activating apoptosis in quickly dividing cells.216 Because 
of its different spectrum of toxicity, methotrexate, carboplatin and oxaliplatin 
have also been used in cases of recurrent and metastatic HNSCC.217,218,219 
 
In order to improve patient outcome and minimise the toxic side effects of less 
specific cytotoxic agents such as cisplatin, increasing emphasis is being placed 
on targeting malignant cells while sparing healthy normal cells from toxic 
therapeutic effects. Prospective targeted therapies in HNSCC principally aim at 
cellular pathways of carcinogenesis.220,221 One such molecular target includes 
EGFR.24 EGFR is a type 1 transmembrane receptor tyrosine kinase (RTK) that 
is involved in numerous aspects of HNSCC pathogenesis. It is one member of a 
superfamily of such receptors, including c-erbB-2 (human epidermal growth 
factor receptor 2(Her-2/neu)), c-erbB-3, and c-erbB-4. The EGFR is activated by 
ligand binding followed either by homodimerisation, or heterodimerisation with 
another member of the EGFR superfamily.190,222 Anti-EGFR agents including 
monoclonal antibodies against the EGFR (cetuximab) and EGFR tyrosine 
kinase inhibitors (TKIs, Gefitinib and Erlotinib) are currently used for the 
management of various types of cancer.223 Cetuximab is a chimeric monoclonal 
antibody that attaches with high affinity at the endogenous ligand-binding site of 
EGFR preventing dimerisation, internalisation, andautophosphorylation, thereby 
inhibiting downstream signalling cascades involved in cellular proliferation. 
Furthermore, it has also been shown that cetuximab promotes EGFR 
degradation, and has antibody-dependent  
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cell-mediated cytotoxicity effects.224 In combination with radiotherapy, 
cetuximab improved survival of HNSCC patients to 49 months compared to 
29.3 months for radiotherapy alone.225Several studies have confirmed that 
EGFR inhibition sensitises HNSCC to the effects of radiation therapy.226-228 
In recent years, the novel targeted therapeutic agent tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL) has been evaluated for its potential in 
the management of several types of cancer. It is an increasingly attractive 
therapeutic option because of its relatively restricted expression on tumor cells 
and its ability to act in concert with various chemotherapeutic agents to promote 
tumor cell death.229 Although the efficacy of recombinant TRAIL for the 
treatment of HNSCC is yet to be determined, this agent has been tested in 
clinical trials for a wide variety of epithelial derived cancers such as breast, 
colon, renal and lung cancers.230 TRAIL is a tumour necrosis factor (TNF) 
receptor family ligand that initiates apoptosis through the extrinsic pathway by 
binding itself to the death receptors (DR4 and DR5). This leads to 
oligomerisation of the death receptors and formation of the death inducing 
signalling complex (DISC) followed by recruitment of the adaptor molecule, Fas-
associated protein with death domain (FADD) and procaspase-8. DISC 
assembly stimulates the auto-cleavage and activation of caspase-8 resulting in 
activation of the effector caspase (caspase-3) that eventually leads to apoptotic 
cell death (Figure 1.2).231-234 
 
The major current limitation of TRAIL therapy is the development of resistance 
to this agent in cancer cells through a variety of mechanisms.  
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1. TRAIL interacts with two agonistic receptors, namely TRAIL-R1 (DR4) 
and TRAIL-R2 (DR5) both capable of signalling apoptosis. TRAIL is also 
able to bind to three antagonistic (non-signalling decoy) receptors TRAIL-
R3 (DcR1), TRAIL-R4 (DcR2) and osteoprotegerin (OPG) that may 
function by sequestering TRAIL extracellularly.235-238 In some cases, 
increased expression of these decoy receptors has been correlated with 
TRAIL resistance in tumour cells.239 
2. Other mechanisms that inhibits TRAIL signalling includes increased 
expression of inhibitors such as cellular FLICE-inhibitory protein (c-FLIP), 
it has sequence homology to caspase-8, but lack protease activity, 
therefore it is suggested that the recruitment of c-FLIP to the DISC in 
place of caspase-8 blocks their activation and consequently confers 
TRAIL resistance.240 
3. The anti-apoptotic function of family of inhibitor of apoptosis proteins 
(IAPs) that comprises a number of members like X-linked inhibitor of 
apoptosis protein (XIAP), cellular IAP (cIAP1 and cIAP2) have been 
shown to prevent activation of caspases-3, -7 and -9 via direct or indirect 
binding thereby exerting protection against TRAIL-mediated cell 
death.241,242 
 
High-risk HPV is known to drive the oncogenic process by attenuating 
component of the extrinsic apoptotic pathway. In particular, HPV-16 E6 has 
been shown to interact with FADD thereby inhibiting the binding and activation 
of caspase-8. There is also evidence to suggest that HPV-16 E6 causes 
enhanced degradation of caspase-8.243,244Other HPV oncoproteins
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Figure 1. 7. Schematic representation of the extrinsic pathway. 
Binding of TRAIL and trimerisation of TRAIL death receptors leads to the recruitment of 
FADD, and procaspase-8. Together these comprise the DISC. This initiates the 
activation of initiator caspase 8, once active it propagates apoptosis via direct cleavage 
of caspase 3.  
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1.8 Management of HPV-positive OPSCC 
Currently, radiotherapy is the most commonly used single modality in patients 
with early-stage OPSCC (stage I/II). 246,247 The treatment of patients with locally 
advanced or stage III/IV OPSCC disease involves combination of surgery, 
radiotherapy and chemotherapy.248 For instance, surgery with adjuvant 
radiation or chemo-radiation with chemotherapy being added for high-risk 
pathologic features found from the surgical specimen,249-252 or radiotherapy with 
concomitant chemotherapy.253-255 
 
The increase in the incidence of HPV-associated OPSCC over the past decade 
has been paralleled with the observation that there is significant overall- and 
disease-free survival (DFS) advantage for patients with these tumours 
compared to HPV-negative counterparts.51,141 Despite the survival advantage, 
HPV-positive and HPV-negative OPSCCs are treated using similar traditional 
standard treatment modalities resulting in possible avoidable toxicities and 
decreased quality of life in HPV-positive patients.256 This has led to some 
authorities to suggest the possibility of offering different treatment regimens for 
HPV-positive and HPV-negative tumours. Although there is currently insufficient 
evidence to support the modification of treatment based on HPV status alone, 
several clinical trials are in progress towards de-escalation of treatment intensity 
in HPV-positive OPSCC with the intent to reduce toxicity and thereby improve 
the long-term quality of life, while maintaining efficacy and without 
compromising outcomes. Possible de-escalation options include reducing 
radiotherapy dosages, withholding
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chemotherapy or replacing chemotherapy with targeted therapies such as the 
EGFR monoclonal antibody, cetuximab. 
 
Current on-going de-intensification trials include Eastern Cooperative Oncology 
Group (ECOG)1308, Radiation Therapy Oncology Group (RTOG 1016), De-
ESCALaTE HPV, NCT1088802/J0988, Trans-Tasman Radiation Oncology 
Group-TROG 12.01, quarterback trial, ADEPT, ECOG 3311 and PATHOS. 
These de-escalation trials are mainly based on reduction in radiotherapy 
intensity (from 70Gy down to 54Gy) or on the substitution of cisplatin with 
cetuximab in concurrent chemotherapy regimens.257-265 Many of the de-
escalation trails for instance RTOG 1016, TROG 12.01 and De-ESCALaTE are 
focused on reducing toxicity by replacement of cisplatin with cetuximab.266 
Preliminary results from ECOG 1308 appear to suggest it may be possible to 
safely reduce radiotherapy dose in a selected cohort of HPV-positive OPSCC 
patients, however the final data on progression free survival and overall survival 
are pending.257 
 
HPV-positive OPSCC may achieve specific targeting of HPV-positive tumour 
cells due to the unique expression of E6 and E7 oncoproteins. For example, 
suppression of cellular E6 and E7 protein levels by short hairpin RNA is able to 
restore p53 and pRb function and induce apoptosis in cell line studies.267 As a 
consequence, small molecule inhibitors that inhibit the protein-protein 
interaction of the viral oncoproteins E6 and E7 are actively being investigated, 
which may sensitize tumor cells to other therapies.268 For instance small 
molecules could inhibit E6 from binding to procaspase 8 and  
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FADD and in turn would restore the normal functioning of the apoptosis 
pathway.269 
 
Tumor expression of E6 and E7 may also provide the possibility of inducing or 
enhancing cell-mediated immunity against tumor cells.270 Harvesting, expanding 
and re-administering tumor-infiltrating lymphocytes to patients with HPV-
associated OPSCC in order to enhance the cytotoxic anti-tumoural immune 
response to these tumours may also be potential treatment strategy.271 
 
Another advancement creating interest in the field of oncology is the inhibition 
of programmed cell death-1 (PD-1) or its associated ligand (PD-L1).272PD-1, 
functions as an immune checkpoint and plays a significant role in down 
regulating the immune system by inhibiting the activation of T-cells.273 
Significant expression of PD-L1 has been shown on HPV-associatedHNCs.274A 
recent study has suggested a role for PD-1–PD-L1 interaction in the initial HPV 
infection and subsequent immune resistance of HPV-associated tonsillar 
cancer.274Initial reports of single agent PD1 monoclonal antibody (mAb), 
MK3475 (MK-3475 is a highly selective, humanised IgG4/kappa isotypemAb 
designed to block PD-1 interaction with its ligands PD-L1 and PD-L2) used for 
checkpoint inhibition and reactivation of the immune system, from the Keynote-
012 trial have been very promising, with a significant percentage of patients 
with recurrent and metastatic HNSCC demonstrating PD-L1 positivity and with 
>50% of patients demonstrating objective responses to treatment.275  
  Chapter 1. Introduction 
 
 72 
These approaches have the intrinsic benefit of using physiologic anti-tumoural 
responses as a treatment modality that theoretically carries decreased risk and 
morbidity otherwise seen in conventional treatments with substantial toxicities. 
 
1.9Rationale, aim and objectives of this study 
In parallel to the ‘epidemic’ rise of HPV-associated OPSCC, there is robust 
evidence to indicate a significantly improved disease-specific and overall 
survival outcome following treatment in these patients compared to HPV-
negative HNCs.4 The mechanisms for improved outcome in HPV-positive 
OPSCC is still poorly understood. The overall aim of this study is elucidate 
potential mechanisms of improved response to therapeutic agents in HPV-
associated HNC. In the longer term, it is anticipated that identification of 
potential mechanisms of improved response in HPV-positive HNC cells may be 
exploited to improve survival outcomes in all HNC patients. 
 
Specific objectives of this study were to: 
 
1. Develop an in vitro cell line model for increased relative sensitivity to 
conventional (radiation and cisplatin) and targeted (cetuximab and 
TRAIL) therapeutic agents in HPV-positive HNC. 
 
2. Evaluate the functional role of p53 and HPV16-E6 in the differential 
response of these cells to radiation, cisplatin, cetuximab and TRAIL.  
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3. Determine whether response to cetuximab in vitrocorrelates with EGFR 
protein expression.  
 
4. Compare HPV status and EGFR protein expression in the cell line model 
with OPSCC tissue specimens and correlate overall survival in the latter. 
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2.1   Materials 
2.1.1   Plastics 
Plastics used in tissue culture were purchased from Griener Bio-one, UK (6, 12, 
24 and 96 well plates; 5, 10 and 25ml pipettes; cell scrapers and cryovials) and 
PAA (T25 and T75 flasks, 15 and 50 ml Falcon tubes, 10 cm dishes). 0.2µm 
and 0.45µm filters were purchased from Fisher Scientific, UK. Cell culture 
media were stored at 4oC. Solutions and Buffers were stored at room 
temperature unless specified. 
 
2.1.2   Chemicals and solutions 




Agarose 100g (Sigma-Aldrich, A9539-100G). 1% (w/v) solution of agarose was 
made up in 100ml 1x TAE (Tris-acetate-EDTA)and boiled to dissolve the 
powder entirely. The solution was cooled down to 32-45oCand ethidiumbromide 
(fluorescent tag-nucleic acid stain) was added to a final concentration of 
0.5µg/ml. 
 
Albumin from bovine serum (BSA) 
1mg/ml ofBSA (SLS, A9647-50G).
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Ammonium persulfate (APS) 
10% APS solution was made up in dH2O and stored at 4
oC for a maximum of 
two weeks. 
Blocking buffer for western blotting 
5 or 10% (w/v) Marvel milk powder (purchased from Sainsbury’s 
supermarket)added in Tris-Buffered Saline-Tween20 (TBST). 
Cell Lysis Buffer 
2mM MgCl2,25mM HEPES KOH pH 7.4and 2mM EGTA(ethylene glycol tetra 
acetic acid), cell lysis buffer was diluted 1:1 in 2% Triton X-100 and the 
following components were added: protease inhibitors aprotinin and leupeptin 
both at a final concentration of 1µg/ml and PMSF at a final concentration of 100 
µg/ml. 
Coumaric acid 
90mM p-coumaric acid in Dimethyl Sulfoxide(DMSO), stored at -20oC. 
Cisplatin 
Cisplatin 1mg/ml (TEVA UK Ltd) provided by Guy’s Hospital Pharmacy stored at 
room temperature. 
Dimethyl sulfoxide (DMSO) 
DMSO from VWR International (317275). 
Dulbecco's Modified Eagle Medium (DMEM) 
Purchased from PAA (E15-810) and supplemented before use with 50ml ofa 
final concentration of 10/15% fetal bovine serum (FBS) (Sigma-Aldrich,  
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F7524), 1ml 100 x Penicillin/Streptomycin (PAA Laboratories, P11-010) and 5 
ml of 1mM sodium pyruvate (Sigma-Aldrich, UK) in 500 ml of medium. 
 
EDTA buffer 
0.5mM disodium ethylenediaminetetraacetic acid (EDTA) was made up in 
dH2O, pH was adjusted to 8.0 with NaOH (sodium hydroxide), the solution was 
sterilised by autoclaving and the solution was stored at 4oC. 
 
Enhanced chemiluminescence (ECL) buffer 
100mM Tris-HCL (tris [hydroxymethyl] aminomethane hydrochloride) pH 8.5, 
stored at 4oC. 10ml of ECL buffer was mixed with3 µl hydrogen peroxide, 25 µl 
of 90 mM coumaric acids and 50µl of 250mM luminol before use for western 
blots. 
 
Freezing medium for cell culture 
10% Dimethyl sulfoxide (DMSO), 20% fetal bovine serum (FBS) and 70% 
Dulbecco's modified eagle medium (DMEM) / Modified eagle medium (MEM) 
with Earle's salts. The cells were stored at -80oC for a week or two before 
transferring them to the liquid nitrogen tanks.  




Recombinant human isoleucine zipper trimerised TRAIL [(TNF)-related 
apoptosis-inducing ligand] was a kind gift from Professor Henning Walczak, 




Isopropanol extra pure (Fisher scientific, 38971). 
 
Laemmli sample buffer (LSB) 
Buffer comprised of 62 mM Tris base (2-amino-2[hydroxymethyl] propane-1, 3, 
diol[tris]) pH 6.8, 10% glycerol, 2% SDS and 5% β-mercatoethanol. The buffer 
was made up in dH2O and stored at -20
oC. Before use: protease inhibitors 
aprotinin and leupeptin both at a final concentration of 1µg/ml, PMSF at a final 




250mM luminol in DMSO, stored at -20oC. 
 
Luria-Bertani (LB) - agar plates 
1.5%(w/v) agar in LB medium, sterilised by autoclaving were cooled to 50oC 
and appropriate antibiotic was added.  
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MEM with Earle’s Salts (Lonza, BE12-611F) 
50ml of a final concentration of 10% FBS, 5ml of 100 x non-essential Amino 
Acids (PAA Laboratories, M11-003), 5ml of 200mM L-Glutamine (PAA 
Laboratories, M11-004) and 550µl of Gentamicin (PAA Laboratories,P11-004) 
were added into 500ml of medium prior to use. 
 
Midi prep solutions 
Plasmid Midi Kit (QIAGEN, 12143). 
 
MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) stock 
5mg/ml MTT (Calbiochem, 475989) was prepared in phosphate buffered saline 
(PBS), sterilised by filtering through a 0.2µm filter and stored at -20oC protected 
from light. 
 
MTT Solubilisation Solution 
50% dimethylformamide (Sigma-Aldrich, 33120), 0.2% glacial acetic acid 
(Sigma-Aldrich, 338826), 20mM HCl, 20% SDS, the solution was made up in 
dH2O. 
 
Page ruler pre-stained protein ladder 
Page Ruler pre-stained protein ladder ready to use (Thermo Scientific, 26616).  




100x Penicillin/Streptomycin (PAA, P11-010). 
 
Phenylmethylsulfonyl fluoride (PMSF) 
10mM PMSF was made up in isopropanol and stored at -20oC. 
 
Phosphate-buffered saline (PBS) 
140mM NaCl (sodium chloride), 2.7mM KCl (potassium chloride), 8mM 
Na2HPO4(disodium hydrogen phosphate), 1.5mM KH2PO4(potassium 
dihydrogen phosphate).The solution was made up in dH2O and sterilised by 
autoclaving. 
 
Protogel 30% Acrylamide Mix 
Protogel 30% Acrylamide Mix (37.5:1 acrylamide to bis-acrylamide stabilised 
solution) was purchased from National Diagnostics(EC-890). 
 
Puromycin 
Puromycin 10mg/ml (InvivoGen, ant-pr). 
 
Running/Transfer buffer (10x) for Western Blotting 
250mM Tris base, 2.5M glycine and 1% SDS, made up in dH2O. 
 
Running buffer (1x) for Western Blotting 
10% of 10xrunning/transfer buffer in 90% of dH2O.




 pMD2.G(Lentivirus)envelope plasmid from Addgene (Plasmid #12259) 
 pCMV-dR8.91(Lentivirus) packaging plasmid, Department of Salivary 
and mucosal research, King’s College London. 
 VSVG(Retrovirus) envelope plasmid from Dr Ulrich Maurer, Institute of 
molecular medicine and cell research, University of Freiburg, Germany. 
 HIT60 (Retrovirus) packaging plasmid from Dr Ulrich Maurer, Institute of 
molecular medicine and cell research, University of Freiburg, Germany. 
 
10% sodium dodecyl sulphate (10% SDS) 
A 10% (w/v) solution of SDS was made up in dH2O, heated to 68°C to dissolve 
and the pH was adjusted to 7.2 with concentrated hydrochloric acid (HCl).  
  Chapter 2. Materials and Methods 
 
 82 
SDS Polyacrylamide Gels 
Table 1:  SDS Polyacrylamide Gels 
Resolving 
gel 










6.7 ml 8.0 ml 10.0 ml 30% 
Acrylamide 
1.0 ml 
ddH2O 7.9 ml 6.6 ml 4.6 ml ddH2O 4.1 ml 
10% SDS 200 µl 200 µl 200 µl 10% SDS 60 µl 
10% APS 200 µl 200 µl 200 µl 10% APS 60 µl 
TEMED 8 µl 8 µl 8 µl TEMED 6 µl 
 
Tris-acetate-EDTA buffer (10x TAE buffer) 
1 L of 10x solution was made up by adding 48.5g Tris (Trizma, T1503), 
11.4ml glacial acetic acid (Sigma, 537020) and 20ml 0.5M EDTA (pH 
8.0)(Sigma,03690) in deionised water. 
 
Tris-buffered saline TBS (10x) 
250mM Tris base (VWR, 103157P), 1.5M NaCl (SLS, L4509) made up in dH2O, 
pH adjusted to 7.4 with concentrated HCl and sterilised by autoclaving.  
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1x Tris-buffered saline-Tween 20 (1x TBST) 
0.1%Tween 20 in 1x TBS. 
 
Tris/EDTA buffer 
10mM Tris base and 1mM EDTA made in dH2O, the pH was adjusted to 9.0 
and stored at 4oC. 
 
Tris-EDTA (TE) 
10mM Tris-HCl pH 8.0, 1mM EDTA pH 8.0 made in dH2O. 
 
Transfer buffer (1x) 
10% of 10x running/transfer buffer, 20% methanol and 70% dH2O. 
 
Trypsin (1x) 
10% 10xTrypsin (Sigma, T4549). 
 
Versene 
0.270mM EDTA pH 8.0 made up in 1x PBS and sterilised by autoclaving.  
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2.1.3   Antibodies 
2.1.3.1Antibodies used for Western Blotting 
Table 2:  Antibodies used for Western Blotting 











Mouse F4 1:1000 *Gift 
 
p21 Mouse DCS60 1:1000 Cell 
Signalling 
2946 












Gift from Prof. William Gullick, Department of Bioscience, University of Kent 
atCanterbury, UK.  
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2.1.3.2   Antibodies used for Immunohistochemistry 
Table 3:  Antibodies used for Immunohistochemistry 
Targets Species Clone Dilution Supplier Catalogue 
Number 
Cyclin-D1 










Rabbit 5B7 1:100 Ventana 790-4347 
p16 
Mouse E6H4 1:40 Ventana 
725-4713 
p53 
Mouse DO-1 1:100 Santa Cruz 
sc-126 
p63 













IgG-B 1:100 Santa Cruz 
sc-2040 
  
  Chapter 2. Materials and Methods 
 
 86 
2.1.4   Primers 
2.1.4.1   Primers used for Standard PCR 
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2.1.4.2   Primers used for RT- PCR 
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2.1.5   Lentiviral and Retroviral shRNA constructs 
2.1.5.1 shRNA scrambled controls 










Negative control shRNA lentiviral plasmid-
A. Commercially available. Puromycin was 








3rd generation lentiviral plasmid- Human 
(empty backbone). Puromycin was used 









MSCV-N GFPFLAGHA tagged- 
mammalian expression, retroviral plasmid. 
Puromycin was used for selection. 
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2.1.5.2   shRNA constructs 









HPV-16 E6 lentiviral plasmid. Commercially 







human. Puromycin was used for selection. 





 pLKO-p53shRNA-941, lentiviral plasmid- 
human. Puromycin was used for selection. 





 pLKO.1puro. 3rd gen lentiviral plasmid-
human. Puromycin used for selection. 
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2.1.5.3   HPV16 E6 forced expression 










MSCV-C terminal on backbone, FLAGHA 
tagged- mammalian expression, retroviral. 
Puromycin was used for selection. 





 MSCV-N terminal on backbone, FLAGHA 
tagged- mammalian expression, retroviral. 
Puromycin was used for selection. 
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2.2   Methods 
2.2.1   Cell culture 
2.2.1.1   Cell lines 
Five HPV-positive and two HPV-negative cell lines were obtained from various 
sources; UPCI-SCC 089, 072, 090,152 and 154 were a gift from Professor S. 
Gollin, University of Pittsburgh. UD-SCC2 was a gift from Professors H. Bier, 
University of Munich and 93-VU-147T was a gift from Dr Steenbergen,VU 
University,Amsterdam. 
 
Cell lines currently available limited this study. All cell lines were obtained from 
external laboratories and none were generated locally in this centre due to 
facility and time limitations. Furthermore, due to its inherent biological 
properties, primary culture of HPV-positive oropharyngeal squamous cell 
carcinoma cells is particularly difficult. In this study, two of the cell lines (UPCI-
SCC090 and UPCI-SCC154) were derived from the tongue base mucosa. The 
tongue base and tonsil are functionally and anatomically similar to that of the 
fauceal tonsil (comprising surface non-keratinising stratified and reticulated 
crypt squamous epithelium. They were therefore considered suitable as models 
to study this disease. 
 
UPCI-SCC 089: The UPCI-SCC 089 cell line was derived from a 58-year old 
Caucasian male smoker and alcoholic patient with primary tumour arising in the 
tonsil. His tumour was staged as T2N2b M0 according to the 4th Edition  
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American Joint Committee on Cancer (AJCC) guidelines, with 11q13 gene 
amplification and HPV status being negative.276,277 
 
UPCI-SCC 072: UPCI-SCC 072 was derived from primary squamous cell 
carcinoma of tonsils, from a Caucasian 61 year old female. The tumour was 
staged as T3N2b, with 11q13 gene amplification and HPV status being 
negative. Tumour DNA showed TP53 missense mutation (14214C˃A) with 
H179N codon change.276-278 
 
UPCI-SCC 090: The UPCI-SCC 090 cell line was derived from a 46-year old 
male who had a history of cigarette and alcohol consumption, with a recurrent 
oropharyngeal squamous cell carcinoma in the base of tongue. Thetumour was 
staged as T2N1M0 with poorly differentiated invasive tumour comprising 
basaloid features. The cell line carries integrated HPV type-16 and the TP53 
status has been detected as wild type.276,279,280 
 
UPCI-SCC 152: One year later the UPCI-SCC090 patient was diagnosed with a 
new invasive moderately differentiated squamous cell carcinoma of the 
hypopharynx termed as UPCI-SCC152, which was staged as T4N2M0. The 
cells also showed presence of HPV type-16 and wild type TP53.276 
 
UPCI-SCC 154: UPCI-SCC 154 was derived from a 54-year old male smoker 
and alcoholic patient; the tumour originated from the tongue and was staged as 
T4N2M0. The cell line also contains integrated HPV-16 and wild type TP53.276
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UD-SCC 2: UD-SCC 2 was derived from a 58-year old male smoker and 
alcoholic patient, tumour occurred in the hypo-pharynx and was staged as 
T1N3M0. The cell line also contains integrated HPV-16 and wild type 
TP53.281,282 
 
93-VU-147T: 93-VU-147T cancer cells were isolated from a 58-year old male 
smoker and alcoholic patient. The tumour stage was T4N2M0 derived from the 
floor of mouth. Although it has been reported to harbour wild-type p53, it was 
found to have a heterozygous mutation in TP53 (c.770T>G, p.L257R) in some 
studies.184 The cell line also contains integrated HPV-16.283  
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2.2.1.2   Culture and maintenance of cell lines 
UPCI-SCC 090, UPCI-SCC 154, UPCI-SCC 089, UPCI-SCC 072, UPCI-SCC 
152 and UD-SCC 2 were cultured in MEM with Earle's salts supplemented with 
5ml L-Glutamine, 550 µl gentamicin, 5 ml non-essential amino acid and 50ml 
FBS. 93-VU-147T cell line was cultured in high glucose DMEM media 
supplemented with 50 ml FBS, 1ml penicillin/streptomycin and 5ml sodium 
pyruvate. 
 
2.2.1.3   Thawing of cell lines 
Frozen aliquots of cells were taken out from liquid nitrogen tank and instantly 
thawed in a water bath at 37oC. Cells from the cryovials were transferred to 
tubes in 5ml of medium and centrifuged for 5 minutes at 1000x g. The 
supernatant was discarded and the pellet was re-suspended in 10 ml of fresh 
medium pre-warmed to 37oC and transferred to 10 cm dishes or 75 cm² flasks, 
incubated at 37oC and 5% CO2. 
 
2.2.1.4   Mycoplasma testing 
Cell lines were regularly tested for the presence of mycoplasma using a PCR-
based detection kit according to the manufacturer’s instructions (AppliChem, 
A3744).  
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2.2.1.5   Sub-culture of cell lines 
Cells in 75cm2 flasks were sub-cultured every 3 to 5 days once the cells were 
70-80% confluent. After removal of the medium the flasks were washed with 
5ml or 10 ml of versene and the cells were incubated with 1ml of 1x trypsin at 
370Cfor several minutes. After detachment from the base of the flask cells were 
re-suspended in fresh medium and seeded in fresh flasks according to desired 
density (1:5/ 1:10) and kept in the incubator at 37oC and 5% CO2. 
 
2.2.1.6   Freezing of cells 
As described above the cells were trypsinised and centrifuged for 5 minutes at 
1000 x g, after removal of the supernatant the cells were re-suspended in fresh 
corresponding medium supplemented with 20% FBS and 10% 
dimethylsulfoxide (DMSO) and transferred to cryovials, These were slowly 
frozen down at -80oC in an isopropanol bath (Nalgene Cryoware) for at least 2 
days before transfer to a liquid nitrogen tank for long term storage. 
 
2.2.1.7   Cell counting 
Following trypsinisation and re-suspension in fresh medium, 10µl of cell 
suspension was pipetted into the haemocytometer (Neubauer chamber from 
SLS, HAE2118) and cells in the outer four large squares were counted. The cell 
concentration (number of cells per ml) was determined by using the formula: 
(counted cells/4) x 104.  
  Chapter 2. Materials and Methods 
 
 96 
2.2.1.8   Cell counting for growth curves 
The cell number was determined by the procedure as described above. 
Identical number of cells (50,000/well) for all cell lines was seeded in a six well 
plate in triplicates, incubated for eight days. The triplicate wells were counted 
after every 24 hours. 
 
2.2.1.9   Standard Polymerase chain reaction (PCR) 
DNA was extracted from pellets of the cell lines following the protocol provided 
with the QIAamp DNA Micro Kit (Qiagen, 56304). DNA concentrations were 
determined on a NanoDrop 1000 spectrophotometer (Thermo Scientific).Basic 
PCR procedure was adapted, in order to detect HPV genotype by GP5+/6+ 
primers and E6 DNA by using E6 primers. 
 
GP5+/6+ and HPV-16 E6 
In order to detect presence of HPV in HPV-positive cell linesthe standard PCR 
protocol was adapted. GP5+/6+ and HPV-16 E6 primers279 (Table 4) were used 
to amplify HPV genotype and E6 DNA in HPV-positive cell lines. β-Actin (Table 
4) was used as loading control. 
 
2 µl of HPV-DNA (approximately 2000 ng/µl) was added to a tube along with 
2.5µl of 10xPCR buffer, 2µl of 3.5mM MgCl2, 0.5µl of 5mM dNTPs, 0.5µl each 
of 100µM forward and reverse primers, 0.125µl of Taq and made up to 15 µl per 
tube with 9.77µl of nuclease free water. Samples were vortexed  
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andcentrifuged briefly. The mixture was kept on ice. Negative control with no 
HPV was also added. 
 
The samples were run in the PCR machine (G-storm), DNA was denatured at 
94°C for 5 minutes, followed by 40 PCR cycles of, 94°C for 1 minute 
(denaturation), 60°C for 1 minute (annealing) and 72°C for 2minutes 
(extension).  An additional extension step of 72°C for 5 minutes was included at 
the end of the reaction. The PCR amplified DNA was analysed by agarose gel 
electrophoresis. 3g of agarose (Sigma, A-9539) in 150ml of 1x TAE buffer was 
heated in a microwave at medium heat until dissolved. 
 
Meanwhile the gel tank was prepared by tightly sealing the sides, a comb was 
placed and filled with 1xTAE buffer. 5 µl ethidium bromide (Bioatlas, BA01902) 
was added to the TAE agarose solution before pouring in the tank. After placing 
the DNA samples in the wells the gel was run for approximately 1 hour at 100 
Volts and it was analysed using Gene genius bio-imaging system (Syngene). 
The images were printed by Sony digital graphic printer UP-D897. 
 
2.2.1.10   Reverse transcription polymerase chain reaction (RT-PCR) 
RT-PCR was carried out using complementary DNA (cDNA) as template. 
Forward and reverse primers (Table 5) were used to assess the expression of 
HPV-16 E6. GAPDH was used as endogenous control(Table 5).  
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PrecedingmakingcDNA,using at least 106 cells were harvested for the extraction 
of total RNA, washed with PBS and placed on ice.RNA extraction wascarried 
out according to manufacturer’s protocol using RNeasy®Mini Kit (Qiagen-
74104).GenomicDNAwasremoved from2μgoftotalRNA using theDNA‐freeDNA 
Removal Kit (Ambion- AM1906)accordingtothemanufacturer’sprotocol. 
 
Master mix for HPV-16 E6 expression was prepared by mixing 5 μl of 10X 
Dream Taq buffer (Thermo scientific, EP0702), 5 μldNTP mix (Thermo 
scientific, R0241), 1.0 μM each of forward and reverse primers, 1 μg of template 
DNA, 1.25 μl of Dream thermusaquaticus (taq) DNA polymerase and nuclease 
free water in order to make the final volume up to 50 μl for each reaction. The 
reactions were placed in a thermal cycler (Veriti® Thermal Cycler). 
 
The thermal cycling conditions are outlined below. 
1. 95C - 2 minutes, 1 cycle 
2. 95C - 15 seconds, 40 cycles 
3. 60C – 6seconds, 1 cycle 
 
To assess the presence of the cDNA, it was separated on 1%(w/v)agarose 
(NBSBiologicals,UK)gelin1xTAEcontaining0.5μg/mlEthidiumBromide(Bio-
Rad;161-0433)at120Vforupto45 minutes, analysed using Gene  
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Genius Bio-imaging System Syngene.The images were printed by Sony Digital 
Graphic printer UP-D897. 
 
2.2.1.11   Radiation 
The planning and administration of radiotherapy to the head and neck is a 
complex process, which takes into account the biological properties of the 
disease, anatomical structure limitations (such as the spinal cord) and, in cases 
of adjuvant treatment, the margin of surgical resection. Therapeutic dose is 
targeted for the tumour with diminishing marginal dose to adjacent structures. 
Furthermore, the tumour microenvironments, including the stromal cell 
population and host immune cells, influence tumour response to radiation. The 
in vitro study of radiation effects in cell lines in monolayer therefore cannot 
entirely recapitulate the clinical situation, but only provide preclinical models to 
define suitability for further study in animal models and Phase 1 clinical trials. 
 
25cm2 flasks were prepared for each dose along with a control flask. Once 70% 
confluent, the cells were irradiated at doses of 2Gy, 4Gy and 6Gy 
(gamma radiation, using Nordion GC-1000S v2.09 cell irradiator [SN. 0242]) 
and incubated overnight. After 24 hours, cells were trypsinised and counted, as 
described previously. After diluting in culture medium, various cell 
concentrations, optimised for each cell line (50,000 to 100,000), were seeded in 
each well of a 96 well culture plate, 6 replicate wells of different radiation doses, 
together with the untreated controls with 200µl of cell culture  
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medium. After 7 days of incubation the assay was stopped when the non-
radiated cells had undergone four or more doublings from the original plating 
number. The cell viability was determined using the MTT assay. All experiments 
were performed in triplicate. 
 
2.2.1.12   Chemotherapy 
Varying concentrations of cells, optimised for each cell line (50,000 to 100,000), 
were seeded in 96 well plates.  After 24 hours the cells were treated with either 
cisplatin (diluted in culture medium at the concentrations of 2.5µg/ml, 5µg/ml 
and 10µg/ml for 24 hours), TRAIL (TNF-related apoptosis-inducing ligand, 
diluted in culture medium at the concentrations of 1.5625ng/ml, 3.125ng/ml, 
6.25ng/ml, 12.5ng/ml, 25ng/ml, 50ng/ml and 100ng/ml for 72 hours) or 
cetuximab (diluted in culture medium at the concentrations of 200nM, 400nM, 
600nM, 800nM, 1000nM, 1200nM and1400nM for 48 hours). Cell viability was 
determined using the MTT assay. All experiments were performed in triplicate. 
 
2.2.1.13   MTT cell viability assay 
MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide)assay is a 
colorimetric assay for measuring the reduction of tetrazolium salts to formazan 
dyes by the respiratory enzymes in metabolically active cells.284 The intensity of 
the colour is directly proportional to the metabolic activity of the cells. By 
measuring the optical density at 570nm wavelength, after solubilisation the 
number of metabolically active cells can be correlated.  
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To assess the viability of cell population in response to different treatments, 
cells were seeded in 96 well plates at a density of 2-4 x 103 cells in 100µl 
medium/well. After incubation for seven days following radiation and at different 
time points for chemotherapeutic drugs, 20µl of MTT (5mg/ml, in PBS) was 
added to each well, which already contained 100µl of medium, incubated for 2-4 
hours at 37oC and 5% CO2 before adding 150µl of solubilisation solution to 
each well. After further incubation at 37°C and 5% CO2 for at least 16 hours 
absorbance of each well was measured at 595nm using a LT-4000 microplate 
reader (Labtech) and Manta software. The results were calculated after 
background subtraction by comparing the readings for treated cells in relation to 
untreated control cells. 
 
2.2.1.14Clonogenic Assay 
Following radiation, cells were counted after 24 hours using same method as 
described in Section 2.2.1.7. Cell densities for each cell line were calculated 
and the cells were seeded in a 60mm culture dish. Triplicate dishes for each 
radiation dose and non-irradiated controls were prepared. The dishes were 
placed in an incubator and left until cells in control dishes had formed 
sufficiently large clones of at least 50 cells per colony. The medium was 
removed from the dishes once the colonies were formed, the cells were washed 
with versene, 2-3ml of 10% of buffered formalin was added and the dishes were 
left for 1 hour for fixation, after that the dishes were rinsed again with versene, 
the colonies were stainedwith 2ml methylene blue 1% in H2O   
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for 1 hour, rinsed and kept overnight at room temperature to dry out. The 
colonies were counted and expressed relative non-irradiated controls. 
 
2.2.2   Immunohistochemistry and DNA in-situ hybridisation 
 
2.2.2.1   Paraffin embedded cell pellets 
Following trypsinisation (at least 1x108 cells), cell pellets were re-suspended in 
1 ml of 10% buffered formalin and centrifuged at 13,000rpm, the formalin was 
removed and the pellets were re-suspended in 1 ml of 1xPBS and stored at 4OC 
until ready for construction of agarose pellets. For preparation of agarose 
pellets, 50ml of 20% agarose gel in PBS was prepared. The formalin-fixed cells 
were re-suspended in PBS then centrifuged at 13000 rpm. The supernatant 
was removed, the pellets were re-suspended in 200µlof 1x PBS and transferred 
to 1.5ml eppendorf tubes, the tubes were centrifuged and the supernatant was 
discarded. The pellets were placed in the 60OC water bath and 200µl of 
agarose gel was added and re-suspended, vortexed briefly and then 
centrifuged at 13000 x g for 1 minute and the eppendorf tubes were left 
vertically placed in a rack for at least 1 hour in order to ensure complete setting 
of the agarose. The agarose pellets were removed from the eppendorf tubes, 
longitudinally bisected and placed in labelled histology cassettes. Agarose 
pellets were forwarded to the Department of Oral Pathology for routine 
processing. Briefly, agarose pellets were further fixed in 10% (v/v) buffered 
formal saline for 24 hours, processed and embedded in paraffin wax. 5μm 
sections were cut, mounted on  
  Chapter 2. Materials and Methods 
 
 103 
polylysine-coated slides, deparaffinised in xylene, dehydrated in 100% (v/v) 
industrial methylated spirit and rinsed in running tapwater. All sections were 
stained with haematoxylin and eosin (H&E). 
 
2.2.2.2   Immunohistochemistry (IHC) staining and scoring 
The paraffin blocks of agarose embedded cell pellets were sectioned at 5μm 
sections using routine histological procedure on a LEICA-RM2235 microtome. 
Sections were cut by Biomedical Scientists in the Department of Oral Pathology 
for routine processing. For IHC, formalin fixed cell monolayers were air-dried 
overnight at 37oC and dehydrated. After antigen retrieval and inactivation of 
endogenous peroxidases, the sections were stained with primary antibodies 
using the avidin-biotin-peroxidase method. 
 
Counterstaining was provided by Mayer’s haemalaun. For each block, the 
sections were stained using four primary antibodies directed against: p53, p63, 
p16, cyclin D1and EGFR (3C6 extracellular domain and 5B7 intracellular 
domain) using methods recommended by manufacturers where available. The 
sections of the pellets were stained for p16 using a propriety kit (CINtec 
Histology, mtm Laboratories) on a Ventana Benchmark Autostainer (Ventana 
Medical Systems). A tonsil squamous cell carcinoma with high p16 expression 
was used as a positive control and the same section without adding the p16 
primary antibody as a negative control.  
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The distribution, pattern and intensity of IHC staining of all sections were 
evaluated using a light microscope under various magnifications. The 
immunohistochemistry staining was interpreted by collective cytoplasmic and 
nuclear staining considering the staining intensity for stains such as p53, p63, 
p16 and cyclin D1. For immunohistochemical evaluation of EGFR in tissue 
samples, two observers independently scored all cases. Where present, the 
non-dysplastic surface or reticulated crypt epithelium was taken as the referent. 
An ordinate value of 0-3 was assigned to the intensity of membrane staining. 
The percentage of each intensity was allotted to the entire tumour within the 
whole mount tissue section and a product of each intensity value and its 
percentage stained within the tumour was determined. An ‘H-Score’ was then 
determined using the following formula: [(1x% cells intensity 1) + (2x% cells 
intensity 2) + (3x% cells intensity 3)].   
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2.2.2.3   HPV DNA in situ hybridisation (ISH) 
High risk HPV DNA ISH was carried out using proprietary reagents (Inform HPV 
III Family 16 Probe (B), Ventana Medical Systems) on a Benchmark Autostainer 
(Ventana Medical Systems). The inform HPV III Family 16 Probe (B) detects 
high-risk genotypes HPV16, 18, 31, 35, 39, 51, 56, 58 and 66. 
 
2.2.3   Western blotting 
2.2.3.1   Preparation of cell pellets 
Cells were collected by trypsinisationin cold 1x PBS and kept on ice. Following 
centrifuging at 4oC at 1000 rpm for 5 minutes the cell pellets were re-suspended 
in 1 ml of cold 1x PBS and transferred to 1.5 ml eppendorf tubes. The 
eppendorfs were centrifuged for 5 minutes at 1000 rpm at 4oC in the microfuge. 
The supernatant was removed and the pellets were stored at - 20oC until 
protein extraction. 
 
2.2.3.2   Preparation of total cell lysates and protein extraction 
Followed by preparation of fresh cell lysis buffer (1ml of fresh lysis buffer 
contained 50% of cell lysis buffer, 50% of triton x 100 2%, A/L [2µl], PMSF 
[6µl]), the cells were re-suspended in 50µl of cell lysis buffer (volume was 
changed depending on the size of the pellet). The cell pellets were incubated on 
ice for 10 minutes followed by centrifugation at 13000 rpm at 4oC. 
Thesupernatant (protein extract) was transferred to newly labelled tubes and 
the protein extracts were stored at -20oC until used for Bradford assay.  
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2.2.3.3   Bradford assay 
Protein concentrations were determined using the Bradford assay. It is based 
on the shift of the dye Coomassie from a doubly-protonated red form to an un-
protonated blue form with an absorbance maximum at 595nm when binding to 
proteins in the sample.285 The resulting increase in the absorbance at 595nm is 
proportional to the protein concentration. 
 
For the assay samples were diluted 1:1000 in dH2O and the bovine serum 
albumin (BSA) standards with concentrations ranging between 0 and 20µg/ml 
were prepared. Of every sample or standard 100µl were mixed on 96-well plate 
with 100µl of Bradford reagent (AppliChem). The absorbance of each well was 
measured at 595nm on a LT-4000 microplate reader (Labtech) and the protein 
concentration in individual samples was calculated based on the BSA standard 
curve. 
 
2.2.3.4   SDS-PAGE (sodium dodecylsulfate polyacrylamaide gel 
electrophoresis) 
This form of gel electrophoresis is used to analyse proteins, which after 
denaturation by the anionic detergent SDS, are separated by size on a 
polyacrylamaide gel.286The smaller the proteins, the faster it migratesthrough 
the gel matrix driven by an electric current. After separation proteins can be 
visualised and analysed by different staining or by western blot analysis. For 
SDS page equal amounts of proteins were re-suspended in 2 x LSB and heated 
at 95oC for 5 minutes to allow denaturation.  
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In case the volume exceeds 50µl samples were boiled for a longer time to 
reduce the volume for loading. Samples were either stored at -20oC or directly 
used for gel electrophoresis. Depending on the size of proteins of interest 
different gel percentages, corresponding to the percentage of polyacrylamide 
cross-linking of the resolving gel, were used. 
 
The vertical gel-casting apparatus was set up according to the manufacturer’s 
instruction (Bio-Rad, Mini PROTEIN II, 165-2940). The resolving polyacrylamide 
gel solution was prepared accordingly and poured, leaving space for the upper 
(stacking) gel. A thin layer of isopropanol was added to flatten the surface and 
avoid evaporation (drying out of the gel). After the gel had set the isopropanol 
was removed with filter paper, then the gel was washed with dH2O and was 
dried with filter paper. The loading gel was prepared and loaded on top and a 
10- or 15- well comb was placed to get wells for sample loading. After the gel 
was set, the comb was removed and the gel was placed in an electrophoresis 
tank filled with1 x running buffer. Protein samples were loaded on the gel after 
boiling for 5 minutes at 95oC with first lane loaded with 4µl of protein molecular 
weight marker. The tank was connected to the power supply and 
electrophoresis was started at80 volts (V) allowing protein migrations through 
the stacking gel, before the voltage was increased to 100V for up to 2 hours.  
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2.2.3.5   Transfer of proteins 
A transfer sandwich was made by placing the gel on the black side of the 
transfer cassette after placement of a sponge and 3 pieces of 3mm filter papers 
(Whatman, 3030917), the nitrocellulose membrane was then put on top of the 
gel and covered by another 2 pieces of filter papers and a sponge. The 
cassettes were closed and locked and placed in the transfer module with 
corresponding colours in the transfer tank (Bio-Rad Mini PROTEIN II) filled with 
1x transfer buffer. Transfer was performed at 400 mA for 90 minutes at 4oC or 
40mA overnight at room temperature. 
 
2.2.3.6   Probing of membrane with antibodies 
After transfer, the membrane was blocked for an hour at room temperature or 
over night at 4oC in 5% milk in TBS-T followed by incubating the membrane with 
primary antibody diluted in 5% milk at appropriate concentrations for overnight 
at 4oC on a shaker. The membrane was washed 3 x 10 minutes with TBS-T. 
The blot was then incubated with secondary anti-mouse or anti-rabbit antibody 
diluted in 5% blocking buffer for an hour at room temperature. Lastly the 
membrane was washed three times with TBS-T for 10 minutes each time.  
  Chapter 2. Materials and Methods 
 
 109 
2.2.3.7   Detection by enhanced chemiluminescence (ECL) 
During the last wash of the membrane ECL solution was prepared (10ml ECL 
buffer with 3µl of H2O2, 25µl coumaric and 50µl of luminol). The membrane was 
incubated with ECL solution for 1 minute, drained, wrapped in cling film, placed 
in the western blot cassette and exposed to RX autoradiograph film (Fuji) for 
varying times depending on signal strength. Before re-probing with another 
primary antibody, the blot was stripped with Re-blot plus strong buffer (Millipore) 
for 15 minutes and incubated with blocking buffer 2 times for 5 minutes at RT on 
a shaker. 
 
2.2.4   Lentivirus methods 
Lately, retroviral and lentiviral vectors have developed into a fundamental tool 
for the efficient delivery of nucleic acids to many cell types in a variety of 
experimental systems. Using lentiviral or retroviral systems allows for the stable, 
heritable integration of a specific nucleic acid sequence into the target cell’s 
genome.  
 
Retroviral replication involves the covalent integration of the reverse transcribed 
viral genome into the host cell chromatin. Provirus, an integrated form of the 
virus, provides a template for viral gene expression. As the provirus is an 
integral part of the host genome, retroviruses stay in the host for the lifespan of 
the infected cell.287 
  Chapter 2. Materials and Methods 
 
 110 
Lentiviruses are a subtype of retrovirus. Main distinction between lentiviruses 
and standard retroviruses is that lentiviruses are capable of infecting non-
dividing and actively dividing cell types whereas standard retroviruses can only 
infect mitotically active cell types. This means that lentiviruses can infect a 
greater variety of cell types than retroviruses.288 
Both lentiviruses and retroviruses use the gag, pol, and env genes for 
packaging; however, they are different viruses and thus use slightly different 
isoforms of these packaging components. Therefore, lentiviral vectors may not 
be efficiently packaged by retroviral packaging systems, and vice versa.288-290 
 
2.2.4.1   Bacterial transformation 
To amplify plasmids chemically competent Escherichia Coli (Mach1™-T1R, 
Invitrogen or MAX Efficiency® Stbl2™, Invitrogen) were transformed by adding 
1 µl of plasmid DNA, leaving them on ice for 30 min followed by a heat shock 
(30 sec at 42°C) and a cold shock (at least 2 min on ice). Bacteria were then 
cultured in 250 µl LB medium for 1 hour at 37°C before they were spread on a 
pre-warmed LB agar plate supplemented with the appropriate antibiotic. The 
plates were incubated overnight at 37°C and then stored at 4°C. Single colonies 
were picked and transferred into 5 ml of LB medium with antibiotic and 
incubated at 37°C while shaking overnight before plasmid extraction.  
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2.2.4.2   Plasmid extraction 
Plasmid DNA was purified from bacterial cultures using a Plasmid Midi Kit 
(Qiagen) or a Wizard Plus SV Miniprep DNA Purification System 
(Promega)according to the manufacturer’s instructions. DNA concentrations 
were determined on a NanoDrop 1000 spectrophotometer (Thermo Scientific). 
 
2.2.4.3   Lentivirus production 
HEK293T cells were plated on 10cm dishes to reach around 70 to 80% 
confluency at the time of transfection. For transfection by calcium phosphate 
precipitation a vector mix of three plasmids was prepared in 250µl sterile dH2O: 
3.5µg of lentiviral construct, 6.5µg of envelope plasmid (pMD2.G) and 10µg of 
packaging plasmid (pCMV-dR8.91). After addition of 250µl 2.5M CaCl2 the 
vector mix was added drop wise to 500µl of 2xHeBS (pH 8.05) while vortexing. 
After 30 min incubation at room temperature the suspension was slowly added 
to the cells which were incubated overnight at 37°C and 5% CO2 before 
changing the medium. The virus-containing supernatant was harvested at 24 
and 48 hours post-transfection, put through a 0.45µm filter and frozen at -70°C 
for long-term storage or kept at 4°C overnight. 2.5x105 UPCI-SCC 090 and 089 
cells were plated on 12-well plates and infected with several dilutions of 
concentrated virus supernatant in the presence of 5µg/ml polybrene (Santa 
Cruz Biotechnology).  
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2.2.4.4   Lentivirus infection 
Target cells were plated 24 hours before infection to reach around 80% 
confluency at the time of infection. Lentivirus stocks were diluted in a minimal 
amount of medium supplemented with 5µg/ml polybrene was added to the cells. 
After 24 hours fresh medium was added and cells were collected at the 
indicated time points for the respective assays. 
 
2.2.4.5   Generation of stable knockdown cell lines 
Target cells were plated approximately 24 hours before infection on 6 cm dishes 
to reach around 80% confluency at the time of infection. Cells were infected 
using 1ml of viral supernatant supplemented with 5µg/ml polybrene and 2ml of 
fresh culture medium were added 8 hours after infection. After several days 
cells were selected depending on their acquired resistance to antibiotics. A 
control of non-transduced cells was treated in parallel to ensure toxicity of the 
antibiotic. 
 
2.2.5   Retrovirus methods 
According to the methods for bacterial transformation and plasmid extraction 
described in sections 2.2.41 and 2.2.4.2 respectively, for retrovirus 
productionHEK293T cells were plated on 10cm dishes to reach around 60 to 
70% confluency at the time of transfection. For transfection bycalcium 
phosphateprecipitation, a vector mix of three plasmids was prepared in 250µl 
sterile dH2O, 3.5µg of retroviral construct, 6.5 µg of envelope plasmid (VSVG) 
and 10 µg of packaging plasmid (HIT 60). After addition of 250µl of2.5M CaCl2, 
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the vector mix was added drop wise to 500µl of 2xHeBS (pH 8.05) while 
vortexing. After 30 min incubation at room temperature the suspension was 
slowly added to the cells which were incubated overnight at 37°C and 5% CO2 
before changing the medium. Next day sodium butyrate was added to the 
selection medium for approximately 10 hours and the virus-containing 
supernatant was harvested at 24 and 48 hours, put through a 0.45µm filter and 
frozen at -70°C for long-term storage or kept at 4°C overnight. 2.5x105 UPCI-
SCC 090 and 089 cells were plated on 12-well plates and infected with several 
dilutions of concentrated virus supernatant in the presence of 5µg/ml polybrene 
(Santa Cruz Biotechnology). 
 
Target cells were plated 24 hours before infection to reach around 80% 
confluency at the time of infection. Lentivirus stocks were diluted in a minimal 
amount of medium supplemented with 5µg/ml polybrene. After 24 hours fresh 
medium was added and cells were collected at the indicated time points for the 
respective assays.Target cells were plated approximately 24 hours before 
infection on 6 cm dishes to reach around 80% confluency at the time of 
infection. Cells were infected using 1ml of viral supernatant supplemented with 
5µg/ml polybrene and 2ml of fresh culture medium were added 8 hours after 
infection.After several days cells were selecteddepending on their acquired 
resistance to antibiotics. A control of non-transduced cells was treated in 
parallel to ensure toxicity of the antibiotic.  
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2.2.6   Survival analysis 
Research Ethics Committee (RECreference 10/H070/027) and Research and 
Development (R&Dreference RJ110/N320) approval has already been granted 
in relation to immunohistochemical evaluation in OPSCC tumour samples and 
correlation with survival outcome. Overall survival data was retrospectively 
obtained from electronic patient records. Kaplan-Meier survival plots were 
generated at various H-score cut-offs using SPSS statistics software version 
(IBM corporation, US). 
 
2.2.7   Statistical analysis 
All data was analysed using Microsoft Excel, GraphPad Prism 6  
software and SPSS statistics software.Bars or data points throughout this study 
represent mean values of independent results while error bars indicate the 
corresponding standard error of the mean (SEM). For experiments involving 
measurement of replicate data such as MTT assays performed in triplicate, 
replicate values were combined into an average value and considered as one 
independently obtained result. 
 
Depending on the experimental design several statistical methods were used 
and analysis were performed. The difference between two groups was 
testedusing an unpaired, two-tailed Student’s t test using GraphPad Prism 6. 
Survival curves were evaluated by the Kaplan-Meier method, and survival 
distributions were compared using the log-rank test using SSPS software.  






Chapter 3 - Characterisation of cell lines and 
differential response of HPV-positive and HPV-
negative HNSCC cells to conventional therapy in 
vitro.




HPV-positive oropharyngeal squamous cell carcinomas (OPSCCs) have a 
significantlyimproved outcome in response to treatment compared to HPV-
negative OPSCCs.65,173 Although the improved clinical response of HPV-
positive OPSCC to conventional therapeutic agents is now well established, the 
biological mechanisms that underpin these observations remain largely 
unknown. Therefore, in order to evaluate the possible mechanisms of improved 
response to treatment in HPV-positive OPSCCs, the initial objective of this 
study was to develop an in vitro model of relative sensitivity of HPV-positive 
cells to therapeutic agents




3.2.1 Confirmation of HPV status 
Five HPV-positive and two HPV-negative HNSCC cell lines were obtained from 
various external research laboratories as detailed in section 2.2.1.1. Prior to 
undertaking further work, the HPV status of each of the cell lines was confirmed 
as follows. 
 
3.2.1.1 Polymerase chain reaction 
3.2.1.1.1 Consensus PCR 
Using the GP5+/6+ primer sets which target the highly conserved region of the 
L1 gene of HPV, conventional PCR by agarose gel electrophoresis confirmed 
the absence of HPV in HPV-negative cell lines (UPCI-SCC 089 and UPCI-SCC 
072). By contrast, the presence of HPV DNA was confirmed in the HPV-positive 
cell lines (UPCI-SCC 090, UPCI-SCC 152, UPCI-SCC 154, UD-SCC 2 and 93-
VU-147T, Figure 3.1) as previously reported.291,292  








Figure 3.1. Conventional PCR for DNA in of HPV-negative and HPVpositive cell 
lines cell lines. 
Amplification of HPV DNA in HPV-negative (lanes 1 and 2) and HPV-positive cell lines 
(lanes 3-7) using consensus primers GP5+/6+ (150 bp). Amplification of β-Actin (500 
bp) and water (negative template, NT; lane 8) were used as a positive loading and 
negative controls, respectively.  
  Chapter 3. Results   
 
 119 
3.2.1.1.2 Genotype-specific PCR 
Following consensus primer PCR, genotype-specific PCR by agarose gel 
electrophoresis was undertaken using primers against HPV-16 E6 DNA as 
detailed in section 2.2.1.9. The results confirmed the presence of HPV-16 E6 




Figure 3.2. Standard PCR for HPV-16 E6 DNA inof HPV-negative and HPVpositive 
cell lines cell lines. 
Amplification of HPV-16 E6 DNA in HPV-negative (lanes 1 and 2) and HPV-positive 
cell lines (lanes 3-7) using HPV-16 E6 DNA primers (477 bp). Amplification of β-Actin 
(500 bp) and water (negative template, NT; lane 8) were used as a positive loading and 
negative controls, respectively.  
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3.2.1.2 HPV DNA in-situ hybridisation 
Following consensus and genotype specific PCR, a further confirmation of HPV 
status was undertaken using DNA in-situ hybridisation (ISH). A cocktail of 
probes against high-risk types (HPV16, 18, 31, 35, 39, 51, 56, 58 and 66) as 
detailed in section 2.2.2.3 were used. The presence of integrated HPV DNA 
was confirmed in the HPV-positive cell lines UPCI-SCC 090, UPCI-SCC 152, 
UD-SCC 2 and 93-VU-147T (Figure 3.3, upper panel) by demonstration of 
strong punctate signal that co-localised with the nuclei with the exception of 
UPCI-SCC 154 that demonstrated weak punctate nuclear signal. By contrast, 
no signal was present in the HPV-negative cells (UPCI-SCC 089 and UPCI-
SCC 072, Figure 3.3 upper panel). 
 
The biological significance of the presence of HPV DNA was next evaluated. 
The viral oncoprotein E7 in high-risk HPV inactivates the retinoblastoma (pRb) 
tumour suppressor protein leading to overexpression of p16.293 The 
overexpression of p16 is a consistent feature of high-risk HPV infection in 
OPSCC and is therefore used as a sensitive surrogate marker for 
transcriptionally active virus.293 
 
Immunohistochemical evaluation of cell lines demonstrated strong and diffuse 
nuclear and cytoplasmic staining of p16 in all HPV-positive cell lines but was 
either negative or weak staining in the HPV-negative cell lines (UPCI-SCC 089 
and UPCI-SCC 072, respectively, Figure 3.3, lower panel).  





Figure 3.3. DNA in situ-hybridisation and immunohistochemistry. 
High-risk HPV DNA in-situ hybridisation (upper panel) showing punctate nuclear staining in the HPV-positive cells (UPCI-SCC 090, UPCI-
SCC 152, UPCI-SCC 154, UD-SCC 2 and 93-VU-147T), but lacking any signal in HPV-negative cells (UPCI-SCC 089 and UPCI-SCC 
072).p16 immunohistochemistry (lower panel) showing diffuse strong nuclear and cytoplasmic staining in HPV-positive cell lines but is 
negative or weak in HPV-negative cell lines.  
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3.2.2 Growth rates of cell lines 
Following confirmation of the HPV status, the proliferation rates of the cell lines 
were determined. This was performed in order to compare HPV-positive and 
HPV-negative proliferation rates and to determine whether compensatory 
seeding densities and temporal lag would be necessary for subsequent cell 
viability and clonogenic assays. The cells were counted for eight days after 
primary seeding of 5x104 cells per well (6-well plate) as detailed in section 
2.2.1.8.From day 3 onwards, HPV-negative cell lines (UPCI-SCC089 and UPCI-
SCC 072) demonstrated greater increase in growth rates compared to HPV-
positive cell lines (UPCI-SCC090, UPCI-SCC152, UPCI-SCC154, UD-SCC2 
and 93-VU-147T, Figure 3.4). Grouped comparison ofHPV-negative with HPV-
positive cell lines following day 3 showed a slower rate in the later 
group(p≤0.001, unpaired t-test). 





Figure 3.4. Cell lines growth rates. 
Bar graph of growth rate analysis of two HPV-negative and five HPV-positive cell lines 
showing average number of cells per well following seeding of 5 x104 cells, performed 
in triplicate, versus time in days. Error bars indicate standard deviation. Graph 
representative of three independent experiments.  
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3.2.3 Response to therapeutic agents 
It is now generally accepted that patients with HPV-positive OPSCC have 
improved overall survival and lower incidence of loco-regional recurrence 
compared to patients with HPV-negative OPSCC.162,173 This may be explained 
at least in part by greater inherent sensitivity to therapeutic agents.294 Having 
undertaken preliminary characterisation of the cell lines, the next stage of this 
study was to develop an in vitro model of relative sensitivity to conventional 
therapeutic agents, namely radiation and cisplatin. 
 
3.2.3.1 Cell viability following radiation 
Cell viability assays were performed as detailed in section 2.2.1.13. In HPV-
positive cells radiation resulted in cell viability ranging from 70%-80%, 60%-65% 
and 35%-40% at 2, 4 and 6 Gy, respectively. By contrast, HPV-negative cell 
lines showed cell viability ranging from 78-80%, 65-70% and 60-65% at 2, 4 
and 6 Gy, respectively(Figure 3.5). HPV-positive cells demonstrated greater 
sensitivity to radiation compared to HPV-negative cells at all radiation doses 
(p≤0.01 for all HPV-positive versus HPV-negative cells at 2 Gy and all HPV-
positive cells versus UPCI-SCC 072 at 6 Gy; p ≤0.001for all HPV-positive 
versus HPV-negative cells at 4 Gyand all HPV-positive cells versus UPCI-SCC 
089 at 6 Gy, unpaired t-test). 






Figure 3.5. Cell viability of HPV-negative and HPVpositive cell lines following 
radiation. 
Bar graph of cell viability expressed relative to control. Radiation was performed in 
triplicate at 2, 4 and 6 Gy. Cell viability was assessed by MTT assay 7 days following 
treatment. Bars represent average value from 6 wells normalised to untreated control 
cells. Error bars indicate standard deviation. This assay is representative of three 
independent experiments.
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3.2.3.2Clonongenic survival following radiation 
Clonogenic survival assay has been considered as the reference standard for 
measurement of radio-sensitivity in vitro because, unlike cell viability assays, it 
determines the ability of a cell to proliferate indefinitely,thus retaining its 
reproductive capacity to form a sizeable colony.295,296 Therefore, in order to 
validate the results of Section 3.2.3.1, clonogenic survival assays were 
performed as detailed in section 2.2.1.14. Figure 3.6 demonstrates 
representative surviving clones in an HPV-positive (UPCI-SCC 090) and HPV-
negative (UPCI-SCC 089) cell line. In HPV-positive cells radiation resulted in 
cell survival ranging from 50%- 60%, 35%- 40% and 10%- 25% at 2, 4 and 6 
Gy, respectively. In contrast, HPV-negative cell lines showed cell survival 
ranging from 85%- 90%, 70- 85% and 45- 70% at 2, 4 and 6 Gy, respectively 
(Figure 3.7). HPV-positive cell lines demonstrated greater sensitivity to radiation 
compared to HPV-negative cell lines at all radiation doses (p ≤0.001for all HPV-
positive versus HPV-negative cells at 2, 4 and 6 Gy, unpaired  
t-test).  






Figure 3.6. Representative photograph of clonongenic survival following 
radiation. 
Representative photograph of colonies of HPV-negative (UPCI-SCC 089) and HPV-
positive (UPCI-SCCC 090) cells at 2, 4 and 6 Gy. Controls were seeded without 
radiation. All dishes were fixed at 15 -25 days following radiation. 






Figure 3.7. Cell survival of HPV-negative and HPVpositive cell lines following 
radiation. 
Bar graph of clonogenic survival expressed relative to control. Radiation was 
performed in triplicate at 2, 4 and 6 Gy. Cell survival was assessed by clonogenic 
analysis 15-25 days following treatment. Bars represent average value from 3 dishes 
normalised to untreated control cells. Error bars indicate standard deviation. This assay 
is representative of three independent experiments.  
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3.2.3.3 Cell viability following cisplatin 
The results of section 3.2.3.1 and 3.2.3.2 demonstrated HPV-positive cell lines 
to be more radiosensitive compared to HPV-negative HNC cell lines.Since 
concomitant chemo-radiation is the current treatment standard for OPSCC, this 
study also sought to determine whether HPV-positive cells showed similar 
relative sensitivity to cisplatin. Cell viability assays were performed as detailed 
in section 2.2.1.13. Cisplatin was used at various concentrations of 2.5, 5 and 
10 µg/ml for 24 hours, resulting in cell viability ranging from 60%-85%, 40-50% 
and 25-30% at 2.5, 5 and 10 µg/ml respectively in HPV-positive cell lines. In 
contrast, HPV-negative cell lines showed cell viability ranging from 80%-90%, 
65- 70% and 55- 60% at 2.5, 5 and 10 µg/ml respectively (Figure 3.8). HPV-
positive cell lines demonstrated greater sensitivity to cisplatin compared to 
HPV-negative cell lines at 5 and 10 µg/ml of cisplatin (p ≤0.001for all HPV-
positive versus HPV-negative cells). At 2.5 µg/ml no significance in survival was 
observed between UPC-SCC 089 and HPV-positive cell lines however the 
sensitivity in between UPCI-SCC 072 and HPV-positive cell lines was 
statistically significant (p ≤0.001, unpaired t-test).  






Figure 3.8. Cell viability of HPV-negative and HPVpositive cell lines following 
cisplatin. 
Bar graph of cell viability expressed relative to control. Cisplatin chemotherapy was 
performed at 2.5, 5 and 10 µg/ml. Cell viability was assessed by MTT assay 7 days 
following treatment. Bars represent average value from 6 wells normalised to untreated 
control cells. Error bars indicate standard deviation. This assay is representative of 
three independent experiments.  







































There is now robust evidence that patients with HPV-positive OPSCC have a 
significantly favourable response to chemo-radiation compared to HPV-negative 
counterparts but the mechanism to explain these observations are largely 
unknown. Furthermore, there are sparse in vitro models available to investigate 
potential mechanisms, all with variable and sometimes conflicting results. 
Therefore, in order to elucidate potential mechanisms of improved response in 
HPV-positive OPSCC to current therapeutic agents, it was first necessary to 
develop a reliable and reproducible in vitro model. 
 
3.3.1 Characterisation of HPV-positive and HPV-negative cell lines 
In this study, all cell lines were obtained from external laboratories, detailed in 
section 2.2.1.1. Therefore in the first instance, it was necessary to confirm the 
HPV status of all cell lines. HPV status of all cell lines used in this study was in 
accordance with previously published reports.276,277,281,283The HPV status of the 
HPV-positive cell lines was confirmed to contain HPV-16 DNA by PCR and viral 
integration was confirmed by punctate staining pattern by DNA in-situ 
hybridization. All HPV-positive cell lines showed increased positivity of 
integrated HPV DNA with the exception of UPCI-SCC 154, which demonstrated 
weak punctate staining. The equivocal DNA ISH signal in UPCI-SCC 154 has 
also previously been observed by fluorescence in-situ hybridisation (FISH) and 
may be explained by presence of a low viral load (viral load=1) in this cell line 
compared to a much higher viral load (viral load=739) in UPCI-SCC 090  
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cells.297Nevertheless, as with all other HPV-positive cell lines, UPCI-SCC 154 
demonstrated p16 over-expression, confirming presence of transcriptionally 
active high-risk HPV oncogenes despite a low viral copy number.193,298 
 
As part of the characterisation of cell lines and to determine whether it is 
necessary to compensate for variation in proliferation indices in subsequent 
experiments, growth rates were evaluated for all cell lines. The current study 
found increased proliferation rates in HPV-negative cell lines compared to the 
HPV-positive cells lines, suggesting a link with the clinical observations where 
HPV-positive tumours are characterised by a higher nodal metastasis rate and 
lower T-stage, implying a relatively low proliferation rate despite enhanced 
metastaticcapacity.65 This study confirms previous findings by Nagel et al 
(2013) who showed similar significantly lower growth rate of HPV-positive 
HNSCC cell lines compared to HPV-negative HNSCC cell lines.299 
 
3.3.2 Response of HPV-positive and HPV-negative cell lines to 
conventional therapeutic agents 
3.3.2.1 Radiosensitivity 
The results of the present chapter demonstrated increased relative 
radiosensitivity of HPV-positive OPSCC cells compared to site-matched HPV-
negative controls, thereby establishing an in vitro model that is concordant with 
clinical observations. Interestingly, although the HPV-positive cell line 93-VU- 
147T was derived from the floor of the mouth, these cells were also relatively 
radiosensitive compared to HPV-negative OPSCC cells. There are several
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recent studies in the literature in agreement with the current findings.179,184-
186,193,300-303 While a comprehensive and integrated explanation for these 
observations is still lacking, emerging data raise the possibility of potential 
molecular pathways. For example, Gupta et al (2009) showed correlation 
between increased sensitivity to radiation and decreased expression of 
phosphorylated AKT and increased expression of phosphorylated phosphatase 
and tensin homolog(PTEN) in HPV-positive HNSCC cell lines. PTEN provides 
negative regulation of the PI3K-AKT pathway, the pathway isgenerally 
upregulated in head and neck cancers.304,300 Furthermore, inactivation of 
mTOR, a downstream target of the PI3K-AKT pathway,in HPV-positive HNSCC 
cell lines led to further radiosensitivity indicating that an attenuated PI3K-AKT 
pathway may be, at least in part, responsible for this improved response in 
HPV-positive HNSCC cells.305,306 
 
Although the capacity of the cell to detect DNA damage and to take over its 
repair could be responsible for increased radiosensitivity, the tumour’s 
oxygenation status might also be a factor for increased response to 
radiation.307The suggestion that HPV-positive HNSCC is less hypoxic compared 
to HPV-negative counterparts may contribute to increased radiosensitivity of 
these tumours.200 It has been also shown that under hypoxic conditions HPV-
positive HNSCC demonstrate similar upregulation of hypoxia responsive genes 
and displays increased resistance to radiation similar to HPV-negative tumours 
regardless of the HPV status.301,308,309Hence, it mightbesuggested that the 
improved prognosis of HPV-positive HNSCC may be partly due to differences in 
hypoxic fraction.  
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By contrast to the majority of reported studies in the literature demonstrating 
increased radiosensitivity, there are occasional studies indicating a dissimilar 
trend, namely HPV-positive HNSCC cell lines being either more resistant or 
equally radiosensitive to HPV-negative cells.299,310,311This discrepancy may be 
explained by investigations carried out by groups using cell lines without 
confirming the presence of integrated HPV DNA in the cells, examining potential 
cell lines with mixed population of cells exhibiting different biological and 
genetic properties or by selection of clones with non-viral DNA containing 
clonogen. Contrary findings could also be explained by loss of viral DNA and 
the presence of viruses in latent or non-producing state. Other factors may 
include cell culture contamination, different handling techniques and 
methodologies used to assess cell lines.184 A growing body of literature 
indicated that high passage number affects cell line characteristics and hence 
the results over time.312,313 Moreover, some studies have directly compared 
HPV–positive oropharyngeal cell lines with non-oropharyngeal HPV-negative 
counterparts and this may lead to discrepant results since the latter is less likely 
to be a suitable control. 
 
The tumour microenvironment may also play a part in the relative 
radiosensitivity of HPV-positive cells. This has been suggested by Spanoset al 
(2009) who showed a dependence of increased radiosensitivity in HPV-
positivecells on an intact immune response.310 It is also been hypothesised that 
immune cellsproduced in reaction to E6 and E7encoded antigens, have a 
positive impact on disease outcome in early development of the 
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tumour.314Further studies are therefore necessary to evaluate the interplay 
between the  
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innate tumour characteristics and the tumour microenvironment in the improved 
clinical outcome of HPV-positive HNSCC. 
 
3.3.2.2Chemosensitivity (cisplatin) 
Cisplatin is currently used as a concomitant therapeutic agent for the 
management of OPSCC and acts by causing DNA crosslinking leading to 
apoptosis.315 However, data pertaining to the relative response of HPV-positive 
HNSCC cell lines to cisplatin is scarce and variable. 
 
In accordance with findings of the present study, Chen et al (2000)showed an 
increased sensitivity of HPV-positive cell lines to treatment with cisplatin 
compared to HPV-negative HNSCC cell lines.316 By contrast to this work, 
Spanoset al (2009) and Nagel et al (2013) showed increased resistance while 
Kawakami et al (2013) demonstrated no effect to cisplatin in HPV-positive 
compared to the HPV-negative HNSCC cell lines.299,310 Interestingly, Spanoset 
al (2009) showed resistance of HPV-positive cell lines when treated with 
cisplatin in vitro but found that HPV-positive tumour xenografts were more 
sensitive to the same agent when treated in vivo. However, they used very low 
doses of cisplatin (0.025 -1.0 μg/mL) and counted colonies with more than 15 
cell, which may be a cause to explain differences with the present study.310 
 
Although Nagel et al (2013) used increased dosages of cisplatin (10-1-103μM) 
compared to the current study, the differencesin observations might be caused 
by their use of only four HPV-positive cell lines and compared them to a large  
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panel (fourteen) of non-oropharyngeal cell lines, the latter being a biologically 
heterogeneous and non-site-matched control group. By contrast, all cell lines in 
this study were of oropharyngeal origin, with the exception of 93-VU-147T, and 
controls were therefore likely to be a more suitable comparison group.299 Also in 
contrast to the current study, Kawakami et al (2013) compared response of 
cisplatin between HPV-positive and HPV-negative oropharyngeal cell lines 
through clonogenic assay and showed no effect to cisplatin even at higher 
doses (10-1-103μM/L) and longer exposure (seventy-two hours), but differences 
in culture conditions cannot be excluded.




The current study established an in vitro model of relative sensitivity to radiation 
and cisplatin in HPV-positive HNSCC cell lines compared to HPV-negative 
HNSCC cell lines. However, there are several limitations to the current section 
of this study. 
 
The currently available repertoire of HPV-positive cell lines and site-matched 
HPV-negative cell lines was a limitation. Primary culture and generation of 
immortalised lines is acknowledged as being particularly challenging and may 
reflect the inherent susceptibility of these tumours to cell death. As such, this 
study sought to obtain HPV-positive cells from external laboratories. The 
selected panel of HPV-positive cells included non-orpharyngeal origins, namely 
hypopharynx, floor of mouth and cervical nodal metastasis. Furthermore, 
several HPV-positive were derived from patients who were tobacco smokers in 
contrast to the clinical situation where the majority of HPV-positive OPSCC 
patients do not smoke. However, until more suitably representative cells 
become more widely available, all in vitro investigations into the mechanisms of 
HPV-positive HNC are limited to laboratory experiments in these few cell lines. 
This study utilised two HPV-negative cell lines as controls. Ideally, a similar or 
greater number HPV-negative cell lines should be used as controls for the five 
HPV-positive cell lines evaluated in this study. However, after careful searching 
of the literature and publicly available databases, only two HNC cancer cell lines 
matched the criterion of having been derived from the oropharynx. The relative 
paucity of cell lines investigated raises the possibility that the observations of 
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increased resistance to radiation and cisplatin may be due to cell line variation 
rather that the inherent biological properties of HPV-negative disease. 
Nevertheless, omission of control cell lines not derived from oropharyngeal sites 
remains a necessity. 
 
The extrapolation of observations from radiation experiments on monolayer of 
cultured cells is another potential limitation. Evaluation of cells grown in 
monolayer fails to consider the effects of diminishing margin of target volume of 
radiation. Furthermore, these experiments do not factor the role of the tumour 
microenvironment, including stromal and host immune responses following 
radiation. While the current model provides the initial foundation to study 
radiation and cisplatin effects in HPV-positive OPSCC, further work is required, 
namely responses to therapeutic agents of these agents in vivo in orthotropic 
animal models using concomitant and/or induction regimes. 
 
Due to constraints of time and other resources, only limited characterisation of 
cell lines were undertaken. Ideally, comparative genomic and expression array 
analysis would have provided more in-depth information of the genotypic 
differences between HPV-positive and HPV-negative cells used in this study. 
Downstream cellular responses to radiation and/or cisplatin, including DNA 
damage pathways, may have been elucidated which may have provided a basis 
for more tailored investigation of these effects. Similarly, prior to evaluating the 
effect of targeted therapy described in subsequent chapters it may have been 
important characterise the cell lines in relation to death receptor and the ErbB 
family of receptors. 




Effects of radiation and cisplatin in the current study was evaluated using cell 
viability and clonogenic survival assays. Determination of cell cycle fraction by 
flow cytometry and the proportion of apoptosis by Annexin V or cleaved 
caspased-3 assays would have provided more robust data to indicate the 
possible mechanisms of sensitivity or resistance to radiation or cisplatin. 




In summary, the current study was able to establish an in vitro model of relative 
sensitivity to radiation and cisplatin in HPV-positive HNSCC cell lines compared 
to HPV-negative HNSCC cell lines. All HPV-positive cell lines (five in total) 
known to be available at the commencement of the study were utilised to 
establish this model. Previously published models did not simultaneously test all 
HPV-positive cells. Since the commencement of this study, several novel HPV-
positive cell lines have been reported.317,318 Moreover, the control cells used in 
this study were specifically selected due to their oropharyngeal origin. To my 
knowledge, no previously published models used site-specific controls. 







Chapter 4 - The role of p53 and HPV-16 E6 in the 
response of head and neck cancer cell lines to 
conventional therapeutic agent





The previous chapter detailed the development of an in vitro model of relative 
sensitivity to conventional therapeutic agents in HPV-positive head and neck 
squamous cell carcinoma (HNSCC) cell lines. HPV-positive HNSCC cell lines 
were more sensitive to radiation and cisplatin compared to the HPV-negative 
cells. Having established a suitable model of improved response of HPV-
positive HNSCC to conventional therapeutic agents, the next stage of this 
study was to investigate the possible underlying mechanisms of increased 
sensitivity. 
 
Two key potential targets were chosen for further evaluation in the current 
study, namely p53 and HPV-16 E6. p53 was selected because of its central 
role in regulating cellular responses to stress. Following DNA damage, hypoxia 
or oncogene activation, several signalling pathways converge on this tumour 
suppressor gene, which is responsible for the induction of cell cycle arrest, 
senescence or apoptosis.319 p53 has been reported to be mutated in a majority 
of HNSCC and the existence of mutant p53 in these tumours promotes 
resistance to cisplatin and radiation treatment.320 An important clinical finding is 
that the majority of HPV-16 positive OPSCC tissue samples contain wild-type 
p53 and it has been proposed that functional p53 may, at least in part, be 
responsible for the improved response to treatment in these patients.321,322  
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The p53 tumour suppressor gene is a nuclear phosphoprotein that 
transcriptionally regulates the expression of a number of target genes including 
p21.323 p21 binds to the G1-S/CDK (CDK4/6, CDK2 and CDK1) complexes 
(molecules important for theG1/S transition in the cell cycle) inhibiting their 
activity.324 When p21 is complexed with CDK2, the cell cannot continue to the 
next stage of cell division.325 
 
HPV-16 E6 was selected for further study because of its direct effect of p53 
inactivation. The oncoprotein interferes with p53 protein by degrading it via the 
ubiquitin-proteasome system resulting in disturbance of cell cycle control, 
which finally leads to increased tumour cell growth.326,327 Although high-risk 
HPV oncoprotein E6 targets p53 for degradation, there is evidence that the 
latter could be reactivated in response to stress in cells with wild-type 
p53.328,329 
 
The objective of this part of the study was to evaluate the role of p53 and 
HPV16-E6 in the increased response of HPV-positive HNSCC cell lines to 
radiation and cisplatin.




4.2.1 Baseline expression of p53 
The p53 gene is frequently mutated in HNC as a whole.330 However, almost all 
HPV-positive OPSCC contain wild type p53.331 Prior to elucidating the 
functional role of p53 in HPV-positive HNSCC cell lines it was important to 
initially establish the baseline expression of p53 in the HNSCC cell lines used 
in this study. 
 
Immunohistochemistry 
Immunohistochemical evaluation of cell lines demonstrated negative or weak 
p53 staining in all HPV-positive cell lines with the exception of 93-VU-147T that 
showed strong and diffuse p53 staining. On the contrary staining was either 
intense or moderate in the HPV-negative cell lines (UPCI-SCC 072 and UPCI-
SCC 089 respectively, Figure 4.1). 
 
Western Blot 
In order to confirm the p53 immunohistochemical staining, protein levels were 
additionally assessed by western blots. The latter confirmed the 
immunohistochemistry findings. HPV-negative cells demonstrated moderate 
(UPCI-SCC 089) and strong (UPCI-SCC 072) p53 protein expression. With 
the exception of 93-VU-147T, all HPV-positive cell lines showed weak or 
undetectable p53 protein expression (Figure 4.2 A).  
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Densitometry quantification of p53 protein expression was undertaken using 
image J analysis. 93-VU-147T and UPCI-SCC 072 showed increased p53/β-
actin ratio when compared to UPCI-SCC 089 and all other HPV-positive cell 
lines that showed low or no protein levels (Figure 4.2 B). p-value was 
determined by unpaired t-test comparing HPV-positive with individual HPV-
negative cell lines separately(p ≤ 0.01 for UPCI-SCC 089 versus UD-SCC 2 
cells and p ≤ 0.001 for each of the HPV-negative cell lines versus UPCI-SCC 
090, UPCI-SCC 154, UPCI-SCC 152 UD-SCC 2 and 93-VU-147T). There was 
no significant difference between UPCI-SCC 072 and 93-VU-147T (p=0.0568). 
  





Figure 4.1. p53 immunohistochemistry. 
Comparison of p53 immunostaining between HPV- negative (UPCI-SCC 072 and UPCI-SCC 089) and HPV-positive (UPCI-SCC 090, 
UPCI-SCC 152, UPCI-SCC 154, UD-SCC 2 and 93-VU-147T) on FFPE cell pellet sections. Original magnification x100.  











Figure 4.2. p53 baseline expression by western blot. 
A) Expression difference of p53 in cells of UPCI-SCC 072 and UPCI-SCC 089 (HPV-
negative) and UPCI-SCC 090, UPCI-SCC 152, UPCI-SCC 154, UD-SCC 2 and 93-VU-
147T (HPV-positive) cell lines by western blot. Arrows indicate molecular weight of the 
pre-stained protein ladder. HNSCC cell line HN5 with mutated p53 was used as a 
positive control. β-actin was used as a loading control. The above is representative of 
two independent experiments. B) The intensity of the bands shown in western blot 
(Figure 4.2 A) was quantified by comparing all HPV-positive cell lines with HPV-
negative cell line separately in relation to β-actin level using Image J. p-value was 
determined by unpaired t-test (*p<0.05, **p<0.01 and ***p<0.001). 
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4.2.2 p53 stabilisation 
In most tobacco and alcohol-related tumours, the tumour suppressor protein 
p53 is mutated and inactive, while the p53 in HPV-infected tumours iswild-type 
(wt) and structurally intact. Although, the protein is degraded by the HPV 
oncoprotein E6,249,332 researches indicate that persistent treatment with certain 
therapeutic agents can suppress E6 oncogenes, allowing the p53 to carry out 
its normal function.333 Therefore, the presence of the wild-type p53 and the 
lower mutation rate observed in HPV-derived SCC may enable these tumour 
cells to undergo an intact apoptotic response when treated with radiotherapy 
and/or chemotherapy, resulting in a greater sensitivity.334 
 
In order to evaluate the role of p53 in the relative sensitivity of HPV-positive cell 
lines in the current in vitro model, two cell lines i.e. UPCI-SCC 089 (HPV-
negative) and UPCI-SCC 090 (HPV-positive) were selected for further study. 
UPCI-SCC 089 (HPV-negative) was selected because it demonstrated 
consistent resistance to radiation and cisplatin while being sensitive to TRAIL 
and Cetuximab. Conversely, UPCI-SCC 090 (HPV-positive) was selected 
because it demonstrated consistent sensitivity to radiation and cisplatin while 
being resistant to TRAIL and Cetuximab. Time constraints limited the study to 
these two cell lines only.  
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4.2.2.1 p53 stabilisation in response to radiation 
UPCI-SCC 089 (HPV-negative) and UPCI-SCC 090 (HPV-positive) cells were 
treated at 4 Gy and harvested at 2, 4 and 6 hours followed by lysate preparation 
as described in section 2.2.3.2. Western blot analysis of UPCI-SCC 089 cells 
following radiation showed almost no alteration in p53 from baseline untreated 
levels (Figure 4.3 A). By contrast, a time-dependent increase of p53 protein 
expression was observed in UPCI-SCC 090 cells following radiation. 
Furthermore, increased p53 protein expression was accompanied by induction 
of p21 in HPV-positive cells at 4 and 6 hours after radiation confirming 
functional activity of p53 (Figure 4.3 A). 
 
Densitometry quantification of p53 protein expression by image J analysis 
showed that p53 protein levels in UPCI-SCC 089 did not appear to be regulated 
by radiation therapy at all time points. By contrast HPV-positive cell line (UPCI-
SCC 090) showed time dependent increase in p53 and p21/β-actin ratio 
compared to the untreated sample (undetectable). p-value was determined by 
unpaired T-test, significant results were appreciated when comparing treated 
cell lines at different time points with their respective untreated controls (Figure 
4.3 B).  







Figure 4.3. Stabilisation of p53 following radiation. 
A) Western blot analysis for p53 and p21 in HPV-negative (UPCI-SCC089) and HPV-
positive (UPCI-SCC090) cell lines following treatment with radiation (4Gy) at 2, 4 and 6 
hours. Arrows indicate molecular weight of the pre-stained protein ladder. Western blot 
is representative of two independent experiments. B) Quantitative analysis of p53 and 
p21 induction at indicated times shown in western blot (Figure 4.3 A) after radiation in 
relation to β-actin level compared to untreated controls using the Image J programme. 
Error bars indicate standard deviation. p-value was determined by unpaired T-test 
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4.2.2.2 p53 stabilisation in response to cisplatin 
HPV-negative (UPCI-SCC 089) and HPV-positive (UPCI-SCC 090) cells were 
treated by 10 µg/ml of cisplatin and harvested at 2, 4 and 6 hours. Lysates were 
prepared as described in section 2.2.3.2. Western blot analysis of UPCI-SCC 
089 cells following treatment showed almost no alteration in p53 from baseline 
untreated levels.By contrast a time-dependent increase in the levels of p53 was 
observed in UPCI-SCC 090 following radiation compared to untreated control. 
Furthermore, increased p53 protein expression was accompanied by induction 
of p21 at 4 and 6 hours following cisplatin treatment confirming functional 
activity of p53 (Figure 4.4 A). 
 
Densitometry quantification of p53 protein expression by image J analysis 
showed that p53 protein levels in UPCI-SCC 089 did not appear to be regulated 
by cisplatin therapy at all time points. HPV-positive cell line (UPCI-SCC 090) 
showed time dependent increase in p53 and p21/β-actin ratio compared to the 
untreated sample (undetectable). p-value was determined by unpaired T-test 
(*p<0.05, **p<0.01 and ***p<0.001) comparing  treated cell lines at different 
time points with their respective untreated controls (Figure 4.4 B).  








Figure 4.4. Stabilisation of p53 following cisplatin. 
A) Western blot analysis for p53 and p21 in HPV-negative (UPCI-SCC089) and HPV-
positive (UPCI-SCC090) cell lines following treatment with cisplatin (10µg/ml) at 2, 4 
and 6 hours. Arrows indicate molecular weight of the pre-stained protein ladder. 
Western blot is representative of two independent experiments. B) Quantitative 
analysis of p53 and p21 induction at indicated times shown in western blot (Figure4.4 
A) following cisplatinin relation to β-actin level compared to untreated controls using the 
Image J programme. Error bars indicate standard deviation. p-value was determined 
by unpaired t-test (*p<0.05, **p<0.01 and ***p<0.001).  
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4.2.3 Effect of p53 attenuation to radiation and cisplatin 
The results of section 4.2.2 showed stabilisation of p53 protein in HPV-positive 
cells (UPCI-SCC 090) following treatment with radiation and cisplatin 
accompanied by the induction of the p53 target protein p21. In order to confirm 
that the relative sensitivity of HPV-positive cells to radiation and cisplatin is 
mediated through p53, the functional effect of p53 attenuation was next 
evaluated. 
 
4.2.3.1 Attenuation of p53 in HPV-positive cells 
p53 in HPV-positive cells (UPCI-SCC 090) was attenuated through stable 
transfection with p53shRNA as detailed in section 2.2.4.p53 protein was 
undetectable in cells stably transfected with p53shRNA (090 p53sh). By 
contrast, p53 was detectable in the parental (UPCI-SCC 090) and control cells 
stably transfected with scrambled control (090 scr control). Unaffected β-actin 
levels with either construct also established the specificity of p53 reduction 
(Figure 4.5 A).








Figure 4.5. Attenuation of p53 in HPV-positive cells. 
A) Western blot analysis of p53 in HPV-positive cell line UPCI-SCC 090 (090), UPCI-
SCC 090 scramble control (090-scr control) and UPCI-SCC 090 p53 attenuated cells 
(090-p53sh). Arrows indicate molecular weight of the pre-stained protein ladder. 
Western blot is representative of two independent experiments.  B) Quantitative 
densitometry of p53 levels following attenuation. Bar represents mean data normalised 
to β-Actin compared with control. Error bars indicate standard deviation. p-value was 
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As described in the previous section (4.2.2.2), cisplatin treatment up-regulated 
p53 protein levels in UPCI-SCC 090 (HPV-positive) cells compared to untreated 
controls. In the current section, in order to confirm the functional attenuation of 
p53, cells stably transfected with p53shRNA and controls were also treated with 
cisplatin. As expected, following cisplatin treatment UPCI-SCC 090 and 
scrambled control (090 p53sc + cisplatin) showed up-regulation of p53. By 
contrast, stably transfected cells (090 p53sh + cisplatin) did not demonstrate 
p53 stabilisation following cisplatin treatment (Figure 4.6 A). 
 
Densitometry quantification of p53 protein bands correlated with the blots of 
both pre and post treatment experiments (p ≤ 0.001 for UPCI-SCC 090 versus 
090-p53shRNA and cisplatin treated UPCI-SCC 090 versus cisplatin treated 
090-p53shRNA, Figure 4.5 B and 4.6 B respectively).  








Figure 4.6. p53 stabilisation in p53shRNA cells following cisplatin. 
A) Western blot analysis of p53 protein in HPV-positive cell line UPCI-SCC 090 (090), 
UPCI-SCC 090 scramble control (090-scr control) and UPCI-SCC 090 p53 attenuated 
cells (090-p53sh) following cisplatin treatment (10 µg/ml) for 6 hours. Arrows indicate 
molecular weight of the pre-stained protein ladder. Western blot is representative of 
two independent experiments. B) Quantitative densitometry of p53 levels in transfected 
cells following cisplatin treatment. Bar represents mean data normalised to β-Actin 
compared with control. Error bars indicate standard deviation. p-value was determined 
by unpaired t-test (*p<0.05, **p<0.01 and ***p<0.001). 
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4.2.3.2 Growth rate of p53 attenuated cells 
In order to elucidate the role of p53 on cell proliferation, growth rate assay 
following p53 attenuation was performed in HPV-positive cells as detailed in 
section 2.2.1.8. 
 
The results showed increased growth rate of the p53shRNA transfected cells 
compared to untreated controls particularly after day 3 of seeding (Figure 
4.7).p-value was determined by unpaired t-test (p ≤0.01 for UPCI-SCC 090 
versus 090-p53shRNA at 4th day and p ≤0.001 for UPCI-SCC 090 versus 090-
p53shRNA from 5th to 8th days of growth).  






Figure 4.7. Growth rate of UPCI-SCC 090 p53shRNA cells. 
Bar graph of growth rate analysis of p53shRNA transfected HPV-positive cells (090-
p53shRNA)and the controls (UPCI-SCC 090 and 090-scr control) showing average 
number of cells per dish versus time in days. Error bars indicate standard deviation. 
This assay is representative of two independent experiments. p-value was determined 
by unpaired t-test (*p<0.05, **p<0.01 and ***p<0.001).  
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4.2.3.3 Cell viability of p53 attenuated cells following radiation 
In order to confirm whether the relative sensitivity of HPV-positive cells to 
radiation as shown in sections 3.2.3.1 and 3.2.3.2 is mediated through p53, 
p53shRNA transfected cells, parental cells and cells transfected with control-
shRNA were radiated at 2, 4 and 6 Gy and the cell viability was assessed by 
MTT assay as detailed in section 2.2.1.13. p53shRNA transfected cells showed 
increased resistance to radiation compared to controls (p ≤0.05 for UPCI-SCC 
090 versus 090-p53shRNA at 2Gy, p ≤0.01 for UPCI-SCC 090 versus 090-
p53shRNA at 4 Gy and p ≤0.001 for UPCI-SCC 090 versus 090-p53shRNA at 
6Gy, Figure 4.8). 
 
Moreover silencing of p53 in HPV-negative cells (089-p53shRA) had no effect 
on cell viability when treated with radiation at aforementioned doses compared 
to the parental cell line (UPCI-SCC 089) and the scrambled control (089-scr 
control, Figure 4.9). No statistical significance was observed comparing 
treatment response at higher doses (p=0.6423 for 089-p53shRA cells versus 
UPCI-SCC 089 at 2 Gy, p=0.0760 for 089-p53shRA cells versus UPCI-SCC 
089 at 4 Gy and p=0.4564 for 089-p53shRA cells versus UPCI-SCC 089 at 6 
Gy; unpaired t-test).Confirming that the p53 mediated therapeutic sensitivity in 
HPV-positive cells was specific and silencing p53 in HPV-negative cells does 
not lead to therapeutic resistance.  






Figure 4.8. Cell viability of UPCI-SCC 090 p53shRNA cells following radiation. 
Bar graph of cell viability expressed relative to control. Radiation was performed in 
triplicate at 2, 4 and 6 Gy. Cell viability was assessed after 7 days of treatment by MTT 
analysis. Error bars indicate standard deviation. This assay is representative of three 
independent experiments. p-value was determined by unpaired t-test (*p<0.05, 
**p<0.01 and ***p<0.001).  









































Figure 4.9. Cell viability of UPCI-SCC 089 p53shRNA cells following radiation. 
Bar graph of cell viability expressed relative to control. Radiation was performed in 
triplicate at 2, 4 and 6 Gy. Cell viability was assessed after 7 days of treatment by MTT 
analysis. Error bars indicate standard deviation. This assay is representative of three 
independent experiments. p-value was determined by unpaired t-test (*p<0.05, 
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4.2.3.4 Clonogenic survival of p53 attenuated cells following radiation 
In order to validate results of section 4.2.3.3, clonogenic survival assays were 
performed as detailed in section 2.2.1.14. Similar to the cell viability assay, 
p53shRNA transfected HPV-positive cell lines demonstrated significant radio-
resistance compared to controls (p ≤0.001 for UPCI-SCC 090 versus 090-
p53shRNA at 2, 4 and 6 Gy, Figure 4.10). Taken together, the results (cell 
viability and cell survival assays) indicate that the relative sensitivity of HPV-
positive cells is, at least in part, mediated through endogenous p53.  






Figure 4.10. Cell survival of UPCI-SCC 090 p53shRNA cells following radiation. 
Bar graph of clonogenic survival expressed relative to control. Radiation was 
performed in triplicate at 2, 4 and 6 Gy. Cell survival was assessed by clonogenic 
analysis 15-25 days following treatment. Bars represent average value from 3 dishes 
normalised to untreated control cells. Error bars indicate standard deviation. This assay 
is representative of three independent experiments.p-value was determined by 
unpaired t-test (*p<0.05, **p<0.01 and ***p<0.001). 
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4.2.3.5 Cell viability of p53 attenuated cells following cisplatin 
Having established that the relative sensitivity of HPV-positive cells to radiation 
was mediated, at least in part, by p53, this study went on to determine whether 
HPV-positive cells showed similar relative resistance to cisplatin. Cell viability 
assays were performed as detailed in section 2.2.1.13.p53shRNA transfected 
cells showed increased resistance to cisplatin compared to controls (p ≤0.001 
for UPCI-SCC 090 versus 090-p53shRNA at 2.5 µg/mland p ≤0.01 for UPCI-
SCC 090 versus 090-p53shRNA at 4 and 6 µg/ml). 
 
Moreover silencing of p53 in HPV-negative cells (089-p53shRA) had no effect 
on cell viability when treated with cisplatin at aforementioned doses compared 
to the parental cell line (UPCI-SCC 089) and the scrambled control (089-scr 
control, Figure 4.12). No statistical significance was observed comparing 
treatment response at higher doses (p=0.0945 for 089-p53shRA cells versus 
UPCI-SCC 089 at 2.5 µg/ml, p=0.7597 for 089-p53shRA cells versus UPCI-
SCC 089 at 5 µg/ml and p=0.8881for 089-p53shRA cells versus UPCI-SCC 089 
at 10 µg/ml; unpaired t-test). Confirming that the p53 mediated therapeutic 
sensitivity in HPV-positive cells was specific and silencing p53 in HPV-negative 
cells does not lead to therapeutic resistance.  






Figure 4. 11. Cell viability of UPCI-SCC 090 p53shRNA cells following cisplatin. 
Bar graph of cell viability expressed relative to control. Cisplatin chemotherapy was 
performed at2.5, 5 and 10 µg/ml. Cell viability was assessed by MTT assay 7 days 
following treatment. Bars represent average value from triplicate wells normalised to 
untreated control cells. Error bars indicate standard deviation. This assay is 
representative of three independent experiments. p-value was determined by unpaired 
t-test (*p<0.05, **p<0.01 and ***p<0.001).  











































Figure 4. 12. Cell viability of UPCI-SCC 089 p53shRNA cells following cisplatin. 
Bar graph of cell viability expressed relative to control. Cisplatin chemotherapy was 
performed at2.5, 5 and 10 µg/ml. Cell viability was assessed by MTT assay 7 days 
following treatment. Bars represent average value from triplicate wells normalised to 
untreated control cells. Error bars indicate standard deviation. This assay is 
representative of three independent experiments. p-value was determined by unpaired 
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4.2.4 Response of HPV-16 E6 attenuation to radiation and cisplatin 
After establishing that HPV positive cell lines were more sensitive to radiation 
and cisplatin (chapter 3) and attenuation of p53 mediated increased resistance 
to radiation and cisplatin in HPV-positive cells (section 4.2.3). The aim of the 
current section was to determine whether E6 attenuation enhances the 
sensitivity of HPV-positive cancer cells since it is hypothesised that repression 
of HPV16 E6 oncogene expression results in stabilisation of the p53 and 
induction of apoptosis in HPV16-positive OPSCC cell lines.267 
 
4.2.4.1 Attenuation of E6 in HPV-positive cells 
Since the previous section showed that attenuation of p53 caused increased 
radio- and chemo-resistance in HPV-positive cancer cells, the current section 
went on to determine whether attenuation of E6 has an effect on endogenous 
p53 levels and response to radiation and cisplatin.HPV-positive cell line (UPCI-
SCC 090) were transfected by E6shRNA through lentivirus detailed in section 
2.2.4. There are currently no suitable commercial antibodies against HPV16-E6 
for use in Western blot analysis or immunohistochemistry. Therefore, success 
of E6 knockdown was assessed by evaluating its downstream effects, namely 
the stabilisation of p53. 
 
Increased p53 expression levels in the E6shRNA transfected cells confirmed 
reactivation of the protein following transfection with E6shRNA. Densitometry 
quantification of p53 protein expression by image J analysis showed up to a  
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fold increase of p53/β-actin ratio in E6shRNA transfected cells (p ≤0.001 for 
UPCI-SCC 090 versus 090-E6shRNA, Figure 4.13 B).














Figure 4.13. Attenuation of E6 in HPV-positive cell lines. 
A) Western blot analysis of baseline p53 in HPV-positive cell line (UPCI-SCC 090), 
UPCI-SCC 090 scramble control (090-scr control) and UPCI-SCC 090 E6 attenuated 
cells (090-E6shRNA). Arrows indicate molecular weight of the pre-stained protein 
ladder. Western blot is representative of two independent experiments. B) Quantitative 
densitometry of p53 levels following attenuation of E6. Bar represents mean data 
normalised to β-Actin compared to control. Error bars indicate standard deviation. p-
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p53 protein levels further increased  in the cisplatin treated E6shRNA cells 
compared to treated controls as well as to untreated samples shown in the 
previous figure (4.14 A). Densitometry quantification of p53 protein expression 
by image J analysis showed increase of p53/β-actin ratio in cisplatin treated 
E6shRNA transfected cells compared to controls (p ≤0.001 for cisplatin treated 
UPCI-SCC 090 versus cisplatin treated 090-E6shRNA, Figure 4.14 B).  









Figure 4.14. p53 stabilisation in UPCI-SCC 090 E6shRNA cells following cisplatin. 
A) Western blot analysis of p53 protein in E6 attenuated HPV-positive cell line (090-
E6sh), UPCI-SCC 090 scramble control (090-sc) and untreated control (090) following 
cisplatin treatment. Arrows indicate molecular weight of the pre-stained protein ladder. 
Western blot is representative of two independent experiments. B) Quantitative 
densitometry of p53 levels in E6 transfected cells following treatment. Bar represents 
mean data normalised to β-Actin compared to control. Error bars indicate standard 
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4.2.4.2 Growth rate of E6 attenuated cells 
The results of the previous section (4.2.4.1) demonstrated that attenuation of 
E6 resulted in up-regulation of p53 protein in HPV-positive HNSCC cells. In 
order to investigate whether E6 attenuation influence growth rate of the 
transfected cells, cell proliferation assay was performed as described in section 
2.2.1.8. 
Results showed slight decrease in the growth rate of the E6shRNA transfected 
cells compared to controls particularly after day 4 of seeding(p ≤0.05 for UPCI-
SCC 090 versus 090-E6shRNA at 5th, 7th and 8th day of cellular proliferation). 
 
 
Figure 4.15. Growth rate of UPCI-SCC 090 E6shRNA cells. 
Bar graph of growth curve analysis of E6shRNA transfected HPV-positive (090-
E6shRNA) and controls (UPCI-SCC 090 and 090-scr control) showing average number 
of cells per dish versus time in days. Error bars indicate standard deviation. p-value 
was determined by unpaired t-test (*p<0.05, **p<0.01 and ***p<0.001).  
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4.2.4.3 Cell viability of E6 attenuated cells following radiation 
In order to investigate the role of E6 attenuation in response to radiation, 
E6shRNA transfected cells were radiated at 2, 4 and 6 Gy and the cell viability 
was assessed by MTT assay detailed in section 2.2.1.13. E6shRNA transfected 
cells showed slight increase in sensitivity to radiation mainly at 4 and 6 Gy 
compared to the controls (UPCI-SCC 090 and 090-scr control, Figure 4.16). 
Statistical significance was determined by unpaired t-test (p˂0.01 for UPCI-SCC 




Figure 4.16. Cell viability of UPCI-SCC 090 E6shRNA cells following radiation. 
Bar graph of cell viability expressed relative to control. Radiation was performed in 
triplicate at 2, 4 and 6 Gy. Cell viability was assessed after 7 days of treatment by MTT 
analysis. Error bars indicate standard deviation. This assay is representative of three 
independent experiments. p-value was determined by unpaired t-test (*p<0.05, 
**p<0.01 and ***p<0.001).  
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4.2.4.4 Clonogenic survival of E6 attenuated cells following radiation 
In order to validate the results of section 4.2.4.3, clonogenic survival assays 
were performed as detailed in section 2.2.1.14. Results showed greater 
sensitivity at 4 and 6 Gy (p˂0.001) compared to MTT assay (Figure 4.17) in the 
E6 attenuated cells.Similar to the results of the cell viability assay, clonogenic 
cell survival assay also shows that attenuation of HPV-16 E6 in HPV-positive 
cells increases sensitivity to radiation. Statistical significance was determined by 




Figure 4.17. Cell survival of UPCI-SCC 090 E6shRNA cells following radiation. 
Bar graph of clonogenic survival expressed relative to control. Radiation was 
performed in triplicate at 2, 4 and 6 Gy. Cell survival was assessed by clonogenic 
analysis 15-25 days following treatment. Bars represent average value from 3 dishes 
normalised to untreated control cells. This assay is representative of three independent 
experiments. Error bars indicate standard deviation. p-value was determined by 
unpaired t-test (*p<0.05, **p<0.01 and ***p<0.001).  
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4.2.4.5 Cell viability of E6 attenuated cells following treatment with 
cisplatin 
The results of the above sections (4.2.3.3 and 4.2.3.4) demonstrated that 
attenuation of E6 in HPV-positive cells increased radio-sensitivity compared to 
controls. In order to determine whether a similar effect, the study went on to 
determine whether HPV-positive cells showed similar relative sensitivity to 
cisplatin following E6 attenuation. Cell viability assays were performed as 
detailed in section 2.2.1.13. Cisplatin was used at various concentrations of 2.5, 
5 and 10 µg/ml for 24 hours.  There was no significant increase in the relative 
sensitivity to cisplatin in E6 attenuated cells (p=0.2 at 5. µg/ml and p=0.07 at 10 
µg/ml).  






Figure 4.18. Cell viability of UPCI-SCC 090 E6shRNA cells following cisplatin. 
Bar graph of cell viability expressed relative to control. Cisplatin chemotherapy was 
performed at 2.5, 5 and 10 µg/ml. Cell viability was assessed by MTT assay 7 days 
following treatment. Bars represent average value from 6 wells normalised to untreated 
control cells. Error bars indicate standard deviation. This assay is representative of 
three independent experiments.  
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4.2.5 HPV-16 E6 expression in HPV-negative cell line 
The next stage of this study sought to evaluate whether HPV gene products 
altered sensitivity of HNSCC cells in response to conventional therapeutic 
agents. In order to determine whether HPV-16 E6 caused increased sensitivity 
to radiation in a p53-independent manner two HPV-16 E6retroviral constructs, 
namely E6-75 targeting the C-terminal and E6-76 targeting the N-terminal of E6 
gene were stably expressed in one of the HPV-negative cell lines (UPCI-SCC 
089) as detailed in section 2.2.5. 
 
4.2.5.1 Expression of HPV-16 E6 in HPV-negative cell line 
In order to confirm successful transfection of HPV-16 E6 in the HPV-negative 
cell line (UPCI-SCC 089), expression of the gene was evaluated by reverse 
transcription polymerase chain reaction (RT-PCR).  The results showed 
presence of HPV-16 E6 plasmids in the HPV-negative cells compared to the 
parental cell line (UPCI-SCC 089) and the MSCV-N GFP (089-GFP, Figure 
4.19). Further in the study HPV-16 E6 expression vectors will be designated as 
E6-75 and E6-76 respectively.  







Figure 4.19. RT-PCR of HPV-16 E6 expressed HPV-negative cells. 
Amplification of HPV-16 E6 mRNA (477 bp) in HPV-negative cell lines (UPCI-SCC 
089), GFP as a control and two expression vectors of E6 (089 E6-75 and 089 E6-
76).mRNA of GAPDH was used as a loading control (556 bp).  
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4.2.5.2 Growth rate of HPV-16 E6 expressed cells 
The results of section 3.3.2 showed greater growth rates of HPV-negative cell 
lines compared to HPV-positive cell lines. This section aimed to determine 
whether the presence of HPV-16 E6 alters growth rates of HPV-negative cells. 
 
HPV-16 E6 expression in HPV-negative cells resulted in significantly decreased 
growth rates particularly from third day compared to controls, suggesting 
possible effect of E6 on growth rate of the cancer cells (p ≤0.001 for UPCI-SCC 
089 versus E6-75 and E6-76 at 4th, 5th, 6th, 7th and 8th day of cellular 
proliferation).  





Figure 4.20. Growth rate of HPV-16 E6 expressed UPCI-SCC 089 cells. 
Bar graph of growth curve analysis of E6 expression vectors in HPV-negative UPCI-
SCC 089 cell lines (E6-75 and E6-76) and controls (UPCI-SCC 089 and 089-GFP) 
showing average number of cells per dish versus time in days. Error bars indicate 
standard deviation. p-value was determined by unpaired t-test (*p<0.05, **p<0.01 and 
***p<0.001).  
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4.2.5.3 Cell viability of HPV-16 E6 expressed cells following radiation 
The current section of the study aimed to investigate any effect mediated by 
HPV-16 E6 oncoprotein, forcefully expressed in HPV-negative OPSCC cells in 
response to RT. Radiation of HPV-negative cells with forced expression of 
HPV16 E6 (E6-75 and E6-76) at 2, 4 and 6 Gy showed increased sensitivity 
compared to the controls (p˂0.05 for UPCI-SCC 089 versus E6-76 and p˂0.01 
for UPCI-SCC 089 versus E6-76 at 4 Gy; p˂0.001 for UPCI-SCC 089 versus 
E6-75 and E6-76 at 6 Gy).  





Figure 4.21. Cell viability of E6 expressed UPCI-SCC 089 cells following radiation. 
Bar graph of cell viability expressed relative to control. Radiation was performed in 
triplicate at 2, 4 and 6Gy. Cell viability was assessed after 7 days of treatment by MTT 
analysis. Error bars indicate standard deviation. This assay is representative of three 
independent experiments. p-value was determined by unpaired t-test (*p<0.05, 
**p<0.01 and ***p<0.001).  
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4.2.5.4 Cell viability of HPV-16 E6 expressed cells following cisplatin 
The results of the previous section (4.2.5.3) demonstrated that forced 
expression of HPV-16 E6 in HPV-negative cells resulted in increased radio-
sensitivity. In order to determine whether a similar effect is seen in response to 
cisplatin treatment, UPCI-SCC 089 cells with E6 were treated with cisplatin at 
2.5, 5 and 10 µg/ml doses. Results showed statistically significant sensitivity at 
all doses (p˂0.05 for UPCI-SCC 089 versus E6-76 at 5 and 10 µg/ml; p˂0.01 
for UPCI-SCC 089 versus E6-76 and E6-76 at 2.5 µg/ml; p˂0.001 for UPCI-
SCC 089 versus E6-76 at 5 and 10 µg/ml).  





Figure 4.22. Cell viability of E6 expressed UPCI-SCC 089 cells following cisplatin. 
Bar graph of cell viability expressed relative to control. Cisplatin chemotherapy was 
performed at 2.5, 5 and 10 µg/ml. Cell viability was assessed by MTT assay 7 days 
following treatment. Bars represent average value from 6 wells normalised to untreated 
control cells. Error bars indicate standard deviation. This assay is representative of 
three independent experiments. p-value was determined by unpaired t-test (*p<0.05, 
**p<0.01 and ***p<0.001)







































The current chapter focused on elucidating the potential mechanisms of 
improved response in HPV-positive OPSCC to conventional therapeutic agents, 
namely radiation and cisplatin. A key cellular protein (p53) and a key viral 
oncoprotein (E6) were selected for study. 
 
The purpose of selecting p53 was that this tumour suppressor remains one of 
the single, most important transcription factors governing the genetic circuitry of 
cells; it has been termed the ‘guardian of the genome’. p53 is a unifying factor 
in the disease because it binds to many regulatory genomic sites and begins 
production of proteins that halt cell division in order for DNA repair to occur. 
Alternatively, if the cellular damage is too severe, p53 initiates the process of 
programmed cell death. Although p53 is the most commonly mutated gene in 
human cancers, HPV-related OPSCC contain inactive wild-type that is p53 
stabilised following cellular stress.335If this protein is functional in HPV-positive 
tumours, p53-induced apoptosis could explain the high response rate of HPV-
positive oropharynx tumors to chemotherapy and radiation and be a reason for 
better response to treatment in patients with this disease.141 
 
The HPV-16 E6 oncoprotein has been appreciated as one of the critical 
regulators of the viral life cycle and driver of tumourigenesis in high-risk HPV 
associated OPSCC.336In HPV-positive tumours, the E6 interaction with E6AP 
and p53 results in ubiquitination, export from the nucleus, and proteasomal 
degradation of p53, thus inhibiting its proapoptotic functions.336  
  Chapter 4. Discussion 
 
 187 
4.3.1 Baseline expression of p53 
p53 in HNSCC caused by traditional risks factors  (alcohol and tobacco) is 
commonly mutated resulting in accumulation of the protein.328,329,337 By contrast, 
HPV-positive OPSCCs are generally associated with wild-type p53.137,184,337The 
wild-type p53 gene encodes a nuclear phosphoprotein having a very short half-
life; consequently this protein does not accumulate in levels high enough to be 
detected immunohistochemically. However most mutated p53 proteins, exhibit 
an enhanced stability and prolonged half-life with a high proportion of missense 
mutation, henceimmunohistochemical p53 detection has been considered an 
appropriate means of detecting p53 mutational alterations.338-340. Although the 
molecular basis of the prolonged half-life of mutant p53 is not fully known, it 
could be explained by the inability of mutant p53 to activate Mdm2 (negative 
regulator of the p53).341 Additionally it is reported that p53 protein in an HPV-
negative tumour not only is inactive as a tumour suppressor but also can bind 
and inactivate any remaining wild-type p53 in a tumour cell.338 
 
In the present study baseline p53 expression by immunohistochemistry (IHC) 
and western blot in vitro showed similar trends.HPV-negative cell lines 
(UPCISCC 072 and UPCI-SCC 089) showed intense and moderate levels, 
respectively (Figures 4.1 and 4.2). The intense staining of UPCI-SCC 072 could 
be related to the presence of missense mutation in the cells (mutation 
13214C>A, codon H179N).278,342,343 The mutation status of p53 in UPCI-SCC 
089 is still not known, but according to the literature it has been used as an 
HPV-negative control, investigating the response of HPV positive and negative 
tumours to treatments.311  
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The majority of HPV-positive cell lines showed undetectable or weak 
expressions of p53 protein, which confirm the presence of wild type p53 in 
accordance with previously published reports. However 93-VU-147T cells 
showed intense immunohistochemical staining and expression by Western blot. 
These cells have been reported as harboring both mutated (L257R) as well as 
wild-type p53. These observations may explain the increased sensitivity to 
conventional therapeutic agents despite high levels of detectable p53.184-
186,276,279,344 
 
In the current study, baseline p53 expression in untreated HPV-positive cells 
was variable. This observation may be explained by presence of low levels of 
residual wild-type p53 despite the down-regulating effects of HPV-16 E6.181,184 
Furthermore, variable baseline p53 expression could also be explained by 
increased passage numbers and conditional differences of the cultures as cells 
in culture are under constant environmental and manipulative stress.312 
 
4.3.2 Role of p53 in increased sensitivity of HPV-positive cells to 
radiation and cisplatin 
Cellular stress signals, such as DNA damage, hypoxia, heat shock, and 
oncogene inactivation induce an increase in the stability of the wild-type p53 
protein. The accumulation of p53 is associated with the transcription of a series 
of p53-responsive genes, including p21 that mediates p53 induction of growth 
arrest and apoptosis.345,346  
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p53 in HPV-positive tumours is one of the crucial cellular targets of high-risk 
HPV-16 E6 oncoprotein. A major strategy employed by the E6 proteins to 
abrogate p53 functions is to induce its degradation by the ubiquitin-proteasome 
pathway through E6-associated protein (E6AP).92,347The degradation of p53 by 
the E6 reduces the net levels of p53 but residual p53 can be activated in 
response to DNA damage and other cellular stresses.182,184,279,348 
 
In accordance with the findings in the present study, several studies have 
demonstrated upregulation of p53 protein following treatment with radiation and 
cisplatin in HPV-positive HNSCC cell lines.179,184,279The results of the current 
study also showed that stabilisation of p53 was accompanied by induction of 
p21 (Figure 4.3 and 4.4), a down-stream target of p53 thereby confirming 
findings in previously published reports.179,184 Furthermore, attenuation of p53 
by shRNA resulted in increased resistance to radiation and cisplatin thereby 
indicating a crucial role of this tumour suppressor protein in the response of 
HPV-positive cells to conventional therapeutic agents. 
 
Although published reports linking p53 to improved treatment response in HPV-
positive OPSCC are sparse, the results of the current study confirm the findings 
by Kimpleet al (2013). This group utilised the 93-VU-147T cell line and showed 
that successful silencing of p53 by small interfering RNA (siRNA) resulted in 
increased radio-resistance of the HPV-positive cells.184 They postulated that 
since E6 induces degradation of p53, there is no selective pressure to favour 
mutation of this tumour suppressor gene in oropharyngeal carcinogenesis; 
potentially explaining the high prevalence of wt-p53 in OPSCC. The current  
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studystrengthens the evidence that rescue of wt-p53 plays a crucial role in the 
response of HPV since it utilised a different HPV-positive cell line (UPCI-SCC 
090) to that of Kimpleet al. 
 
It should be noted, however, that near complete silencing of p53, both in this 
study and by Kimpleet al. (2013)184, resulted in only partial resistance to 
conventional therapeutic agents; HPV-positive cells with attenuated p53 was 
still relatively sensitive compared to HPV-negative cells. This raises the 
possibility that while p53 is important, p53-independent mechanism may also 
play a role in increased radio- and chemo-sensitivity of HPV-positive OPSCC 
cells. 
 
The observation that p53 stabilisation is important for relative radio- and chemo-
sensitivity in HPV-positive cells raises therapeutic implications. Is it possible that 
agents potentiating p53 stabilisation may form part of multi-modality de-
escalation treatment in HPV-positive OPSCC patients. Furthermore, clinical 
evaluation of the p53 status in tumour samples may also have a possible 
prognostic and/or predictive role for patients with this disease. 
 
4.3.3Attenuation of HPV-16 E6 
The E6 protein is thought to promote cell proliferation by stimulating 
degradation of the tumour suppressor p53 protein via the formation of a trimeric 
complex comprising of E6, p53 and the cellular ubiquitination enzyme E6-AP. 
E6-stimulated degradation interferes with biological functions of p53; thus  
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perturbing the control of cell cycle progression, leads to increased tumour cell 
growth.326 Since theresults of the current chapter showed that sensitivity of 
HPV-positive cells was p53-dependent, this study went on to postulate that 
silencing of HPV-16 E6 leads to liberation of functional p53. This would, in turn, 
result in even greater sensitivity of HPV-positive cell lines to therapeutic agents 
due to apoptotic and cell cycle arrest functions of p53. 
 
The current study showed shRNA-mediated repression of HPV-16 
E6 oncogene expression resulted in activation of the p53 tumour suppressor 
protein, decrease in cell proliferation and increased sensitivity in HPV16- 
positive oropharyngeal cancer cells to radiation and slightly but insignificantly to 
cisplatin (section 4.2.4). In head and neck clinical oncology, chemotherapy as a 
single modality treatment is not used for therapeutic intent in management of 
head and neck cancer. Cisplatin, when used, is only an adjunct to radiotherapy; 
it is therefore only a ‘sensitising agent’ to radiation. The DNA adducts formed by 
platinum as a single modality are insufficient to cause cell death. Several clinical 
trials are now considering the omission of cisplatin in the management of 
oropharyngeal cancer. However, effects of p53 knockdown on response to 
cisplatin in this study are preliminary and further work, utilising more cell lines, 
are necessary. 
 
In accordance to the results of the current study, experimental data from several 
groups highlight the potential of E6 oncogene repression as a therapeutic 
strategy in HPV16-positive OPSCC cells since this leads toactivation of the p53 
tumor suppressor pathways and induction of apoptosis.267  
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Ferris et al (2005) showed p53 restoration in UPCI-SCC 090 cells following 
E6siRNA transfection of  
UPCI-SCC 090 cells.279Rampiaset al (2009) showed that shRNA mediated 
silencing of E6 and E7 in HPV-positive oropharyngeal cancer cell line (93-VU-
147T and UPCI-SCC 090) resulted in activation of p53 and Rb proteins and 
induction of increased apoptosis of tumour cells, indicating that the oncoprotein 
is important in the etiology of HPV-positive opropharyngeal carcinogenesis. The 
group showed that E6 is key in maintaining resistance to apoptosis since 
E6shRNA transfection increased the percentage of annexin V–positive cells 
from 13.4% to 84.3% and  3.3% to71.2% 93-VU-147T and UPCI-SCC 090 cells, 
respectively.267Similarly Adhimet al (2013) used the HPV-16-positive UMSCC47 
cell line to demonstratethat repression of E6 resulted in recovery of p53 protein 
with increased induction of apoptosis in vitro and reduction of tumour volume in 
vivo.349 
 
All of the above studies showed that siRNA/shRNA-mediated down-regulation 
of E6/E7 RNA in HPV-positive HNSCC cell lines resulted in p53 up-regulation, 
while also inducing apoptosis. In addition to this Li et al (2013) investigated 
dependence of apoptosis on p53 and the benefit and impact of liberating wild-
type p53. The group used two distinct approaches to liberate p53 in a panel of 
HPV-positive HNSCC cell lines (UPCI-SCC 090, UD-SCC 2 and UM-SCC-47): 
Firstly initiated siRNA suppression of E6/E7 RNA and proteasome inhibition 
with bortezomib. Secondly they used siRNA to prevent p53 up-regulation 
caused by these approaches, evaluating the role and impact of p53 on 
apoptosis and cell cycle arrest in the HPV-positive HNSCC cells. The findings  
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demonstrated that p53 and the p53 targets p21 were up-regulated following 
E6/E7 suppression or proteasome inhibition. However by preventing p53 
expression, apoptosis induced byE6/E7siRNA or treatment with bortezomib in 
HPV-positive cells was repressed, confirming that cell death resulting from 
E6/E7siRNAs was dependent on p53.350 
 
The results of the current study, and those of previously published reports 
indicate that silencing of the HPV-16 E6 oncogene does not fully abrogate the 
malignant phenotype in vitro. Nevertheless, these data also suggest that 
repression of HPV-16 E6 results in liberation of functional p53, which could be a 
potential therapeutic strategy in future multi-modality management of patients 
with HPV-positive OPSCC. 
 
4.3.4Expression of HPV-16 E6 
While p53 is an important mediator of HPV-associated sensitivity to chemical- 
and radiation-induced cell death, several groups have reported p53-
independent mechanisms as contributing to increased susceptibility of these 
cells to conventional therapeutic agents.90,303 The current study postulated that 
HPV gene products, namely HPV-16 E6, may contribute to improved outcome 
of HPV-positive OPSCC cells to radiation and cisplatin. Interestingly, forced 
expression of HPV-16 E6 in an HPV-negative cell line (UPCI-SCC 089) resulted 
in increased sensitivity to radiation and cisplatin (sections 4.2.5.3 and 4.2.5.4), 
suggesting that the improved outcome in HPV-positive OPSCC patient may be 
partly due to the direct effect of this viral oncoprotein.  
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While the status of p53 in UPCI-SCC089 cells is still unknown, baseline 
expression of this protein by Western blot analysis and 
immunohistochemistrymarkedly increased indicating an abrogated pathway, 
likely mutation resulting in inability for targeted degradation. It was therefore 
assumed that any effect of forced E6 overexpression in UPCI-SCC 089 cells 
would be independent of functional p53. Nevertheless, I acknowledge that 
mutant p53 may have some residual function and the effect of E6 
overexpression on mutant forms of this protein should have been evaluated, for 
example by Western blot analysis. 
 
Increased susceptibility to therapeutic agents in HPV-negative cells by the 
introduction on E6 has been shown by several other groups.90,184 For example, 
Kimpleet al (2013) demonstrated increased radiosensitivity in immortalised 
human tonsillar epithelial (HTE) cells transfected by E6 and this was 
accompanied by increased apoptosis.184 However, their report did not proffer 
any possible explanation for this observation. 
 
Pang et al (2011) stably expressed the total open reading frame and an isoform 
of HPV-16 E6 (E6 total and E6*I, respectively) in two p53 mutant oropharyngeal 
HPV-negative cell lines (UM-SCC4 and WSU-HN6). UM-SCC4 has severely 
truncated p53 whereas WSU-HN6 has a H179L substitution in the DNA-binding 
domain of protein. Their results demonstrated that both E6 total and 
E6*Isubstantially increased the rate of cell death caused by moderate doses of 
ionizing radiation indicating that the viral oncoprotein conferred sensitivity to 
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OPSCC cells despite mutant p53.90 Following optimisation of wt-p53 in these 
cells, they showed that while E6 total inhibited p53 transactivation activity, E6*I  
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was non-inhibitory. This group therefore went on to suggest that E6*I sensitized 
cells to radiationinduced death in a p53-independent manner directing them to 
either apoptosis or mitotic catastrophe after a delay in G2M upon irradiation.90 
 
p53-independent mechanisms involved in increased sensitivity of HPV-positive 
cells have also been explored by Gubanova et al (2012). They showed a 
decrease levels in suppressor with morphogenetic effect on genitalia (SMG-1), 
a potential tumor suppressor and often deregulated in cancer, following 
expression of E6/E7 in HPV-negative cell lines, resulting in increased radio-
sensitivity. To confirm their findings, radio-resistance in HPV-positive cells was 
observed following SMG-1 shRNA or E6shRNA transfection.303 
 
The mechanisms of radio- and chemo-sensitivity conferred by E6 are still 
largely unknown. One possible explanation may be the induction of genomic 
instability by E6. A recent study by Marulloet al (2015) showed that chronic 
oxidative stress is a distinct property of HPV-positive HNSCC cells. The state is 
due to the induction of reactive oxygen species (ROS) mediated by 
nicotinamide adenine dinucleotide phosphate oxidases (NOXs) rendering them 
more susceptible to DNA damage following radiation. The work of this group 
suggests a distinct mechanism of sustained genomic instability that contributes 
to the inherent radio-sensitivity of HPV-positive cells.351 
 
Hence the apparent contradictions in response E6 knockdown and over 
expression to radiation and cisplatin may be explained by p53 status. In HPV-  
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positive cells with wild-type p53, knockdown of E6 abrogates the attenuating 
effect of p53 by this viral oncoprotein; p53 function is restored and able to 
induce celldeath following radiation. By contrast, E6 was overexpressed in 
HPV-negative cells with perturbed p53 function where the viral protein has little 
or no effect on the latter. Under these circumstances, E6 may confer 
radiosensitivity by mechanisms independent of p53.The mechanisms for E6-
induced sensitivity is not known, but possible pathways are discussed above.  
 
The mechanisms of HPV-16 E6-induced sensitivity in HPV-negative cells 
require further study. Nevertheless, it is a potential avenue of investigation for 
the improved therapeutic management of HPV-negative HNSCC.
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4.4  Limitations 
The results of the current show that the increased sensitivity of HPV-positive 
cells to radiation and cisplatin in vitro are p53-dependent. However, there are 
several limitations to the current study that prevent generalisation and 
extrapolation to the clinical setting. 
 
The previous chapter described a model of relative sensitivity to radiation and 
cisplatin in HPV-positive OPSCC using a panel of five HPV-positive cell lines 
and two HPV-negative cell lines. In the current chapter, due to time and other 
resource constraints, only two cell lines, namely UPCI-SCC 089 (HPV-negative) 
and UPCI-SCC 090 (HPV-positive) were selected for further study to determine 
the mechanism of HPV-associated sensitivity to these therapeutic agents. 
Therefore, the data should be interpreted with caution since the role of p53 in 
the relative sensitivity of HPV-positive cells may be due to cell line variation and 
should not be generalised to all HPV-positive OPSCCs. 
 
The current study also investigated two targets for further study; one cellular 
protein (p53) and one viral oncoprotein (E6). These targets were selected 
because of their key function in HPV-associated carcinogenesis. A more 
structured method of target selection could have been applied. Key targets from 
comparative HPV-positive and HPV-negative public genomic and expression 
array databases could have been interrogated. In addition, expression array 
analysis of HPV-positive and HPV-negative cells following treatment with 
radiation or cisplatin could have been obtained. Pathway analysis could have 
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been undertaken to elucidate importantcellular regulators in the differential 
response of HPV-positive and HPV-negative cells to these therapeutic agents. 
It is possible that, in addition to p53, other key targets, including those important 
for cell cycle control, induction of apoptosis and/or DNA damage repair may 
have been elucidated. Similarly, although the viral oncoprotein E6 was 
investigated in the current study, the function of other viral proteins such as E5 
and E7 may play an important role in the differential response to radiation and 
cisplatin in these cells. 
 
UPCI-SCC 089 cell line was used to investigate the effects of E6 
overexpression in HPV-negative OPSCC. The effectiveness of stable E6 
transfection was evaluated by RT-PCR. Since there was intense baseline p53 
protein expression in these cells by Western blot analysis and 
immunohistochemistry, it was assumed that there was functional abrogation of 
the p53 pathway in these cells. Sequencing of the p53 gene in UPCI-SCC 089 
cells, to identify specific mutations, would have provided greater clarity to this 
study. There is evidence that E6 is able to target mutant p53 degradation.352 
Therefore, the effect of E6 overexpression on presumed functionally abrogated 
p53 in UPCI-SCC 089 cells, both at baseline and following treatment with 
radiation or cisplatin, would have provided further important information on the 
role of these proteins to explain sensitivity of HPV-positive and HPV-negative 
cells to these agents. 




In summary, the results of the current chapter show that, increased sensitivity of 
HPV-positive cells to radiation and cisplatin in vitro is p53-dependent. 
Furthermore attenuation of E6 in HPV-positive cells resulted in stabilisation of 
p53 and a modest increase in sensitivity to radiation and cisplatin.Forced 
expression of E6 in HPV-negative cells results in increased sensitivity to 
radiation and cisplatin. 
 
The results of Chapter 4 confirm the findings of some previous reports. 
However, the literature also suggests some conflicting data, namely HPV-
positive cells may be as sensitive or more resistant than HPV-negative cells 
depending on selection of controls and/or culture conditions. Chapter 4 utilised 
controls that were site matched while containing mutant p53 (UPCI-SCC072) or 
likely mutant p53 (UPCI-SCC089). This data suggests that, in HPV-positive 
cells, wild-type p53 is necessary to confer radiosensitivity. There are therefore 
clinical implications where, in HPV-positive disease, the determination of p53 
status may be of further prognostic value. Furthermore, novel data from this 
chapter raises the possibility that p53, while playing an important role, may not 
entirely explain the relative radiosensitivity of HPV-positive cells since 
overexpression of HPV16-E6 resulted in increased radiosensitivity in HPV-
negative cells. While only preliminary, these data is novel and warrants further 
study of the potential protective effect of this viral oncoprotein. 






Chapter 5 - Differential response of HPV-positive 
and HPV-negative HNSCC cells to targeted 
therapy in vitro and association of EGFR with 
HPV status.




Despite its influence on prognosis, tumour HPV status is still not routinely used 
to inform therapeutic management. Current OPSCC therapeutic protocols 
implicate high doses of toxic radiation/chemotherapy, which may prove 
unnecessary for HPV-positive disease. Short- and long-term complications of 
current therapeutic protocols significantly impact on quality of life, especially in a 
younger cohort of patients with a long life expectancy.353Subsequently, 
advancements in molecular research have made the identification of targeted 
therapies an attractive alternative therapeutic approach due to possible reduced 
toxicity and improved efficacy.354,355 
 
The results of Chapter 3 demonstrated that HPV-positive HNC cells are 
relatively more sensitive to conventional therapeutic agents, namely radiation 
and cisplatin, compared to site-matched HPV-negative cells. In order to 
determine whether HPV-positive and HPV-negative cells respond in a 
similartrend to targeted and novel therapeutic agents, this section of the study 
evaluated the response of these cells to cetuximab and TRAIL, respectively. 
 
Having evaluated the role of p53 and HPV16-E6 in the response of these cells 
to cetuximab and TRAIL, this study went on to correlate EGFR protein 
expression with the former. Finally, findings of the in vitro association between 
HPV status and EGFR protein expression levels were correlated in tissue 
specimens in vivo.
  Chapter 5. Results 
 
 203 
5.2   Results 
5.2.1 Response to targeted therapy 
In relation to targeted therapy, cetuximab was selected since it is a recombinant 
chimeric monoclonal antibody specifically targeting the extracellular domain of 
EGFR. This receptor is overexpressed in more than 90% of HNSCC and is 
associated with poorer prognosis.156,356 Cetuximab is the most extensively 
studied of the anti-EGFR antibodies and is the first and only targeted therapy 
approved for the treatment of HNC.357-359 Furthermore, the impact of cetuximab 
on response and treatment outcome in HPV-positive OPSCC still remains to be 
defined. Several currently recruiting clinical trials compare cetuximab with 
cisplatin as concomitant agents in HPV-associated OPSCCs as part of a de-
intensification protocol.257-259,261 In relation to this, results from in vitro data 
might be able to inform optimum treatment strategies in this subgroup of 
patients in future. 
 
5.2.1.1 Cell viability following cetuximab treatment 
Cell viability assays were performed as detailed in section 2.2.1.13. In HPV-
positive cells treatment with cetuximab resulted in cell viability ranging from 
100-90% at all doses from 200-1200nM.  By contrast, HPV-negative cell lines 
showed cell viability ranging from 95-90%, 90-85%, 95-80%, 70-65% and 65-
60% at 200, 400, 600, 800, 1000 and 1200 nM, respectively(Figure 5.1). HPV-
negative cells demonstrated greater sensitivity to cetuximab compared to HPV-
positive cells (p ≤0.01 for HPV-negative cells versus UPCI-SCC 152and UPCI-  
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SCC 154 cells at 1000 nM; p ≤0.001 for HPV-negative cells versus UPCI-SCC 
090, UD-SCC 2 and 93-VU-147T cells at 1000 nM andall HPV-positive cells at 




Figure 5.1. Cell viability HPV-negative and HPV-positive cell lines following 
cetuximab. 
Bar graph of cell viability expressed relative to control. Cetuximab chemotherapy was 
performed at 200, 400, 600, 800, 1000 and 1200 nM. Cell viability was assessed by 
MTT assay 7 days following treatment. Bars represent average value from 6 wells 
normalised to untreated control cells. Error bars indicate standard deviation. This assay 
is representative of three independent experiments.  
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5.2.1.2   Cell viability following cetuximab treatment in E6-attenuated cells 
The results of Chapter 4 showed that shRNA-induced attenuation of E6 
expression in HPV-positive cells led to the restoration of p53 protein and 
greater sensitivity to conventional therapeutic agents. Since HPV-positive cells 
were resistant to treatment with cetuximab, this study went on to determine 
whether this observation was due to the oncogenic properties of E6. 
 
The results show that silencing of E6 in HPV-positive cells (090-E6shRA) had 
no effect on cell viability when treated with cetuximab at aforementioned doses 
compared to the parental cell line (UPCI-SCC 090) and the scrambled control 
(090-scr control, Figure 5.2). No statistical significance was observed 
comparing treatment response at higher doses (p=0.9854 for 090-E6shRA cells 
versus UPCI-SCC 090 at 1000 nM and p=0.3247 for 090-E6shRA cells versus 
UPCI-SCC 090 at 1200 nM, unpaired t-test).  






Figure 5.2. Cell viability of UPCI-SCC 090 E6shRNA cells following cetuximab. 
Bar graph of cell viability expressed relative to control. Assay was performed in 
triplicate with 200, 400, 600, 800, 1000 and 1200 nM of cetuximab. UPCI-SCC 090 and 
scrambled control (090-scr control) were used as negative controls. Error bars indicate 
standard deviation. This assay is representative of three independent experiments.  































  Chapter 5. Results 
 
 207 
5.2.1.3   Cell viability of E6 expressed cells following cetuximab 
 
In order to confirm the findings in section 5.2.1.3, HPV-16 E6 was forcibly 
expressed in an HPV-negative cell line (UPCI-SCC 089) using two separate 
HPV16-E6 plasmids (E6-75 and E6-75) by stable transfection. Following 
treatment with cetuximab, cell viability was assessed by MTT assay. HPV-
negative cells expressing E6 or a scrambled control showed similar responses 
to cetuximab; E6 expressed cells had no effect on cell viability (Figure 5.3). No 
statistical significance was observed between test and control cells (p=0.0916 
for E6-75 and p=0.1441 for E6-76 versus UPCI-SCC 089 respectively at 1000 
nM and p=0.3694 for E6-75 and p=0.3224 for E6-76 versus UPCI-SCC 089 
respectively at 1200 nM, unpaired t-test).  





Figure 5.3. Cell viability of E6 expressed UPCI-SCC 089 cells following treatment 
with cetuximab. 
Bar graph of cell viability expressed relative to control. Assay was performed in 
triplicate. Transfected plasmids of HPV-negative cell line (E6-75 and E6-76) and 
controls (UPCI-SCC 089 & 089-GFP) were treated at dosages of 200, 400, 600, 800, 
1000 and 1200 nM. Error bars indicate standard deviation. This assay is representative 
of three independent experiments.  
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5.2.2 Association of EGFR with HPV status 
The results of section 5.2.1.1 showed that HPV-positive cells were more 
resistant to cetuximab treatment in vitro compared to HPV-negative cells. In 
order to determine whether resistance to cetuximab in HPV-positive and HPV-
negative cells was associated to baseline expression levels of EGFR, 
immunohistochemistry and western blot analysis was undertaken on untreated 
cells. 
 
5.2.2.1   Baseline EGFR expression 
5.2.2.1.1 Immunohistochemistry 
Immunohistochemical evaluation of cell lines was undertaken using separate 
antibodies against the external domain (3C6) and internal domain (5B7) of 
EGFR. HPV-positive cell lines demonstrated variable staining intensity; UPCI-
SCC 152 and UPCI-SCC 090 showed weak staining whereas moderate to 
intense staining was observed in UD-SCC 2, UPCI-SCC 154 and 93-VU-147T. 
By contrast, both HPV-negative cell lines (UPCI-SCC 072 and UPCI-SCC 089) 
demonstrated diffuse intense staining (Figure 5.4).





UPCI-SCC 089    UPCI-SCC 072    UPCI-SCC 090    UPCI-SCC 152      UPCI-SCC154       UD-SCC 2       93-VU-147T 
Figure 5.4. EGFR Immunohistochemistry. 
Intense EGFR staining in UPCI-SCC 072 and UPCI-SCC 089 (HPV-negative) cell lines. Negative or weak in UPCI-SCC 090, UPCI-SCC 
152, UPCI-SCC 154 and UD-SCC 2 and 93-VU-147T (HPV-positive) cell lines. All sections shown are 40 x magnification.
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5.2.2.1.2 Western Blot 
In order to confirm the EGFR immunohistochemical staining in cell lines, protein 
levels were additionally analysed by western blot. The latter confirmed the 
immunohistochemistry findings; namely UPCI-SCC 072 and UPCI-SCC 089 
showed increased levels of EGFR. Similarly, in HPV-positive cell lines protein 
was undetectable in UPCI-SCC 090 and UPCI-SCC152 and weak to moderate 
in UPCI-SCC 154, UD-SCC 2 and 93-VU-147T (Figure 5.5 A). Quantification of 
EGFR by image J analysis showed 2-2.5 fold increase in the p53/β-actin ratio in 
UPCI-SCC 072 and UPCI-SCC 089 (HPV-negative) cell lines. In contrast to 
HPV-positive cell lines that showed 0-1 fold increase, (p ≤ 0.001 for HPV-
negative cells versus HPV-negative cells, Figure 5.5 B).  

























Figure 5.5. Western blot analysis of baseline expression of EGFR. 
A) Expression difference of EGFR in cells of UPCI-SCC 072 and UPCI-SCC 089 (HPV-
negative) and UPCI-SCC 090, UPCI-SCC 152, UPCI-SCC 154, UD-SCC 2 and 93-VU-
147T (HPV-positive) cell lines by western blot. Arrows indicate molecular weight of the 
pre-stained protein ladder. HN5 cell line was used as positive control for EGFR 
expression. β-actin was used as a loading control. The above is representative of two 
independent experiments. B) The intensity of the bands shown in western blot (Figure 
5.5 A) was quantified in relation to β-actin level using Image J. p-value was determined 
by unpaired t-test (p<0.001).  
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Overall, response of the panel of cell lines to cetuximab broadly corresponded 
to EGFR protein expression levels with immunohistochemistry and western blot. 
UPCI-SCC 154, UD-SCC 2 and 93-VU-147T with variable expression of EGFR 
showed slight sensitivity to cetuximab and UPCI-SCC 090 and UPCI-SCC 152 
(HPV-positive), cell lines that showed no expression of EGFR were most 
resistant to cetuximab. By contrast HPV-negative cell lines, with intense staining 
were relatively more sensitive (Figure 5.1). 
 
5.2.2.2   EGFR expression in patient tumour samples 
The results of section 5.2.2 indicate that there was trend towards an inverse 
correlation between HPV status and EGFR protein expression in HNSCC cell 
lines. In order to determine whether this cell line model was an accurate 
representation of the clinical situation, EGFR immunohistochemistry was carried 
out OPSCC patient tumour samples. 
 
Tumour samples from 93 OPSCC patients were used (51 HPV-positive, 42 
HPV-negative).Clinicopathological features of the patient characteristic e.g. 
gender, site, disease stage and treatment modality of 93 patients with OPSCC 
have been summarised in table 9. Two separate EGFR antibodies were used: 
EGFR (3C6, Figure 5.6), which recognises the external domain, including those 
with the vIII truncation and EGFR (5B7, Figure 5.7) targeting the intracellular 
domain. In order to overcome intra-tumour heterogeneity of staining (Figure 
5.8), immunohistochemistry was undertaken in on whole sections and a 
  Chapter 5. Results 
 
 214 
composite H-score was ascertained (see section 2.2.2.2, materials and 
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Table 9: Summary of patient characteristics. Gender, site, disease stage 
and treatment modality of 93 patients with OPSCC.  






Figure 5.6. Photomicrographs of EGFR (3C6) immunohistochemistry. 
Photomicrographs for the extracellular domain of EGFR (3C6) in four separate OPSCC 
tumour samples (A & B low power view, C & D high power view). A & C were HPV-
positive and B & D were HPV-negative. The overall H-score for the tumour samples in 
A, B, C and D were 100, 300, 90 and 280, respectively. In all cases, the overlying non-
dysplastic epithelium served as intra-sectional controls.  






Figure 5.7. Photomicrographs of EGFR (5B7) immunohistochemistry. 
Photomicrographs for the intracellular domain of EGFR (5B7) in four separate OPSCC 
tumour samples (A & B low power view, C & D high power view). A & C were HPV-
positive and B & D were HPV-negative. The overall H-score for the tumour samples in 
A, B, C and D were 100, 300, 90 and 280, respectively. In all cases, the overlying non-
dysplastic epithelium served as intra-sectional controls.  
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Dot over box-and-whisker plots for EGFR (C36) and EGFR (5B7) are shown in 
Figure 5.8. The mean, mode, median and range for EGFR (3C6) in HPV-
positive cases were 63, 45, 50 and 15-230, respectively. By contrast, the mean, 
mode, median and range for EGFR (3C6) in HPV-negative tumours were 192, 
190, 190 and 30-295, respectively. There was an overall trend for lower H-
scores in HPV-positive OPSCCs compared to HPV-negative tumours, (p>0.001 
for EGFR 3C6 and EGFR 5B7, Wilcoxon Signed Rank Test).  




Figure 5.8. Dot over box-and whisker plot of EGFR. 
Dot over box-and whisker plot of EGFR H-scores for EGFR (3C6) and EGFR (5B7) in 
HPV-positive (n=51) and HPV-negative (n=42) OPSCC tumour samples. Median 
indicated by horizontal bar.  




Figure 5.9. Photomicrograph of an OPSCC with EGFR (3C6) immunohistochemistry. 
Photomicrograph demonstrating marked intra-tumour heterogeneity for the extra-cellular domain of EGFR (3C6). The overall H-score for 
this specimen was 200.  
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5.2.3   Survival analysis 
5.2.3.1   Overall survival by HPV status 
Figure 5.10 shows the Kaplan–Meier survival plot by HPV status. The mean 
overall survival for HPV-positive was 107 months (95% confidence interval 
[CI]= 91-123). By contrast, the mean overall survival for HPV-negative was 40 
months (95% CI= 29-50). The overall survival for HPV-positive patients was 
significantly greater than HPV-negative patients (p<0.001, Log Rank).In Kaplan-
Meier plots, the term ‘censored’ refers to the event (namely death in the case of 
overall survival survival) not having occurred at the time point the data was 
collected.  






Figure 5.10. Kaplan–Meier survival plot for overall survival by HPV status. 
Survival analysis by HPV status. Overall survival curves ofHPV-positive (n=51) and 
HPV-negative (n=42) OPSCC tumour samples were analysed throughthe Kaplan–
Meier method.  
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5.2.3.2   Overall survival analysis by EGFR status 
Figure 5.11 shows the Kaplan–Meier survival plot by EGFR expression levels at 
various H-score cut-off (50, 100, 150 and 200). The H-scores were calculated 
as described in section 2.2.2.2. Low EGFR 3C6 levels correlated with improved 
overall survival for H-score cut-offs of 100, 150 and 200, (p=0.001, p=0.002 and 
p=0.012, respectively, Log Rank).  Low EGFR 5B7 levels correlated with 
improved overall survival for H-score cut-offs of 100 and 200 (p=0.008 and 
p=0.001, respectively, Log Rank).  




Figure 5.11. Kaplan–Meier survival plot for overall survival by EGFR status. 
Survival analysis by EGFR expression. Overall survival of 3C6 and 5B7 curves based on the Kaplan–Meier method were analysed. 
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5.2.3.3   Overall survival by HPV and EGFR status 
The results of the previous two sections indicate that, individually, HPV status 
and EGFR levels have prognostic utility. In order to determine whether there is 
prognostic utility in a combination of these two factors, Kaplan-Meier survival 
plots were undertaken following stratification of patients according to EGFR 
levels within the HPV-positive (HPV+) and HPV-negative (HPV-) cohorts 
separately (Figure 5.12). Within the HPV-positive group, there was a trend 
towards improved survival in the low EGFR 5B7 subgroup at a H-score cut-off 
of 100, but this was not statistically significant (p=0.137, Log Rank). Within 
HPV-positive and HPV-negative groups, further stratification by EGFR at all 
other H-score cut-off levels did not show any statistically significant differences 
in overall survival.  















Figure 5.12. Overall survival Kaplan-Meier plots for HPV+ and HPV- patients at incremental EGFR C36 and EGFR 5B7 H-scores. 
Survival analysis by HPV and EGFR expression. Overall survival 3C6 (top row) and 5B7 (bottom row) curves based on the Kaplan–Meier 
method were analysed. 
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5.2.4   Response to novel therapeutic agent -TRAIL 
TRAIL has been shown to demonstrate selective cytotoxicity in several types of 
malignant cell lines360 and recombinant TRAIL has shown promising results in 
phase I/II clinical trials for the treatment of patients with advanced tumours.361 In 
HPV-negative HNSCC cell lines, TRAIL has been shown to demonstrate 
variable death-inducing activity.362 This agent induces apoptosis by activating 
caspase-8. Since it has been shown that HPV-16 E6 protein has the ability to 
interact with caspase 8 and target it for degradation,363,364 the next stage of this 
study sought to investigate the relative sensitivity of the current panel of cell 
lines to TRAIL.  
 
 
5.2.4.1   Cell viability following TRAIL treatment 
Cell viability assays were performed as detailed in section 2.2.1.13. In HPV-
positive cells treatment with TRAIL resulted in cell viability ranging from 90-
100% at all doses from 3.13 -100 ng/ml. By contrast, HPV-negative cell lines 
showed cell viability ranging from 5-10%, 20-30%, 20-40%, 25-45%, 30-45 and 
50-55 at 3.13, 6.25, 12.5, 25, 50 and 100 ng/ml, respectively (Figure 5.13). 
HPV-negative cells demonstrated greater sensitivity to TRAIL compared to 
HPV-positive cells (p ≤0.001 for HPV-negative cells versus all HPV positive cell 
lines at 50 and 100 ng/ml with the exception of UPCI-SCC 072 versus 93-VU-
147T with p˂0.01, unpaired t-test).  







Figure 5.13. Cell viability of HPV-negative and HPV-positive cell lines following 
TRAIL. 
Bar graph of cell viability expressed relative to control. TRAIL chemotherapy was 
performed for 48 hours at 3.13, 6.25, 12.5, 25, 50 and 100 ng/ml. Cell viability was 
assessed by MTT assay 7 days following treatment. Bars represent average value 
from 6 wells normalised to untreated control cells. Error bars indicate standard 
deviation. This assay is representative of three independent experiments.  
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5.2.4.2   Cell viability in response to TRAIL following attenuation of E6 
In order to determine whether the relative resistance of HPV-positive cells to 
TRAIL was a direct effect of viral oncoprotein, treatment of these cells were 
undertaken following attenuation of E6 in HPV-positive cells. There was no 
effect on cell viability by MTT assay of E6-attenuated cells (090-E6shRA) when 
treated with TRAIL at aforementioned doses compared to the parental cell line 
(UPCI-SCC 090) and the scrambled control (090-scr control, Figure 5.14). No 
statistical significance was observed between test and control cells (p=0.1969 
for 090-E6shRA cells versus UPCI-SCC 090 at 50 ng/ml and p=0.3822 for 090-
E6shRA cells versus UPCI-SCC 090 at 100 ng/ml, unpaired t-test).  







Figure 5.14. Cell viability of UPCI-SCC 090 E6shRNA cells following TRAIL. 
 
Bar graph of cell viability expressed relative to control. Assay was performed in 
triplicate with 3.13, 6.25, 12.5, 25, 50 and 100 ng/ml of TRAIL through MTT assay. 
UPCI-SCC 090 and scrambled control (090-scr control) were used as negative 
controls. Error bars indicate standard deviation. This assay is representative of three 
independent experiments.  
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5.2.4.3   Cell viability of E6 expressed cells following TRAIL 
To confirm that relative resistance to TRAIL was not a direct effect HVP-16 E6, 
cell viability MTT assay was undertaken following treatment with this agent of 
stably expressed HPV-16 E6 HPV-negative cells (E6-75 and E6-76). Cells 
forcibly expressing E6 or a control vector showed similar responses following 
treatment with TRAIL; E6 expressed cells had no effect on cell (Figure 5.15). No 
statistical significance was observed between test and control cells (p=0.9336 
for E6-75 and p=0.4284 for E6-76 versus UPCI-SCC 089 respectively at 50 
ng/ml and p=0.7048 for E6-75 and p=0.3674 for E6-76 versus UPCI-SCC 089 
respectively at 100 ng/ml, unpaired t-test).  






Figure 5.15. Cell viability of E6 expressed UPCI-SCC 089 cells following TRAIL. 
Bar graph of cell viability expressed relative to control. Assay was performed in 
triplicate. Transfected plasmids of HPV-negative cell line (E6-75 and E6-76) and 
controls (UPCI-SCC 089 & 089-GFP) were treated at dosages of 3.1, 6.3, 12.5, 25, 50 
and 100 ng/ml. Error bars indicate standard deviation. This assay is representative of 
three independent experiments
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5.3   Discussion 
The results of Chapter 3 indicated that HPV-positive cells demonstrate 
increased relative sensitivity to radiation or cisplatin compared to site-matched 
HPV-negative cells. This finding provided a useful in vitro model for improved 
survival in HPV-associated OPSCC since radiation and cisplatin are current 
mainstay treatment modalities for this disease. Nevertheless, these 
conventional therapeutic agents are associated with significant toxic effects and 
there is therefore a trend towards more targeted therapy which maintains 
current response rates whilst reducing the side effects of treatment. In order to 
pre-empt clinical studies of the utility of alternatives to radiation and cisplastin, 
this section of the current study focussed on the in vitro response of HPV-
positive and HPV-negative HNC cell lines to targeted and novel agents, namely 
cetuximab and TRAIL, respectively. 
 
5.3.1   Response of cell lines to cetuximab 
Cetuximab is a monoclonal chimeric (human/mouse) antibody that targets 
EGFR with high affinity, and inhibits endogenous ligand binding, thereby 
blocking receptor dimerisation, tyrosine kinase phosphorylation, and pro-
survival signal transduction.365,366 This drug, in combination with radiotherapy, is 
approved for the treatment of HNSCC and there are currently several clinical 
trials in progress to determine whether cetuximab is an efficacious alternative to 
cisplatin for the management of this disease.258,259,367  
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Unlike the relative sensitivity of HPV-positive cells to radiation and cisplatin 
(Chapter 3), somewhat surprisingly, the results of current study demonstrated 
that HPV-positive cells were relatively resistant to treatment with cetuximab. 
Furthermore, modulation of HPV16-E6 (either through attenuation of 
endogenous E6 in HPV-positive cells, or forced expression in HPV-negative 
cells) did not significantly alter response to this agent, suggesting a virus-
independent role in resistance to cetuximab. 
 
Investigation into the relationship between HPV and EGFR has largely centred 
on the E5 protein.72,81,82 Little is known about the direct relationship between 
EGFR and E6. Unlike HPV-negative carcinomas where increasing 
overexpression of EGFR corresponds to stepwise carcinogenesis, EGFR 
‘oncogene addiction’ may not to be necessary in HPV-positive disease. 
Therefore, the inverse relationship between EGFR and HPV may be an 
epiphenomenon. The relative resistance of HPV-positive cells to cetuximab may 
be directly related to the quantity of EGFR expression. 
 
Data on the in vitro response of HPV-positive cells to cetuximab is sparse. In 
contrast to the current study, Nagel et al (2013) showed no difference in 
response of HPV-positive and HPV-negative cells to cetuximab.299 The 
discrepancy with the current study may be partly explained by the lack of site-
matched controls and the greater cumulative range of cetuximab dose. 
Pogorzelskiet al (2014) also evaluated the effect of HPV on cetuximab-treated 
cells treatment in HNC cells. They described cell-line variation even among 
HPV-positive cells (i.e. sensitivity in UPCI-SCC 090 and resistance in  
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UD-SCC2.368 Furthermore, through enforced transgene activation of E6 and E7, 
they found that modulation of viral oncoproteins did not significantly affect 
response to cetuximab. Their results concur with those of the current study 
where resistance to cetuximab was independent of HPV16-E6.  
 
In a recent report using a similar cell line panel to that of the current study, 
Gusteret al (2014) showed that concomitant cetuximab failed to further 
radiosensitise HPV-positive cells.369 In support of the findings of the current 
study their data indicate that the response of HPV-positive cells to 
cetuximaband radiation are likely to be divergent. To date, there are no reports 
of adirect mechanistic pathway of HPV proteins in the down-regulation of 
EGFR. The inverse correlation between HPV and EGFR may also be a function 
of smoking. Some groups have demonstrated that EGFR expression was 
significantly higher in current smokers than in past smokers, with never smokers 
demonstrating lowest levels of the protein.370 Since patients with HPV-
associated OPSCC tend to be never, or past smokers, this group of patients are 
most likely to demonstrate low EGFR levels.  
 
Having determined that HPV-positive cells demonstrated increased resistance 
to cetuximab, the current study went on to determine whether this may be 
explained by increased levels of EGFR protein expression. Using 
immunohistochemistry and western blot analysis, there was a clear correlation 
between resistance to cetuximab and EGFR protein expression in the panel 
ofcell lines in this study. Since there was a trend towards an inverse correlation 
between HPV status and EGFR protein expression, this  
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study went on to determine whether the current panel of cell lines provided a 
suitable in vitro model that reflected the clinical situation. Notwithstanding the 
possibility that these findings may be explained by cell line variation alone, 
these data indicate that the current in vitro model corresponds to the clinical 
findings (section 5.2.2), as discussed in the ensuing section (5.3.2). 
 
 
5.3.2   Association of EGFR with HPV status in OPSCC tissue 
specimens 
The current study demonstrated that EGFR protein levels are significantly 
downregulated in HPV-positive cells in comparison to HPV-negative cells in 
vitro. Furthermore, this study also demonstrated a similar pattern in patient 
tissue samples in vivo. For semi-quantification by immunohistochemical H-
score, EGFR protein levels were evaluated against intra-sectional controls of 
normal surface and reticulated crypt epithelium (Figure 5.8). Therefore, the 
downregulation of EGFR in HPV-positive cells are not a result of subsite 
differences within the head and neck Nevertheless, the mechanisms of HPV-
associated downregulation of EGFR remain largely unknown. In HPV-negative 
carcinomas, associated with tobacco use and alcohol excess, there is a 
stepwise increase EGFR protein expression from normal to premalignancy to 
invasive carcinoma. In these tumours, EGFR is likely to be a necessary driver 
for carcinogenesis. By contrast, no observable premalignant phase is seen in 
HPV-positive tumours, raising the possibility that the oncogenic drive may be 
independent of EGFR. However, further  
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studies, beyond the scope of this thesis, are necessary to test this hypothesis.  
The cell line model described above provided a suitable model for evaluating 
response to cetuximab because it correlated with the findings in OPSCC tissue 
samples; there was an inverse correlation between HPV status and EGFR 
protein expression. The inverse correlation was more pronounced for the 
extracellular domain (EGFR 3C6) compared to the intracellular domain (EGFR 
5B7, Figure 5.5). A growing number of previous reports aresupportive of this 
data. Reimerset al. (2007) found a trend towards an inverse correlation 
between EGFR protein expression and p16-positive OPSCC (p=0.083).156 
Since then, up to eight independent studies with a combined cohort of 1231 
patients have confirmed this inverse relationship.128,188,189,370-374 By contrast, 
Perroneet al. (2006) and Rampiaset al (2013) did not demonstrate this inverse 
correlation.375,376 Although this discrepancy may be explained by the use of 
different antibodies, a more likely explanation is the lack of standardised EGFR 
scoring criteria. Indeed, there are no agreed cut-off with some groups defining 
EGFR positivity as ‘membrane staining of at least moderate intensity of 10% of 
cancer cells’ while others defining it as ‘more than 50% of the cell membranes 
of the tumour cells’.156,188 
 
5.3.3   Survival analysis 
In the cohort of patients studied, patients with HPV-associated OPSCC 
demonstrated improved overall survival compared to site and tumour  
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matched patients. This data add to the pool of already robust findings of 
improvedprognosis in HPV-positive OPSCC patients. Similarly low EGFR 3C6 
(H-score cut-offs of 100, 150 and 200) and low EGFR 5B7 (H-score cut-offs of 
100 and 200) were also associated with improved overall survival. These results 
are supported by several previous reports that have shown poorer survival 
outcome in HNC patients with high EGFR protein expression.24,377,378 
 
Several reports have indicated that a combination of HPV status and EGFR 
protein levels may have prognostic value.188,370,371 The current study failed to 
demonstrate any further prognostic value when HPV-positive and HPV-negative 
patients were further stratified into high and low EGFR groups, respectively. 
There are several possible reasons for this discrepancy. In the current cohort, 
there was a strong correlation between HPV status and EGFR protein 
expression; very few HPV-positive OPSCC tumours demonstrated high EGFR 
levels (Figure 5.9) thereby limiting sub-group analysis. Furthermore, by 
evaluating H-scores, this current study took into account intra-tumour 
heterogeneity and therefore, within a single specimen, semi-quantitative 
evaluation of areas expressing high EGFR intensity levels may have been 
‘diluted’ by foci with low levels of the protein. Nevertheless, further work is 
necessary, especially is standardising semi-quantitative IHC assessment and 
cut-offs, to determine whether a combination of HPV and EGFR are useful 
prognostic indicators in OPSCC.  
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5.3.4   Impact on management of OPSCC 
In light of the fact that HPV-associated OPSCC express less EGFR, the 
question of importance is, ‘is anti-EGFR treatment useful in patients with HPV-
positive HNSCC?’ Against this background, it is important to highlight that, to 
date, no study using EGFR inhibitor drugs in HNSCC has shown that EGFR 
gene copy number or expression level is predictive of clinical tumour 
response.379,380 For example, even amongst those patients with HPV-negative 
HNSCCs that have high EGFR expression, only 8–13% respond toa single-
agent EGFR inhibitor.381 In the current study, it was not possible to further 
evaluate whether pre-treatment expression levels of EGFR impacted on 
response to cetuximab because only 3 patients within the cohort were treated 
with this agent as an alternative to cisplatin. 
 
To answer the question above, several clinical trails with cetuximab combined 
with radiation in an effort to reduce long term side effects of treatment whilst still 
preserving survival outcomes in HPV-positive patients are in progress. The 
Radiation Therapy Oncology Group (RTOG) 1016 is a multi-centre based in the 
United States phase III trial recruiting patients with Stage III or IV p16-positive 
OPSCC patients with the goal of evaluating the replacement of cisplatin with 
cetuximab. Patients have been randomised to receive weekly cetuximab or 
intravenous cisplatin with concurrent accelerated intensity-modulated radiation 
therapy (IMRT) to 70 Gy.258 Similarly, in the United Kingdom, the De-
ESCALaTE HPV trial aims to recruit 304 p16-positive OPSCC patients 
randomised to conventionally fractionated intensity-modulated radiation therapy 
(IMRT) with either cetuximab or  
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cisplatin. Theprimary outcome measure is rates of long term (i.e. 2-years post 
treatment) toxic effects, whilst overall survival and disease recurrence are 
secondary outcome measures.259 Data from these trials, with appropriate follow-
up period will not be available for several years. Once available, these results 
will inform the clinical community whether cetuximab can replace cisplatin for 
the management of HPV-positive OPSCC with the aim of reducing treatment-
related toxicity while maintaining the same cure rates. Furthermore, post-hoc 
analysis of tissue sample may shed light on whether pre-treatment levels of 
EGFR are predictive of response to cetuximab. 
 
5.3.5   Response of cell lines to TRAIL 
TRAIL is now being considered as a promising anti-tumour approach since it 
selectively kills several types of malignant cell lines with little effect on normal 
cells.360 However, to date, there have been no clinical trials evaluating this 
agent in the management of HNSCC. Pre-clinical investigation has 
demonstrated HNSCC cell line variation in response to recombinant TRAIL 
where it appears that high levels of endogenous caspase-8 is associated with 
sensitivity to this agent.362 Since HPV-16 E6 interferes with caspase-8 activation 
by accelerating its degradation; this study postulated that HPV-positive cells 
were likely to be more resistant to TRAIL. Some reports have suggested that 
small molecules could inhibit E6 from binding to procaspase-8 thereby restoring 
the apoptotic pathway.269 Although this study demonstrated greater resistance 
of HPV-positive cells to TRAIL, attenuation of E6 failed to sensitise these cells 
to the drug. Furthermore, forced  
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expression of E6 in HPV-negative cells, previously sensitive to TRAIL, did not 
significantly alter itssensitivity thereby suggesting that HPV-associated 
resistance to TRAIL may be E6-independent.  
 
The mechanisms if TRAIL resistance in HPV-positive cells is beyond the scope 
of this thesis. Parallel work within this group has shown that TRAIL resistance in 
HPV-positive cells is independent of levels of endogenous caspase 3, caspase 
8 and XIAP.382 However, larger expression profiling data is necessary to dissect 
the pathways involved. Nevertheless, from the current study and previous work 
within this group, it appears that the mechanisms are independent of E6. 
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5.4   Limitations 
The results of the current section of this study demonstrated that HPV-positive 
cells in vitro are more resistant to cetuximab in comparison to HPV-negative 
cells. Furthermore, the relative resistance to cetuximab in vitro is inversely 
correlated to EGFR protein expression as determined by Western blot analysis. 
A limitation of the current study is the lack of further characterisation of EGFR 
status of the cell line panel. Although rare in HNC, missense mutations, 
truncations and amplifications have been reported.2,3 More detailed 
characterisation of EGFR status is likely to have provided greater accuracy of 
the utility of this in vitro panel as a model that mimics the clinical situation. 
 
As with previous chapters, this section of the study investigated mechanisms of 
response to therapeutic agents in only one HPV-positive and one HPV-negative 
cell line. Comparison of therapeutic responses between HPV-positive and HPV-
negative cells in a larger panel of cell lines would mitigate against cell line 
variation independent of viral status. Similarly, this study only evaluated the role 
of HPV16-E6 in response to novel and targeted therapeutic agents. No 
significant effect was observed in response to cetuximab or TRAIL when E6 
was knocked down in HPV-positive cells, or when the oncoprotein was 
overexpressed in HPV-negative cells. However, evaluation of the role of E6 
alone does not exclude possibility that HPV may still play a role in resistance to 
therapeutic targeting of EGFR or death receptors. The potential roles of E5 and 
E7 in resistance to these therapeutic agents still require investigation. 
Characterisation of these cells in relation EGFR, other ErbB receptor family,  
  Chapter 5. Limitation 
 
 242 
death receptor family and their downstream targets as well as response to 
EGFR tyrosine kinase inhibitors and a larger panel of death receptor targeting 
agents are necessary prior to extrapolation to the clinical situation. Parallel in 
vitro studies including response to cetuximab following overexpression of EGFR 
in HPV-positive cells are also likely to add value to the current study. 
 
This study also demonstrated a trend towards an inverse correlation between 
HPV status and EGFR protein expression in vivo in patient OPSCC tumour 
samples. However, the study is limited by the small cohort size, which 
precludes immediate clinical applicability. The high estimated overall survival 
rate in the HPV-positive group, coupled with the small sample size, may explain 
the inability of the combination of HPV status and EGFR expression to further 
refine survival estimates. Multivariate analysis of HPV status, EGFR expression, 
tumour stage, smoking and alcohol history and therapeutic modality (including 
equal numbers of patients treated with Cetuximab versus cisplatin combination 
therapy) is likely to inform translational benefit of this study.  
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5.5   Conclusion 
In summary, the results of the current chapter show that: 
1. HPV-positive cells are relatively resistance to treatment with cetuximab 
compared to HPV-negative cells. 
2. Resistance to cetuximab was independent of HPV16-E6, but correlated 
with EGFR protein expression levels in vitro. 
3. The in vitro cell line model was representative of the clinical tumour 
samples. 
4. As prognostic marker, HPV status and EGFR protein levels 
demonstrated utility when used separately. However, used in 
combination, these markers did not demonstrate further refinement of 
prognostic utility. 
5. HPV-positive cells are relatively resistance to treatment with TRAIL 
compared to HPV-negative cells.Resistance to TRAIL was independent 
of HPV16-E6.
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6.1.   Summary and Conclusions 
In summary, this thesis describes an in vitro model of relative radio- and chemo-
sensitivity, which mirrors clinical observations. Sensitivity to radiation and 
cisplatin was associated with stabilisation of functional p53 in HPV-positive 
cells. Forced expression of HPV-16 E6 in HPV-negative, mutant p53 cells, also 
resulted in sensitivity to radiation and cisplatin. This study therefore describes 
both p53-dependent and HPV-16 E6-dependent/p53-independent mechanisms 
of sensitivity of HNC cells to radiation and cisplatin. 
 
By contrast to radiation and cisplatin, HPV-positive cells were relatively resistant 
to an EGFR-targeted therapeutic agent (cetuximab) and to TRAIL. In inverse 
correlation between HPV status and EGFR protein expression was 
demonstrated in cell lines in vitro and OPSCC tissue sample in vivo, but EGFR 
protein expression in the later did not confer additional prognostic value beyond 
HPV status in the latter.
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6.2   Future Work 
1. Validation of the in vitro model of relative radio- and chemo-sensitivity. 
Since the development of this model, described in Chapter 3, several novel 
HPV-positive cell lines have been reported in the literature.317,318 Demonstration 
of the relative sensitivity in these new described HPV-positive cell lines will 
strengthen the model and overcome the possibility of cell line variation. 
Furthermore, in vivo validation using animal xenografts for the evaluation of 
tumorigenicity and response to treatment will further validate the current in vitro 
model. 
 
2. E6-mediated induction of radio- and chemo-sensitivity. 
The results of Chapter 4 showed that forced expression of HPV-16E6 in HPV-
negative HNC cells resulted in increased radio- and chemo-sensitivity in p53-
independent manner. The mechanisms to explain this observation are 
unknown. Investigation of this potential ‘protective’ effect of HPV16-E6, 
including the possibility of viral oncoprotein-mediated induction of genetic 
instability, may have therapeutic implications. 
 
3. Mechanisms of resistance to EGFR-targeted therapy.  
The mechanisms for resistance to cetuximab in vitro demonstrated in Chapter 5 
are still not known. Since there was an inverse correlation between HPV status 
and EGFR protein expression, an observation confirmed in tissue samples in 
vivo, a clinically important and timely research  
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question is ‘Are pre-treatmentlevels of EGFR protein expression in OPSCC 
predictive of response to chemo-radiation?’. This question may be answered by 
post-hoc evaluation of clinical trial material. 
 
4. Mechanisms of resistance to TRAIL 
Further characterisation of the panel of cell lines used in this study in relation to 
the death receptor (DR)-mediated apoptotic pathway, including caspase-8, 
FADD and c-FLIP, are likely to explain possible mechanisms of resistance to 
treatment with TRAIL. Furthermore, evaluation of the possible interaction 
between HPV-16 E6 and DR pathway genes and proteins will inform whether 
TRAIL is likely to be a viable therapeutic option in the management of HPV-
associated OPSCC. 
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